2016/17 General Medical Services (GMS) contract Quality and Outcomes Framework (QOF)

Guidance for GMS contract 2016/17

April 2016
## Contents

<table>
<thead>
<tr>
<th>Section 1</th>
<th>Introduction</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Changes for 2016/17</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>National Institute for Health and Care Excellence (NICE)</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Disease registers</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>Achievement</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>Verification</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Disputes</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Business Rules</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Exception reporting</td>
<td>13</td>
</tr>
<tr>
<td>Section 2</td>
<td>Summary of all indicators</td>
<td>14</td>
</tr>
<tr>
<td>Section 3</td>
<td>Clinical domain</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>Atrial fibrillation (AF)</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>Secondary prevention of coronary heart disease (CHD)</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>Heart failure (HF)</td>
<td>39</td>
</tr>
<tr>
<td></td>
<td>Hypertension (HYP)</td>
<td>43</td>
</tr>
<tr>
<td></td>
<td>Peripheral arterial disease (PAD)</td>
<td>46</td>
</tr>
<tr>
<td></td>
<td>Stroke and transient ischaemic attack (STIA)</td>
<td>50</td>
</tr>
<tr>
<td>Condition</td>
<td>Page</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus (DM)</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>Asthma (AST)</td>
<td>66</td>
<td></td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease (COPD)</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>Dementia (DEM)</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td>Depression (DEP)</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>Mental health (MH)</td>
<td>86</td>
<td></td>
</tr>
<tr>
<td>Cancer (CAN)</td>
<td>95</td>
<td></td>
</tr>
<tr>
<td>Chronic kidney disease (CKD)</td>
<td>97</td>
<td></td>
</tr>
<tr>
<td>Epilepsy (EP)</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Learning disabilities (LD)</td>
<td>101</td>
<td></td>
</tr>
<tr>
<td>Osteoporosis: secondary prevention of fragility fracture (OST)</td>
<td>104</td>
<td></td>
</tr>
<tr>
<td>Rheumatoid arthritis (RA)</td>
<td>110</td>
<td></td>
</tr>
<tr>
<td>Palliative care (PC)</td>
<td>113</td>
<td></td>
</tr>
<tr>
<td><strong>Section 4</strong> Public health domain</td>
<td>116</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular disease – primary prevention (CVD-PP)</td>
<td>117</td>
<td></td>
</tr>
<tr>
<td>Blood pressure (BP)</td>
<td>121</td>
<td></td>
</tr>
<tr>
<td>Obesity (OB)</td>
<td>122</td>
<td></td>
</tr>
<tr>
<td>Section</td>
<td>Topic</td>
<td>Page</td>
</tr>
<tr>
<td>---------</td>
<td>------------------------------------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td></td>
<td>Smoking (SMOK)</td>
<td>124</td>
</tr>
<tr>
<td>Section 5</td>
<td>Exception reporting</td>
<td>136</td>
</tr>
<tr>
<td></td>
<td>Exception reporting FAQs</td>
<td>142</td>
</tr>
<tr>
<td>Section 6</td>
<td>Glossary of acronyms</td>
<td>144</td>
</tr>
<tr>
<td>Section 7</td>
<td>Queries</td>
<td>149</td>
</tr>
<tr>
<td>Section 8</td>
<td>QOF quick guide</td>
<td>150</td>
</tr>
<tr>
<td></td>
<td>Public health – additional services</td>
<td>131</td>
</tr>
<tr>
<td></td>
<td>Cervical screening (CS)</td>
<td>131</td>
</tr>
<tr>
<td></td>
<td>Contraception (CON)</td>
<td>134</td>
</tr>
</tbody>
</table>
Section 1: Introduction

The Quality and Outcomes Framework (QOF) rewards contractors for the provision of quality care and helps to standardise improvements in the delivery of primary medical services. Contractor participation in QOF is voluntary.

Changes to QOF are agreed as part of wider changes to the General Medical Services (GMS) contract. Changes to the GMS contract are negotiated annually by NHS Employers (on behalf of NHS England) and the British Medical Association’s (BMA) General Practitioners Committee (GPC).

The following principles have been agreed by the negotiating parties:

- Indicators should, where possible, be based on the best available evidence. The number of indicators in each clinical condition should be kept to the minimum number compatible with an accurate assessment of patient care.
- Data should never be created purely for audit purposes.
- Only data which is useful in patient care should be collected. The basis of the consultation should not be distorted by an over emphasis on data collection. An appropriate balance has to be struck between excess data collection and inadequate sampling. Data should never be collected twice eg data required for audit purposes should be data routinely collected for patient care and obtained from existing practice clinical systems.

In addition to the above principles:

- Indicators should consist only of anonymised data except for the purposes of post-payment verification (see ‘Verification’)
- Commissioners and practices undertaking QOF work should be mindful of the information governance standards for each practice and seek appropriate assurance in line with the governing contract.

The QOF is different across England and the Devolved Administrations. This guidance applies in England only.

The term NHS CB (NHS Commissioning Board) is the organisation legally responsible for the commissioning of primary care in England. From 1 April 2013 the NHS CB has operated under the name NHS England. NHS England is referenced throughout this guidance, excepting where it is necessary to use NHS CB to reflect the Statement of Financial Entitlements (SFE)¹ Directions. From 1 April 2015, co-commissioning arrangements are available in England. As such references to ‘commissioners’ in the document could be NHS England or a clinical commissioning group (CCG).

Section two summarises all indicators for 2016/17 QOF, which is extracted from Annex D of the SFE. This guidance is effective from 1 April 2016 and replaces

---

versions issued in previous years. Annex D to the SFE forms part of the GMS contract.

Changes for 2016/17

NHS Employers and the GPC have agreed that there will be no changes to existing indicators and no new or retired indicators for 2016/17. A summary of the QOF indicators for this year are available in section eight.

GPs will use their professional judgement and continue to treat patients in accordance with best clinical practice guidelines and will continue to undertake work and code activity as clinically appropriate in relation to those indicators no longer in QOF. Practices are encouraged to facilitate data collection on these indicators. Periodically, NHS England will collect anonymised data from practices’ clinical systems which will provide statistical information, be processed for audit and publication and will help inform commissioners and practices. It is not intended for performance management purposes.

For 2016/17 there are 559 points in QOF across two domains for clinical and public health indicators. The value of a QOF point for 2016/17 has been adjusted to recognise any changes in population and practice list size from 1 January 2015 to 1 January 2016. This figure is subject to change in future years. In addition, the planned changes to thresholds have been deferred for a further year to 1 April 2017.

The national average practice population figure for the 2016/17 QOF year is taken from the Calculating Quality Reporting Service (CQRS) on 1 January 2016 and is 7,460. The value of a QOF point for 2016/17 is £165.18.

Indicators are prefixed by an abbreviation of the category to which they belong, for example coronary heart disease (CHD) indicator number one, becomes CHD001. Changes to indicator IDs from April 2015 relate to those indicators where there has been a change to wording or timeframes, or significant changes to coding or the data collection logic. This is to ensure that indicators are not compared to previous years’ indicators.

National Institute for Health and Care Excellence

The National Institute for Health and Care Excellence (NICE) is responsible for managing an independent and transparent approach to developing and maintaining the QOF clinical and public health improvement indicators.

The focus for new indicators is informed by priorities for new indicators identified by NHS England and representatives from the devolved administrations. Supporting guidance for new indicators is provided by NICE Quality Standards (QS), NICE guidance and NICE accredited guidance. Interested individuals/organisations are encouraged to register with NICE as a stakeholder in the development of individual quality standards. Once registered, stakeholders are able to comment on the content of quality standards during their development. The comments facility and full details of quality standards in development are available on the NICE website².

---

Indicators that have been developed through the NICE process\(^3\) are identified by the reference 'NICE [YEAR] menu ID: NMXX' for information. The term 'based on NICE menu ID XX' is used to refer to NICE indicators amended by negotiations.

In 2015, NICE completed a retrospective mapping exercise on non-NICE indicators to review where they are in line with the latest NICE guidance. As such, a number of additional indicators now appear on the NICE menu.

References to NICE guidance throughout this document relate to the guidance that has been used to underpin the stated indicators. In some cases new or updated guidance may have been recently published, or will be published before the end of the QOF year. These guidelines will be reviewed by NICE in due course and any recommendations concerning amending current indicators or development of new indicators will be published in future NICE QOF menus for consideration by relevant parties.

**Disease registers**

An important feature of the QOF is the establishment of disease registers. These are lists of patients registered, created by collating data from patient records to provide an overview of those coded appropriately with the relevant condition, with the contractor who have been diagnosed with the disease or risk factor described in the register indicator. While it is noted that these may not be completely accurate, it is the responsibility of the contractor to demonstrate that it has systems in place to maintain a high quality register and this may be verified by commissioners by comparing the reported prevalence with the expected prevalence and ask contractors to explain any reasons for variations. The report generated does not contain patient identifiable data.

The purpose of a register in QOF is to define a cohort of patients with a particular condition or risk factor. In some cases, this register then informs other indicators in that disease area. QOF registers must not be used as the sole input for the purposes of individual patient care and clinical audit ie call and recall of patients for check-ups, treatments etc. There are patients for whom a particular treatment or activity is clinically appropriate but they may not meet the criteria as defined by the QOF register and therefore would not be picked up by a search based solely on the QOF register. As such, although QOF registers can be used to supplement clinical audit, they should be supported by appropriate clinical judgement to define which patients should be reviewed, invited for consultation etc. to ensure patients do not miss out on appropriate and sometimes critical care.

For some indicators, there is no disease register, but instead there is a target population group. For example, for cervical screening the target population group is women who are aged 25 years or over and under the age of 65. Indicators in the clinical and public health (PH) domain are arranged in terms of clinical areas. Most of these areas either relate to a register or to a target population group.

---

Some areas in the clinical and PH domain do not have a register indicator, or there may be more than one register to calculate the Adjusted Practice Disease Factor (APDF) for different indicators within the area. For all relevant disease areas, the register population used to calculate the APDF are set out in the summary of indicators section.

Patients with co-morbidities will be included in all relevant registers where they meet the relevant criteria. For example, a patient could be on the asthma register and also the COPD register as they could have both conditions. This means they would be eligible for the care outlined for both disease areas.

Some indicators refer to a sub-set of patients on the relevant disease register, or in the target population group. Patients who are on the disease register or in the target group for the clinical area concerned, but not included in an indicator denominator for definitional reasons, are called “exclusions”.

**Achievement**

When calculating achievement payments, contractor achievement against QOF indicators is measured:

- on the last day of the relevant financial year (31 March); or
- in the case where the contract terminates mid-year, on the last day on which the contract subsists. For example, for payments relating to the financial year 1 April 2016 to 31 March 2017, unless the contract terminates mid-year, achievement is measured on 31 March 2017 (this is when the data is collected from practice clinical systems). If the GMS contract ends on 30 June 2016, achievement is measured on 30 June 2016.

Indicators set out the target, intervention or measurement to be recorded within a specified time period to establish eligibility for achievement payments. Unless otherwise stated, time periods referred to mean the period which ends on the last day of the financial year to which the achievement relates. For example:

- **CHD002** – “The percentage of patients with coronary heart disease in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less”, the phrase “in the preceding 12 months” means the period of 12 months which ends on 31 March in the financial year to which the achievement payments relate
- **CAN003** – “The percentage of patients with cancer, diagnosed within the preceding 15 months, who have a patient review recorded as occurring within 6 months of the date of diagnosis”, the phrase “within the preceding 15 months” means the period of 15 months which ends on 31 March in the financial year to which the achievement payments relate
- **CS002** – “The percentage of women aged 25 or over and who have not attained the age of 65 whose notes record that a cervical screening test has been performed in the preceding 5 years” the phrase “in the preceding 5 years” means the period of five years which ends on 31 March in the financial year to which the achievement payments relate
- **CHD007** – “The percentage of patients with coronary heart disease who have had influenza immunisation in the preceding 1 August to 31 March” the phrase
“in the preceding 1 August to 31 March” means the period of eight months which ends on 31 March in the financial year to which the achievement payments relate

The following principles apply to any indicators where age or date ranges are referenced:

- where an indicator refers to the financial year, this means the period of 12 months from 1 April to 31 March
- where an indicator refers to patients diagnosed after a specified date (and does not specify a period within which the care described in the indicator is to be carried out), the indicator is looking for any record of the care described at any time on or after the diagnosis date (provided that the diagnosis date is on or after the specified date) up to and including the date that the achievement is measured. This type of indicator is called a "cumulative" indicator. AST002 is an example "The percentage of patients aged 8 years or over with asthma (diagnosed on or after 1 April 2006), on the register, with measures of variability or reversibility recorded between 3 months before or any time after diagnosis". This indicator is looking for any record of the specified care at any time on or after the diagnosis date (provided that the diagnosis date is on or after 1 April 2006), up to and including the date that the achievement is measured
- patients are considered to be 'currently treated' with a specified medicine if they have had a prescription for that medicine within the preceding six months ending on the last day of the financial year to which the achievement payments relate.

In the case of a contract that has come to an end before 31 March in any relevant financial year, the reference to periods of time are still calculated on the basis that the period ends on 31 March in the financial year to which the achievement payments relate. Annex D of the SFE sets out the rules that apply to measuring achievement for contracts that end before the end of the financial year.

Patients are eligible for the care outlined in the QOF indicators as soon as they are fully registered with the practice and treatment begins.

Practices are rewarded for the care delivered to patients registered within the practice at the 31 March each year. Therefore, if a patient moves to a new practice after having care outlined in QOF delivered in their previous practice, the new practice would be rewarded for this as long as the electronic patient record is up-to-date and accurate. If the patient’s old practice only delivered part of the care as outlined in the indicator and then the patient moved to a new practice, the new practice will need to ensure that the care outlined in the indicator is delivered accordingly in order for the patient to be included in the numerator. However, should the indicator require that certain activity is done within a particular timeframe and the old practice has not done this, then the patient may not be included in the numerator.

The formula used to calculate the achievement of indicators in the clinical domain is:

\[
\text{actual achievement} \times \left( \frac{\text{number of points available for indicator}}{\text{maximum potential achievement}} \right) \times £xx \text{ (value of a QOF point)}
\]
All payments are weighted by list size (the Contractor Population Index (CPI)) and in the clinical domain by disease prevalence. A target population factor adjustment applies to those indicators within the public health additional services sub domain.

Verification

For indicators where achievement is not automatically collected from GP clinical systems by the General Practice Extraction Service (GPES), ie CS001, the guidance outlines the evidence which commissioners may require the contractor to produce for verification purposes. This evidence will not need to be submitted unless specifically requested by the commissioner.

The SFE sets out the basis for the reporting requirements for contractors and the rules for the calculation of QOF payments.

Anonymised data from GP clinical systems will be automatically collected by GPES and reported to CQRS. Where automatic collection is not available, achievement should be reported by self-declaration on CQRS through a web-based server. CQRS will calculate achievement and payments for QOF and report to commissioners and practices.

The following propositions are taken or adapted from the SFE and the Confidentiality and Disclosure of Information (GMS, PMS, APMS) Directions 2013 and its Code of Practice: The Directions and Code of Practice apply equally to NHS England and CCGs operating under delegated commissioning.

The contractor must ensure that it is able to provide any information that the NHS CB or commissioner may reasonably request of it to demonstrate that it is entitled to each achievement point to which it says it is entitled, and the contractor must make that information available to the commissioner on request. In verifying that an indicator has been achieved and information correctly recorded, the Board may choose to inspect the output from a computer search that has been used to provide information on the indicator, or a sample of patient records relevant to the indicator.

Commissioners and practices will be aware of the requirements of access to patient identifiable data. Where patients have expressed a desire that their information is not shared for this purpose, practices will need to advise the commissioner and make an appropriate note in the record.

Commissioners and practices will be aware of the need to:

- obtain the minimum necessary information for the specific purpose
- anonymise data where possible

It is recommended that practices record access to confidential patient data in the relevant patient record, so that an audit trial is in place to fulfil the obligations of the practice towards their patients and that of commissioners to practices.

---

Disputes

When a QOF related contractual dispute arises, the commissioner and the contractor, would be expected to make every reasonable effort to communicate and co-operate with each other with a view to resolving the dispute without the need to refer it for formal determination by the NHS Litigation Authority Appeals Unit (or in certain cases, the courts). Further information is available in the SFE.

Where 'reporting and verification' is included it provides additional information to support practices in meeting the criteria for the indicator. However, commissioners and practices should be aware that the reporting and verification sections for indicators should be considered in conjunction with the requirements outlined in the verification section of this introduction and Annex D of the SFE also sets out the full requirements in relation to verification.

The terms 'notes' and 'patient record' are used throughout this document to indicate either electronic or paper patient records.

Business Rules

The Dataset and Business Rules that support the reporting requirements of the QOF are based entirely on Read codes (version 2 and Clinical Terms Version 3 (CTV3)) and associated dates.

Read codes are an NHS standard. Contractors using proprietary coding systems and/or local/practice specific codes will need to be aware that these codes will not be recognised within QOF reporting. Contractors utilising such systems may need to develop strategies to ensure that they are using appropriate Read codes in advance of producing their achievement report.

The Dataset and Business Rules are updated twice a year around April and October and are available on the Health and Social Care Information Centre (HSCIC) website.

To better facilitate extraction and certification there have been changes to the Business Rules from 1 April 2016 for instances where the logic is looking for activity to have taken place within a specified timeframe Where an indicator based on a clinical event such as a diagnosis that can happen at any point and a period of time where an intervention must be delivered ie if a diagnosis is made in the middle of February and the time period is six months for the action, then it is difficult for system suppliers to calculate this exactly using 'months' as the time period. Issues such as months having varying days, leap years etc. make the specification impossible and suppliers were implementing this in different ways leading to problems with certification.

As such, it was agreed that this type of time frame scenario would be converted to a number of days rather than months on the basis of a 31 day month. For example:

STIA008. The percentage of patients with a stroke or TIA (diagnosed on or after 1 April 2014) who have a record of a referral for further investigation.

---

5 HSCIC. [http://www.hscic.gov.uk/qofesextractspecs](http://www.hscic.gov.uk/qofesextractspecs)
between 3 months before or 1 month after the date of the latest recorded stroke or the first TIA

would be (3 \times 31 \text{ days} =) 93 \text{ days before or (1 month =) 31 days after the date of the}...

This change will apply to the Business Rules only, timeframes in indicator wording will remain how they are currently written.

As some timeframes are based on three months from a known fixed date of 31 March each year ie recent diagnosis, recent registration etc – exclusions applied automatically at the end of the year - there is no need to convert this to days.

Further information on the Business Rules process is available on the NHS Employers website\(^6\).

**Exception reporting**

Exception reporting applies to indicators in any domain of the QOF, where the achievement is determined by the percentage of patients receiving the specified level of care.

“Exceptions” relate to registered patients who are on the relevant disease register or in the target population group and would ordinarily be included in the indicator denominator, but who are excepted by the contractor on the basis of one or more of the exception criteria. Patients are removed from the denominator and numerator for an indicator if they have been both excepted and they have not received the care specified in the indicator wording. If the patient has been excepted but subsequently the care has been carried out within the relevant time period, the patient will be included in both the denominator and the numerator (achievement will always override an exception).

When an appropriate exception code has been added to the patient record, it applies only to the QOF year in which it was added. If the timeframe defined to deliver the care described in the indicator wording spans two QOF years, the exception would need to be added for each of the QOF years.

See ‘section 5: ‘Exception reporting guidance’ or Annex D of the SFE for the exception reporting criteria.

---

\(^6\) NHS Employers. Developing the QOF Business Rules. [www.nhsemployers.org/PayAndContracts/GeneralMedicalServicesContract/QOF/DevelopingQOFbusinessrules/Pages/DevelopingtheQOFbusinessrules.aspx](www.nhsemployers.org/PayAndContracts/GeneralMedicalServicesContract/QOF/DevelopingQOFbusinessrules/Pages/DevelopingtheQOFbusinessrules.aspx)
Section 2: Summary of all indicators

Section 2.1: Clinical domain (435 points)
Section 2.1. applies to all contractors participating in QOF.

Atrial fibrillation (AF)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AF001. The contractor establishes and maintains a register of patients with atrial fibrillation</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AF006. The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring system in the preceding 12 months (excluding those patients with a previous CHADS2 or CHA2DS2-VASc score of 2 or more) [NICE 2014 menu ID: NM81]</td>
<td>12</td>
<td>40-90%</td>
</tr>
<tr>
<td>AF007. In those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more, the percentage of patients who are currently treated with anti-coagulation drug therapy [NICE 2014 menu ID: NM82]</td>
<td>12</td>
<td>40-70%</td>
</tr>
</tbody>
</table>

For AF007, patients with a previous score of 2 or above using CHADS2, recorded prior to 1 April 2015 will be included in the denominator.

Secondary prevention of coronary heart disease (CHD)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD001. The contractor establishes and maintains a register of patients with coronary heart disease</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD002. The percentage of patients with coronary heart disease in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less [NICE 2015 menu ID: NM86]</td>
<td>17</td>
<td>53–93%</td>
</tr>
</tbody>
</table>

---

7 The ‘summary of indicators’ section is an extract from Annex D of the SFE.
**CHD005.** The percentage of patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken

*NICE 2015 menu ID: NM88*

<table>
<thead>
<tr>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>56–96%</td>
</tr>
</tbody>
</table>

**CHD007.** The percentage of patients with coronary heart disease who have had influenza immunisation in the preceding 1 August to 31 March

*NICE 2015 menu ID: NM87*

<table>
<thead>
<tr>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>56–96%</td>
</tr>
</tbody>
</table>

### Heart failure (HF)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HF001. The contractor establishes and maintains a register of patients with heart failure</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td><strong>Initial diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HF002. The percentage of patients with a diagnosis of heart failure (diagnosed on or after 1 April 2006) which has been confirmed by an echocardiogram or by specialist assessment 3 months before or 12 months after entering on to the register</td>
<td>6</td>
<td>50–90%</td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HF003. In those patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, the percentage of patients who are currently treated with an ACE-I or ARB</td>
<td>10</td>
<td>60–100%</td>
</tr>
<tr>
<td>HF004. In those patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction who are currently treated with an ACE-I or ARB, the percentage of patients who are additionally currently treated with a beta-blocker licensed for heart failure</td>
<td>9</td>
<td>40–65%</td>
</tr>
</tbody>
</table>

### Disease registers for heart failure

There are two disease registers used for the HF indicators for the purpose of calculating APDF (practice prevalence):

- a register of patients with HF is used to calculate APDF for HF001 and HF002,
- a register of patients with HF due to left ventricular systolic dysfunction (LVSD) is used to calculate APDF for HF003 and HF004.

Register 1 is defined in indicator HF001. Register 2 is a sub-set of register 1 and is composed of patients with a diagnostic code for LVSD as well as for HF.
### Hypertension (HYP)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYP001. The contractor establishes and maintains a register of patients with established hypertension</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYP006. The percentage of patients with hypertension in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less</td>
<td>20</td>
<td>45–80%</td>
</tr>
</tbody>
</table>

### Peripheral arterial disease (PAD)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAD001. The contractor establishes and maintains a register of patients with peripheral arterial disease</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAD002. The percentage of patients with peripheral arterial disease in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less</td>
<td>2</td>
<td>40–90%</td>
</tr>
<tr>
<td>PAD004. The percentage of patients with peripheral arterial disease with a record in the preceding 12 months that aspirin or an alternative anti-platelet is being taken</td>
<td>2</td>
<td>40–90%</td>
</tr>
</tbody>
</table>

### Stroke and transient ischaemic attack (STIA)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STIA001. The contractor establishes and maintains a register of patients with stroke or TIA</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>Initial diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STIA008. The percentage of patients with a stroke or TIA (diagnosed on or after 1 April 2014) who have a record of a referral for further investigation between 3 months before or 1 month after the date of the latest recorded stroke or the first TIA</td>
<td>2</td>
<td>45–80%</td>
</tr>
<tr>
<td>Indicator</td>
<td>Points</td>
<td>Achievement thresholds</td>
</tr>
<tr>
<td>------------------------</td>
<td>--------</td>
<td>-------------------------</td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>STIA003. The percentage of patients with a history of stroke or TIA in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less</td>
<td>5</td>
<td>40–75%</td>
</tr>
<tr>
<td><strong>Diabetes mellitus (DM)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Records</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DM017. The contractor establishes and maintains a register of all patients aged 17 or over with diabetes mellitus, which specifies the type of diabetes where a diagnosis has been confirmed</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Ongoing management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DM002. The percentage of patients with diabetes, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less</td>
<td>8</td>
<td>53–93%</td>
</tr>
<tr>
<td>DM003. The percentage of patients with diabetes, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 140/80 mmHg or less</td>
<td>10</td>
<td>38–78%</td>
</tr>
<tr>
<td>DM004. The percentage of patients with diabetes, on the register, whose last measured total cholesterol (measured within the preceding 12 months) is 5 mmol/l or less</td>
<td>6</td>
<td>40–75%</td>
</tr>
<tr>
<td>DM006. The percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs)</td>
<td>3</td>
<td>57–97%</td>
</tr>
<tr>
<td>Indicator</td>
<td>Points</td>
<td>Achievement thresholds</td>
</tr>
<tr>
<td>-----------</td>
<td>--------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>DM007. The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 59 mmol/mol or less in the preceding 12 months NICE 2010 menu ID: NM14</td>
<td>17</td>
<td>35–75%</td>
</tr>
<tr>
<td>DM008. The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 64 mmol/mol or less in the preceding 12 months NICE 2015 menu ID: NM96</td>
<td>8</td>
<td>43–83%</td>
</tr>
<tr>
<td>DM009. The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months NICE 2015 menu ID: NM97</td>
<td>10</td>
<td>52–92%</td>
</tr>
<tr>
<td>DM012. The percentage of patients with diabetes, on the register, with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes in previous ulcer) or 4) ulcerated foot within the preceding 12 months NICE 2010 menu ID: NM13</td>
<td>4</td>
<td>50–90%</td>
</tr>
<tr>
<td>DM014. The percentage of patients newly diagnosed with diabetes, on the register, in the preceding 1 April to 31 March who have a record of being referred to a structured education programme within 9 months after entry on to the diabetes register NICE 2011 menu ID: NM27</td>
<td>11</td>
<td>40–90%</td>
</tr>
<tr>
<td>DM018. The percentage of patients with diabetes, on the register, who have had influenza immunisation in the preceding 1 August to 31 March NICE 2011 menu ID: NM139</td>
<td>3</td>
<td>55–95%</td>
</tr>
</tbody>
</table>

Asthma (AST)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Records</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST001. The contractor establishes and maintains a register of patients with asthma, excluding patients with asthma who have been prescribed no asthma-related drugs in the preceding 12 months</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Initial diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST002. The percentage of patients aged 8 or over with asthma (diagnosed on or after 1 April 2006), on the register, with measures of variability or reversibility recorded between 3 months before or any time after diagnosis NICE 2015 menu ID: NM101</td>
<td>15</td>
<td>45–80%</td>
</tr>
<tr>
<td>Ongoing management</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
AST003. The percentage of patients with asthma, on the register, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control using the 3 RCP questions  
*NICE 2011 menu ID: NM23*

<table>
<thead>
<tr>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>45–70%</td>
</tr>
</tbody>
</table>

AST004. The percentage of patients with asthma aged 14 or over and who have not attained the age of 20, on the register, in whom there is a record of smoking status in the preceding 12 months  
*NICE 2015 menu ID: NM102*

<table>
<thead>
<tr>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>45–80%</td>
</tr>
</tbody>
</table>

### Chronic obstructive pulmonary disease (COPD)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD001. The contractor establishes and maintains a register of patients with COPD</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>Initial diagnosis</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| COPD002. The percentage of patients with COPD (diagnosed on or after 1 April 2011) in whom the diagnosis has been confirmed by post bronchodilator spirometry between 3 months before and 12 months after entering on to the register  
*NICE 2015 menu ID: NM103* | 5      | 45–80%                  |
| **Ongoing management**                                                   |        |                         |
| COPD003. The percentage of patients with COPD who have had a review, undertaken by a healthcare professional, including an assessment of breathlessness using the Medical Research Council dyspnoea scale in the preceding 12 months  
*NICE 2015 menu ID: NM104* | 9      | 50–90%                  |
| COPD004. The percentage of patients with COPD with a record of FEV₁ in the preceding 12 months  
*NICE 2015 menu ID: NM105* | 7      | 40–75%                  |
| COPD005. The percentage of patients with COPD and Medical Research Council dyspnoea grade ≥3 at any time in the preceding 12 months, with a record of oxygen saturation value within the preceding 12 months  
*NICE 2012 menu ID: NM63* | 5      | 40-90%                  |
| COPD007. The percentage of patients with COPD who have had influenza immunisation in the preceding 1 August to 31 March  
*NICE 2015 menu ID: NM106* | 6      | 57-97%                  |

**Dementia (DEM)**
<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEM001. The contractor establishes and maintains a register of patients diagnosed with dementia</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEM004. The percentage of patients diagnosed with dementia whose care plan has been reviewed in a face-to-face review in the preceding 12 months <em>NICE 2015 menu ID: NM107</em></td>
<td>39</td>
<td>35–70%</td>
</tr>
<tr>
<td>DEM005. The percentage of patients with a new diagnosis of dementia recorded in the preceding 1 April to 31 March with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded between 12 months before or 6 months after entering on to the register <em>Based on NICE 2010 menu ID: NM09</em></td>
<td>6</td>
<td>45–80%</td>
</tr>
<tr>
<td><strong>Depression (DEP)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Initial management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEP003. The percentage of patients aged 18 or over with a new diagnosis of depression in the preceding 1 April to 31 March, who have been reviewed not earlier than 10 days after and not later than 56 days after the date of diagnosis <em>Based on NICE 2012 menu ID: NM50</em></td>
<td>10</td>
<td>45–80%</td>
</tr>
</tbody>
</table>
**Disease register for depression**

There is no register indicator for the depression indicator. The disease register for the depression indicator for the purpose of calculating the APDF is defined as all patients aged 18 or over, diagnosed on or after 1 April 2006, who have an unresolved record of depression in their patient record.

**Mental health (MH)**

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MH001. The contractor establishes and maintains a register of patients with schizophrenia, bipolar affective disorder and other psychoses and other patients on lithium therapy</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MH002. The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a comprehensive care plan documented in the record, in the preceding 12 months, agreed between individuals, their family and/or carers as appropriate <em>NICE 2015 menu ID: NM108</em></td>
<td>6</td>
<td>40–90%</td>
</tr>
<tr>
<td>MH003. The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood pressure in the preceding 12 months <em>NICE 2010 menu ID: NM17</em></td>
<td>4</td>
<td>50–90%</td>
</tr>
<tr>
<td>MH007. The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of alcohol consumption in the preceding 12 months <em>NICE 2010 menu ID: NM15</em></td>
<td>4</td>
<td>50–90%</td>
</tr>
<tr>
<td>MH008. The percentage of women aged 25 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years <em>NICE 2010 menu ID: NM20</em></td>
<td>5</td>
<td>45–80%</td>
</tr>
<tr>
<td>MH009. The percentage of patients on lithium therapy with a record of serum creatinine and TSH in the preceding 9 months <em>NICE 2010 menu ID: NM21</em></td>
<td>1</td>
<td>50–90%</td>
</tr>
<tr>
<td>MH010. The percentage of patients on lithium therapy with a record of lithium levels in the therapeutic range in the preceding 4 months <em>NICE 2010 menu ID: NM22</em></td>
<td>2</td>
<td>50–90%</td>
</tr>
</tbody>
</table>

**Disease register for mental health**
Due to the way repeat prescribing works in general practice, patients on lithium therapy are defined as patients with a prescription of lithium within the preceding six months.

**Remission from serious mental illness**

Making an accurate diagnosis of remission can be challenging. In the absence of strong evidence of what constitutes ‘remission’ from serious mental illness, clinicians should only consider using the remission codes if the patient has been in remission for at least five years, that is where there is:

- no record of anti-psychotic medication
- no mental health in-patient episodes; and
- no secondary or community care mental health follow-up for at least five years.

Where a patient is recorded as being ‘in remission’ they remain on the MH001 register (in case their condition relapses at a later date) but they are excluded from the denominator for mental health indicators MH002, MH003, MH007 and MH008.

The accuracy of this coding should be reviewed on an annual basis by a clinician. Should a patient who has been coded as ‘in remission’ experience a relapse then this should be recorded as such in their patient record.

In the event that a patient experiences a relapse and is coded as such, they will again be included in all the associated indicators for schizophrenia, bipolar affective disorder and other psychoses and their care plan should be updated.

Where a patient has relapsed after being recorded as being in remission, their care plan should be updated subsequent to the relapse. Care plans dated prior to the date of the relapse will not be acceptable for QOF purposes.

**Cancer (CAN)**

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAN001. The contractor establishes and maintains a register of all cancer patients defined as a ‘register of patients with a diagnosis of cancer excluding non-melanotic skin cancers diagnosed on or after 1 April 2003’</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>CAN003. The percentage of patients with cancer, diagnosed within the preceding 15 months, who have a patient review recorded as occurring within 6 months of the date of diagnosis <em>Based on NICE 2012 menu ID: NM62</em></td>
<td>6</td>
<td>50–90%</td>
</tr>
</tbody>
</table>
### Chronic kidney disease (CKD)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CKD005. The contractor establishes and maintains a register of patients aged 18 or over with CKD with classification of categories G3a to G5 (previously stage 3 to 5)</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td><em>NICE 2014 menu ID: NM83</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Epilepsy (EP)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EP001. The contractor establishes and maintains a register of patients aged 18 or over receiving drug treatment for epilepsy</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

### Learning disability (LD)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LD003. The contractor establishes and maintains a register of patients with learning disabilities</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td><em>NICE 2015 menu ID: NM73</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Osteoporosis: secondary prevention of fragility fractures (OST)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OST004 The contractor establishes and maintains a register of patients: 1. Aged 50 or over and who have not attained the age of 75 with a record of a fragility fracture on or after 1 April 2012 and a diagnosis of osteoporosis confirmed on DXA scan, and 2. Aged 75 or over with a record of a fragility fracture on or after 1 April 2014 and a diagnosis of osteoporosis</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><em>NICE 2011 menu ID: NM29</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OST002. The percentage of patients aged 50 or over and who have not attained the age of 75, with a fragility fracture on or after 1 April 2012, in whom osteoporosis</td>
<td>3</td>
<td>30–60%</td>
</tr>
</tbody>
</table>
is confirmed on DXA scan, who are currently treated with an appropriate bone-sparing agent
*NICE 2011 menu ID: NM30*

OST005. The percentage of patients aged 75 or over with a record of a fragility fracture on or after 1 April 2014 and a diagnosis of osteoporosis, who are currently treated with an appropriate bone-sparing agent
*NICE 2011 menu ID: NM31*

<table>
<thead>
<tr>
<th>Disease register for osteoporosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Although the register indicator OST004 defines two separate registers, the disease register for the purpose of calculating the APDF is defined as the sum of the number of patients on both registers.</td>
</tr>
</tbody>
</table>

**Rheumatoid arthritis (RA)**

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| RA001. The contractor establishes and maintains a register of patients aged 16 or over with rheumatoid arthritis
*NICE 2012 menu ID: NM55* | 1 | |
| **Ongoing management** | | |
| RA002. The percentage of patients with rheumatoid arthritis, on the register, who have had a face-to-face review in the preceding 12 months
*NICE 2012 menu ID: NM58* | 5 | 40–90% |

**Palliative care (PC)**

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PC001. The contractor establishes and maintains a register of all patients in need of palliative care/support irrespective of age</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| PC002. The contractor has regular (at least 3 monthly) multi-disciplinary case review meetings where all patients on the palliative care register are discussed
*NICE 2015 menu ID: NM111* | 3 | |

**Disease register for palliative care**

There is no APDF calculation in respect of the palliative care indicators. In the rare case of a nil register at year end, if a contractor can demonstrate that it established
and maintained a register during the financial year then they will be eligible for payment for PC001.
Section 2.2: Public health domain

Section 2.2.1: Public health domain (124 points)
Section 2.2.1. applies to all contractors participating in QOF.

Cardiovascular disease – primary prevention (CVD-PP)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVD-PP001. In those patients with a new diagnosis of hypertension aged 30 or over and who have not attained the age of 75, recorded between the preceding 1 April to 31 March (excluding those with pre-existing CHD, diabetes, stroke and/or TIA), who have a recorded CVD risk assessment score (using an assessment tool agreed with the NHS CB) of ≥20% in the preceding 12 months: the percentage who are currently treated with statins</td>
<td>10</td>
<td>40–90%</td>
</tr>
</tbody>
</table>

Disease register for CVD-PP

The disease register for the purpose of calculating the APDF for the CVD-PP indicator is defined as "patients diagnosed in the preceding 12 months with a first episode of hypertension, excluding patients with the following conditions:

- CHD or angina
- stroke or TIA
- peripheral vascular disease
- familial hypercholesterolemia
- diabetes
- CKD with classification of categories G3a to G5.

Blood pressure (BP)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP002. The percentage of patients aged 45 or over who have a record of blood pressure in the preceding 5 years</td>
<td>15</td>
<td>50–90%</td>
</tr>
</tbody>
</table>
## Obesity (OB)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>OB002. The contractor establishes and maintains a register of patients aged 18 years or over with a BMI ≥30 in the preceding 12 months</td>
<td>8</td>
<td></td>
</tr>
</tbody>
</table>

*NICE 2014 menu ID: NM85*

## Smoking (SMOK)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMOK002. The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months</td>
<td>25</td>
<td>50–90%</td>
</tr>
</tbody>
</table>

*NICE 2011 menu ID: NM38*

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ongoing management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SMOK003. The contractor supports patients who smoke in stopping smoking by a strategy which includes providing literature and offering appropriate therapy</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

*NICE 2015 menu ID: NM113*

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMOK004. The percentage of patients aged 15 or over who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 24 months</td>
<td>12</td>
<td>40–90%</td>
</tr>
</tbody>
</table>

*Based on NICE 2011 menu ID: NM40*

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>SMOK005. The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months</td>
<td>25</td>
<td>56–96%</td>
</tr>
</tbody>
</table>

*NICE 2011 menu ID: NM39*

## Disease register for smoking

The disease register for the purpose of calculating the APDF for SMOK002 and SMOK005 is defined as the sum of the number of patients on the disease registers for each of the conditions listed in the indicators. Any patient who has one or more co-morbidities eg diabetes and CHD, is only counted once on the register for SMOK002 and SMOK005.
There is no APDF calculation for SMOK003 and SMOK004.

Requirements for recording smoking status

Smokers

For patients who smoke this recording should be made in the preceding 12 months for SMOK002.

Non-smokers

It is recognised that life-long non-smokers are very unlikely to start smoking and indeed find it quite irritating to be asked repeatedly regarding their smoking status. Smoking status for this group of patients should be recorded in the preceding 12 months for SMOK002 until the end of the financial year in which the patient reaches the age of 25.

Once a patient is over the age of 25 years (eg in the financial year in which they reach the age of 26 or in any year following that financial year) to be classified as a non-smoker they should be recorded as:

- never smoked which is both after their 25th birthday and after the earliest diagnosis date for the disease which led to the patient's inclusion on the SMOK002 register (eg one of the conditions listed on the SMOK002 register).

Ex-smokers

Ex-smokers can be recorded as such in the preceding 12 months for SMOK002. Practices may choose to record ex-smoking status on an annual basis for three consecutive financial years and after that smoking status need only be recorded if there is a change. This is to recognise that once a patient has been an ex-smoker for more than three years they are unlikely to restart.
Section 2.2.2: Public health (PH) domain – additional services sub domain

Section 2.2.2. applies to contractors who provide additional services under the terms of the GMS contract and participate in QOF.

Cervical screening (CS)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>CS001. The contractor has a protocol that is in line with national guidance agreed with the NHS CB for the management of cervical screening, which includes staff training, management of patient call/recall, exception reporting and the regular monitoring of inadequate sample rates</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>CS002. The percentage of women aged 25 or over and who have not attained the age of 65 whose notes record that a cervical screening test has been performed in the preceding 5 years</td>
<td>11</td>
<td>45–80%</td>
</tr>
<tr>
<td>CS004. The contractor has a policy for auditing its cervical screening service and performs an audit of inadequate cervical screening tests in relation to individual sample-takers at least every 2 years</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

Contraception (CON)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>CON001. The contractor establishes and maintains a register of women aged 54 or under who have been prescribed any method of contraception at least once in the last year, or other clinically appropriate interval eg last 5 years for an IUS</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>CON003. The percentage of women, on the register, prescribed emergency hormonal contraception one or more times in the preceding 12 months by the contractor who have received information from the contractor about long acting reversible methods of contraception at the time of or within 1 month of the prescription Based on NICE 2015 menu ID: NM115</td>
<td>3</td>
<td>50–90%</td>
</tr>
</tbody>
</table>
Section 3: Clinical domain

The clinical indicators are organised by disease category. The disease categories have been selected for the following reasons:

- where the responsibility for ongoing management rests principally with the general practitioner and the primary care team
- where there is good evidence of the health benefits likely to result from improved primary care – in particular if there is an accepted national clinical guideline
- where the disease area is a priority.

Where evidence-based national guidance has not been included, this has usually been to limit the size and complexity of the framework, where this is the case links and/or references have been included.

A summary of the indicators for each disease category is provided at the beginning of each disease area.

Establishing and maintaining disease registers is good professional practice and ensures a defined population is identified for undertaking further evidence-based interventions. Disease registers also make it possible to call and recall patients effectively to provide systematic care and to undertake care audits.

For each indicator detailed guidance supporting the indicator is provided under ‘rationale’ and where appropriate additional detail around ‘reporting and verification’ requirements are also included.

The drugs which count towards achievement for the clinical and health improvement indicators are included in the Business Rules for the relevant year. The Business Rules can be found on the HSCIC website.

‘xxx.1 Rationale’

This sub section explains why the indicator has been selected. Wherever possible, the evidence source is described and if available, a web address (hyperlink in an electronic version of this guidance) is provided. When available, national guidelines have been used as the main evidence source, but individual papers are also quoted.

In some areas, more extensive information is provided. The aim is to achieve a balance of providing helpful information without attempting to provide a textbook of medicine or replicating guidelines.

The indicators included in the QOF are not intended to cover all the process issues or outcomes for each disease category. In some areas, the indicators cover only a very small part of the care for those conditions.

‘xxx.2 Reporting and verification’

8 HSCIC. [http://www.hscic.gov.uk/qofesextractspecs](http://www.hscic.gov.uk/qofesextractspecs)
Commissioners and practices should be aware that the reporting and verification sections for indicators should be considered in conjunction with the requirements outlined in the verification section one and Annex D of the SFE also sets out the full requirements in relation to verification.
Atrial fibrillation (AF)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Records</th>
<th>Ongoing management</th>
</tr>
</thead>
<tbody>
<tr>
<td>AF001</td>
<td>The contractor establishes and maintains a register of patients with atrial fibrillation</td>
<td>5</td>
</tr>
<tr>
<td>AF006</td>
<td>The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using the CHA2DS2-VASc score risk stratification scoring system in the preceding 12 months (excluding those patients with a previous CHADS2 or CHA2DS2-VASc score of 2 or more)</td>
<td>12</td>
</tr>
<tr>
<td>AF007</td>
<td>In those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more, the percentage of patients who are currently treated with anti-coagulation drug therapy</td>
<td>12</td>
</tr>
</tbody>
</table>

AF – rationale for inclusion of indicator set

AF is the most common sustained cardiac arrhythmia. Men are more commonly affected than women and the prevalence increases with age with prevalence in those over 65 years 7.2 per cent and over 75 years ten per cent. In people who have had a stroke, concurrent AF is associated with a higher rate of mortality, greater disability, a longer stay in hospital and a lower rate of discharge home. Many people with AF are asymptomatic and are picked up in general practice opportunistically. They may present with serious complications such as heart failure, stroke or thromboembolism, and AF is detected at the same time. How long the person has had AF, and whether it was the cause or effect of the associated medical problem, may be uncertain. Stroke prevention with appropriate thromboprophylaxis is central to the management of AF.

AF indicator 001

The contractor establishes and maintains a register of patients with atrial fibrillation

---


AF001.1 Rationale

The register includes all patients with an initial event; paroxysmal; persistent and permanent AF.

AF 001.2 Reporting and verification

See indicator wording for requirement criteria.

Where a patient has been diagnosed with AF and been subsequently successfully treated, if there is an 'AF resolved code' present in their record after the latest AF recording, they will be removed from the register.

AF may resolve in some specific situations. It should be noted that the population where it can be said the AF has 'resolved' is generally limited. Contractors should consider this before using the AF resolved code.

AF indicator 006 (NICE 2014 menu ID: NM81)

The percentage of patients with atrial fibrillation in whom stroke risk has been assessed using CHA2DS2-VASc score risk stratification scoring system in the preceding 12 months (excluding those patients with a previous CHADS2 or CHA2DS2-VASc score of 2 or more)

AF 006.1 Rationale

The NICE guideline on atrial fibrillation recommends that people with symptomatic or asymptomatic paroxysmal, persistent or permanent AF, atrial flutter and/or a continuing risk of arrhythmia recurrence after cardioversion back to sinus rhythm should have an assessment of their stroke risk using the CHA2DS2-VASc risk assessment tool.

The scoring system recommended is CHA2DS2-VASc, which is validated and gives a score that allows a better stratification of low-risk patients than the CHADS2 score. There is a clinical benefit in using a stroke risk score to identify patients at risk. The review of cohort studies found that there may be a slight benefit of CHA2DS2-VASc over the other scores considered (CHADS2, ACCP and the ACC/AHA/ESC).

The CHA2DS2-VASc is a refinement of CHADS2. The revised CHA2DS2-VASc system scores one point, up to a maximum of nine, for each of the following risk factors (except previous stroke or TIA, or age ≥75 which scores double, hence the ‘2’):

- C: congestive HF (one point)
- H: hypertension (one point)
- A2: age 75 or over (two points)
- D: diabetes mellitus (one point)
- S2: previous stroke or TIA or thromboembolism (two points).
- V: vascular disease (eg PAD, MI, aortic plaque) (one point)
- A: age 65-74 years (one point)
- Sc: sex category (ie female sex) (one point)

AF 006.2 Reporting and verification

See indicator wording for requirement criteria.
AF indicator 007 (NICE 2015 menu ID: NM82)

In those patients with atrial fibrillation with a record of a CHA$_2$DS$_2$-VAS$_c$ score of 2 or more, the percentage of patients who are currently treated with anti-coagulation drug therapy.

**AF 007.1 Rationale**

This indicator aims to support the identification of people with AF who are at increased risk of stroke so that they may be offered anti-coagulation drug therapy.

Around 800,000 people in England are known to be at risk of stroke from AF. Of these, around half are taking anti-coagulants and around a quarter are currently taking aspirin$^{11}$. However, around 60 per cent of people admitted to a hospital with a stroke caused by AF are not taking recommended anti-coagulants$^{12}$. NICE estimates that with effective detection and protection with anti-coagulant drugs, 7,000 strokes and 2,000 premature deaths could be avoided each year$^{13}$.

Practices should not offer aspirin monotherapy solely for stroke prevention to people with AF. Evidence shows that aspirin is not as effective as anti-coagulants at preventing stroke in people with AF who are at increased risk of stroke and is also not as safe in terms of causing bleeding. Although the risks of anti-coagulation also increase with age, the evidence also shows that its benefits outweigh the risks in the vast majority of people with AF.

Stroke prevention therapy should not be offered to patients under 65 years with AF and no risk factors other than their sex (that is, very low risk of stroke equating to a CHA$_2$DS$_2$-VAS$_c$ score of zero for men or one for women). Subsequent to this step, stroke prevention should be offered to those AF patients with one or more stroke risk factors.

Anti-coagulation should be offered to those patients with one or more stroke risk factors. A CHA$_2$DS$_2$-VAS$_c$ score of one in women (women under age 65 with no other risk factors) should be regarded as low risk and should not receive anti-coagulation. Men with a CHA$_2$DS$_2$-VAS$_c$ score of one should be regarded as at intermediate risk and a group in whom anti-coagulation should be considered.

All patients with AF and a CHA$_2$DS$_2$-VAS$_c$ score of two or above should be offered anti-coagulation therapy taking their bleeding risk into account.

Anti-coagulation may be with apixaban, dabigatran etexilate, rivaroxaban or a vitamin K antagonist.

Anti-coagulation would not necessarily be indicated if the episode of AF was an isolated event that was not expected to re-occur (for example, one-off AF with a self-limiting cause).

---


$^{12}$ RCP. Sentinel Stroke National Audit Programme (SSNAP). 2015. [https://www.strokeaudit.org/results/PostAcute/National.aspx](https://www.strokeaudit.org/results/PostAcute/National.aspx)

When developing the guideline, NICE considered aspirin monotherapy to have limited benefits for AF patients in preventing strokes and made a strong recommendation that aspirin monotherapy should not be offered to patients at increased risk of stroke. Therefore, the AF guideline highlights the importance of offering people with AF a personalised package of care which should cover stroke awareness and measures to prevent stroke.

NICE has produced a patient decision aid\textsuperscript{14} to support this guideline.

**AF 007.2 Reporting and verification**

See indicator wording for requirement criteria.

The Business Rules will look for the latest CHA\textsubscript{2}DS\textsubscript{2}-VAS\textsubscript{c} score in the patient record and if the score is equal to, or greater than two, the patient will be included in the denominator. If the patient does not have a CHA\textsubscript{2}DS\textsubscript{2}-VAS\textsubscript{c} score, but does have a CHADS\textsubscript{2} score of greater than, or equal to two recorded before 1 April 2015, they will be included in the denominator.

\textsuperscript{14} NICE. Patient decision aid. June 2014. \url{http://pathways.nice.org.uk/pathways/atrial-fibrillation}
Secondary prevention of coronary heart disease (CHD)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Records</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD001. The contractor establishes and maintains a register of patients with coronary heart disease</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Ongoing management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHD002. The percentage of patients with coronary heart disease in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less</td>
<td>17</td>
<td>53–93%</td>
</tr>
<tr>
<td>CHD005. The percentage of patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken</td>
<td>7</td>
<td>56–96%</td>
</tr>
<tr>
<td>CHD007. The percentage of patients with coronary heart disease who have had influenza immunisation in the preceding 1 August to 31 March</td>
<td>7</td>
<td>56–96%</td>
</tr>
</tbody>
</table>

CHD – rationale for inclusion of indicator set

CHD is the single most common cause of premature death in the UK. The research evidence relating to the management of CHD is well established and if implemented can reduce the risk of death from CHD and improve the quality of life for patients. This indicator set focuses on the management of patients with established CHD consistent with clinical priorities.

**CHD indicator 001 (NICE 2015 menu ID: NM86)**

The contractor establishes and maintains a register of patients with coronary heart disease

**CHD 001.1 Rationale**

The register includes all patients who have had coronary artery revascularisation procedures, such as coronary artery bypass grafting (CABG). Patients with Cardiac Syndrome X are not included on the CHD register.

Contactors should record those with a past history of myocardial infarction (MI) as well as those with a history of CHD.

**CHD 001.2 Reporting and verification**

See indicator wording for requirement criteria.
CHD indicator 002 (NICE 2015 menu ID: NM88)

The percentage of patients with coronary heart disease in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less

CHD 002.1 Rationale

This indicator measures the intermediate health outcome of a blood pressure of 150/90 mmHg or less in patients with hypertension and CHD. Its intent is to promote the secondary prevention of cardiovascular disease (CVD) through satisfactory blood pressure control. This intermediate outcome can be achieved through lifestyle advice and the use of drug therapy.

The NICE clinical guideline on hypertension\(^\text{15}\) sets blood pressure thresholds for the initiation of drug treatment of hypertension and these are outlined in the hypertension indicator set. To summarise, patients with CHD and stage one hypertension are recommended drug therapy for hypertension.

The NICE clinical guideline on hypertension recommends a target blood pressure below 140/90 mmHg in patients aged 79 or under with treated hypertension and a clinic blood pressure below 150/90 mmHg in patients aged 80 or over, with treated hypertension. For the purpose of QOF, an audit standard of 150/90 mmHg has been adopted for this indicator.

A reduction of 5–6 mmHg in blood pressure sustained over five years achieved a relative reduction in stroke of 42 per cent and CHD of 14 per cent.

CHD 002.2 Reporting and verification

See indicator wording for requirement criteria.

CHD indicator 005 (NICE 2015 menu ID: NM88)

The percentage of patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken

CHD 005.1 Rationale

Both NICE\(^\text{16, 17}\) and SIGN\(^\text{18, 19}\) clinical guidelines recommend that aspirin (75–150 mg per day) is given routinely and continued for life in all patients with CHD unless there is a contra-indication. Clopidogrel (75 mg/day) is an effective alternative in patients with contra-indications to aspirin, or who are intolerant of aspirin.

CHD 005.2 Reporting and verification

See indicator wording for requirement criteria.

---


CHD indicator 007 (NICE 2015 menu ID: NM87)

The percentage of patients with coronary heart disease who have had influenza immunisation in the preceding 1 August to 31 March

CHD 007.1 Rationale

This is a current recommendation from the Chief Medical Officer (CMO) and the Joint Committee on Vaccination and Immunisation (JCVI).

Further information

CHD 007.2 Reporting and verification

See indicator wording for requirement criteria.
## Heart failure (HF)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HF001. The contractor establishes and maintains a register of patients with heart failure</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td><strong>Initial diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HF002. The percentage of patients with a diagnosis of heart failure (diagnosed on or after 1 April 2006) which has been confirmed by an echocardiogram or by specialist assessment 3 months before or 12 months after entering on to the register</td>
<td>6</td>
<td>50–90%</td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HF003. In those patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, the percentage of patients who are currently treated with an ACE-I or ARB</td>
<td>10</td>
<td>60–100%</td>
</tr>
<tr>
<td>HF004. In those patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction who are currently treated with an ACE-I or ARB, the percentage of patients who are additionally currently treated with a beta-blocker licensed for heart failure</td>
<td>9</td>
<td>40–65%</td>
</tr>
</tbody>
</table>

**HF – rationale for inclusion of indicator set**

HF represents the only major cardiovascular disease with increasing prevalence and is responsible for dramatic impairment of quality of life, carries a poor prognosis for patients and is very costly for the NHS to treat (second only to stroke). This indicator set refers to all patients with HF unless specified otherwise.

**HF indicator 001**

The contractor establishes and maintains a register of patients with heart failure

**HF 001.1 Rationale**

All patients with a diagnosis of HF, are included on the register.

**HF 001.2 Reporting and verification**

See indicator wording for requirement criteria.
There are two disease registers used for the purpose of calculating APDF for the HF indicators:

- a register of patients with HF is used to calculate APDF for HF001 and HF002.
- a register of patients with HF due to left ventricular systolic dysfunction (LVSD) is used to calculate APDF for HF003 and HF004.

Register 1. is defined in indicator HF001. Register 2. is a sub-set of register 1. and is composed of patients with a diagnostic code for LVSD as well as HF.

**HF indicator 002 (NICE 2015 menu ID: NM116)**

The percentage of patients with a diagnosis of heart failure (diagnosed on or after 1 April 2006) which has been confirmed by an echocardiogram or by specialist assessment 3 months before or 12 months after entering on to the register.

**HF 002.1 Rationale**

This indicator requires that all patients with suspected HF are investigated and this is expected to involve, as a minimum, further specialist investigation (such as echocardiography) and often specialist opinion. Serum natriuretic peptides can be used to determine whether patients with clinically suspected HF need a referral for echocardiography and their use is recommended as below. Specialists may include GPs identified by NHS England as having a special interest in HF. Many HF patients will be diagnosed following specialist referral or during hospital admission and some will also have their diagnosis confirmed by tests such as cardiac scintography or angiography rather than echocardiography.

Current NICE guidance recommends that patients with suspected HF receive both echocardiography and specialist assessment. The guidance also recommends that serum natriuretic peptides are measured in patients with suspected HF without previous MI. Patients with suspected HF who have had a previous MI or who have very high levels of serum natriuretic peptide are considered to require urgent referral due to their poor prognosis. The SIGN clinical guideline on the management of chronic HF recommends that echocardiography is performed in patients with suspected HF who have either a raised serum natriuretic peptide or abnormal electrocardiograph result to confirm the diagnosis and establish the underlying cause.

**HF 002.2 Reporting and verification**

See indicator wording for requirement criteria.

---

**HF indicator 003 (NICE 2015 menu ID: NM89)**

In those patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, the percentage of patients who are currently treated with an ACE-I or ARB

**HF 003.1 Rationale**

There is strong clinical and cost-effectiveness evidence to support the use of ACE-I in all patients with HF with LVSD. ACE-I improve symptoms, reduce the hospitalisation rate and improve the survival rate. This is applicable in all age groups. ARBs are also effective in the treatment of patients with HF due to LVSD, but may only be used in patients intolerant of ACE-I.

It is possible to have a diagnosis of LVSD without HF, for example, asymptomatic people who might be identified coincidently but who are at high risk of developing subsequent HF. In such cases, ACE-I’s delay the onset of symptomatic HF, reduce cardiovascular events and improve long-term survival. This indicator only applies to patients with HF and therefore excludes this other group of patients who are nevertheless to be considered for treatment with ACE-I.

NICE clinical guideline CG108 and SIGN clinical guideline 95 recommend that ACE-I is used as first-line therapy in all patients with HF due to LVSD and that ARBs are used only in patients who are intolerant of ACE-I.

**HF 003.2 Reporting and verification**

See indicator wording for requirement criteria.

**HF indicator 004 (NICE 2015 menu ID: NM90)**

In those patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction who are currently treated with an ACE-I or ARB, the percentage of patients who are additionally currently treated with a beta-blocker licensed for heart failure

**HF 004.1 Rationale**

The evidence base for treating HF due to LVSD with beta blockers is at least as strong as the evidence base guiding the HF004 indicator on ACE-I (level 1a), with a 34 per cent reduction in major endpoints of beta-blockers on top of ACE-I compared to placebo and is a standard recommendation in all HF guidelines including NICE. The belief that beta-blockers are contraindicated in HF was disproved, at least for the licensed beta-blockers, in the late 1990s and in some countries (especially in Scandinavia) beta-blockers have never been contraindicated in HF. Furthermore, there are no data to suggest excess risk in the elderly (SENIORS with nebivolol only randomised patients aged over 70 with significant benefits and no safety signal) and there are no contraindications for use in patients with COPD.

However, despite the evidence above, initiating beta-blockers in HF, or switching from one not licensed for HF, is more difficult because of the need to titrate from low doses and small increments over repeated visits. Patients also often suffer a temporary deterioration in symptoms with beta-blocker initiation which needs monitoring.
The British National Formulary (BNF) states that “the beta-blockers bisoprolol and carvedilol are of value in any grade of stable HF and LVSD; nebivolol is licensed for stable mild to moderate HF in patients aged over 70, beta-blocker treatment should be initiated at a very low dose and titrated very slowly over a period of weeks or months by those experienced in the management of HF. Symptoms may deteriorate initially, calling for adjustment of concomitant therapy”\textsuperscript{23}.

NICE guideline CG108 and SIGN clinical guideline 95 recommend that beta-blockers licensed for HF are used as first-line therapy in all patients with HF due to LVSD. CG108 recommends that beta-blockers are used in patients with defined co-morbidities such as older adults and those with peripheral vascular disease (PVD), erectile dysfunction (ED), DM, interstitial pulmonary disease and COPD without reversibility. The only co-morbidities with a clear contra-indication to beta-blocker use are those with asthma and reversible airways obstruction (these groups were excluded from clinical trials).

Contractors are advised that patients already prescribed an unlicensed beta-blocker prior to diagnosis of HF due to LVSD do not have their drug therapy changed to meet the criteria of this indicator. Those patients already prescribed an unlicensed beta-blocker will be excluded.

**HF 004.2 Reporting and verification**

See indicator wording for requirement criteria.

Patients already prescribed a beta-blocker unlicensed for heart failure will be excluded from this indicator.

\textsuperscript{23} BNF. \url{http://www.evidence.nhs.uk/formulary/bnf/current}
Hypertension (HYP)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYP001. The contractor establishes and maintains a register of patients</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>with established hypertension</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HYP006. The percentage of patients with hypertension in whom the last</td>
<td>20</td>
<td>45–80%</td>
</tr>
<tr>
<td>blood pressure reading (measured in the preceding 12 months) is 150/90</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mmHg or less</td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>NICE 2015 menu ID: NM91</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**HYP – rationale for inclusion of indicator set**

Hypertension is a common medical condition which is largely managed in primary care and represents a significant workload for GPs and the primary care team. Trials of anti-hypertensive treatment have confirmed a significant reduction in the incidence of stroke and CHD in patients with treated hypertension.

**HYP indicator 001**

The contractor establishes and maintains a register of patients with established hypertension

**HYP 001.1 Rationale**

A number of patients may be wrongly coded in this group, for example patients who have had one-off high blood pressure readings or women who have been hypertensive in pregnancy.

The NICE clinical guideline on hypertension\(^{24}\) uses the following definitions:

**Stage 1 hypertension**

Clinic blood pressure is 140/90 mmHg or higher and subsequent ambulatory blood pressure monitoring (ABPM) daytime average or home blood pressure monitoring (HBPM) average blood pressure is 135/85 mmHg or higher.

**Stage 2 hypertension**

Clinic blood pressure is 160/100 mmHg or higher and subsequent ABPM daytime average or HBPM average blood pressure is 150/95 mmHg or higher.

**Severe hypertension**

Clinic systolic blood pressure is 180 mmHg or higher or clinic diastolic blood pressure is 110 mmHg or higher.

Elevated blood pressure readings of greater than 140/90 mmHg on three separate occasions have generally been used to confirm sustained high blood pressure.

---

\(^{24}\) NICE CG127. Hypertension in adults: diagnosis and management. 2011.  
[https://www.nice.org.uk/guidance/CG127](https://www.nice.org.uk/guidance/CG127)
However, the 2011 updated NICE clinical guideline on hypertension now recommends the use of ABPM to confirm the diagnosis of hypertension, particularly if a clinic blood pressure reading is 140/90 mmHg or higher.

The use of ABPM to confirm the diagnosis of hypertension is a change in practice and may take time to be integrated into routine clinical practice.

For patients aged 39 or under with stage 1 hypertension and no evidence of target organ damage, CVD, renal disease or diabetes, NICE recommend that practitioners consider seeking specialist evaluation of secondary causes of hypertension and a more detailed assessment of potential target organ damage. This is because 10-year cardiovascular risk assessments can underestimate the lifetime risk of cardiovascular events in these patients.

Further information

[https://www.nice.org.uk/guidance/PH25](https://www.nice.org.uk/guidance/PH25)

HYP 001.2 Reporting and verification

See indicator wording for requirement criteria.

The contractor may be required by commissioners to discuss their plans for ensuring that new diagnoses are confirmed using ABPM or HBPM as appropriate.

**HYP indicator 006 (NICE 2015 menu ID: NM91)**

The percentage of patients with hypertension in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less

**HYP006.1 Rationale**

This indicator measures the intermediate health outcome of a blood pressure of 150/90 mmHg or less in patients with hypertension. Its intent is to promote the primary and secondary prevention of CVD through satisfactory blood pressure control. This intermediate outcome can be achieved through lifestyle advice and the use of drug therapy.

The NICE clinical guideline on hypertension recommends drug therapy in patients who are aged 79 or under with stage 1 hypertension who have one or more of the following:

- target organ damage
- established CVD
- renal disease
- diabetes mellitus
- a 10-year CVD risk equivalent to 20 per cent or greater.

The NICE guideline recommends anti-hypertensive drug treatment for patients of any age with stage 2 hypertension.

The guideline recommends that a referral for specialist evaluation of secondary causes of hypertension and a more detailed assessment of potential target organ damage is considered for patients aged 39 or under with stage 1 hypertension and
no evidence of target organ damage, CVD, renal disease or diabetes. This is because 10-year cardiovascular risk assessments can underestimate the lifetime risk of cardiovascular events in these patients.

The guideline also recommends that patients with hypertension have their care reviewed annually to monitor blood pressure, provide support and discuss lifestyle, symptoms and medication. However, the frequency of follow-up depends on factors such as the severity of hypertension, variability of blood pressure, complexity of the treatment regime, patient compliance and the need for non-pharmacological advice.

For the purpose of QOF, a measurement of 150/90 mmHg has been adopted for this indicator.

Further information


**HYP006.2 Reporting and verification**

See indicator wording for requirement criteria.
Peripheral arterial disease (PAD)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAD001. The contractor establishes and maintains a register of patients with peripheral arterial disease <em>NICE 2011 menu ID: NM32</em></td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PAD002. The percentage of patients with peripheral arterial disease in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less <em>NICE 2011 menu ID: NM34</em></td>
<td>2</td>
<td>40–90%</td>
</tr>
<tr>
<td>PAD004. The percentage of patients with peripheral arterial disease with a record in the preceding 12 months that aspirin or an alternative anti-platelet is being taken <em>NICE 2011 menu ID: NM33</em></td>
<td>2</td>
<td>40–90%</td>
</tr>
</tbody>
</table>

**PAD – rationale for inclusion of indicator set**

PAD is one of the three main categories of CVD and patients with PAD, including those who are asymptomatic, have an increased risk of mortality from CVD due to MI and stroke. The relative risks of all-cause mortality are two to three times that of age and sex matched to groups without PAD.

Treatment of PAD focuses on cardiovascular risk factor management. Smoking is a very important risk factor for PAD and management of PAD includes smoking cessation (see smoking indicator set). Other established risk factors are high blood pressure and diabetes. This would mean that patients with PAD and high blood pressure would also be included in the hypertension indicator set and patients with diabetes and PAD would also be included in the diabetes indicator set.

The intent of the PAD indicators is to improve the identification and management of PAD and ensure all patients, including those without established risk factors already covered in QOF, are managed for their cardiovascular risk.

Further information

NICE clinical guideline CG147. Lower limb PAD. 2012. [https://www.nice.org.uk/guidance/cg147](https://www.nice.org.uk/guidance/cg147)

**PAD indicator 001 (NICE 2011 menu ID: NM32)**

The contractor establishes and maintains a register of patients with peripheral arterial disease
PAD 001.1 Rationale

Patients with PAD may have symptoms, but can also be asymptomatic. About 20 per cent of patients aged 60 or over have PAD, although only a quarter of these patients have symptoms. Symptoms become severe and progressive in approximately 20 per cent of patients with symptomatic PAD.

Reduced ankle brachial pressure index (ABPI) is an independent predictor of cardiac and cerebrovascular morbidity and mortality and may help to identify patients who would benefit from secondary prevention.

The SIGN clinical guideline on the diagnosis and management of PAD\textsuperscript{25} states that a resting ABPI of 0.9 or under has been shown in several clinical studies to be up to 95 per cent sensitive in detecting angiogram positive disease and around 99 per cent specific in identifying supposedly healthy subjects. The guideline also states that there is no strict definition of what constitutes a normal ABPI. In practice, an ABPI of below 0.9 is considered to be abnormal. The ABPI of patients with intermittent claudication typically lies between 0.5 and 0.9. Imaging may be appropriate to exclude PAD when there is a discrepancy between clinical presentation and ABPI.

PAD 001.2 Reporting and verification

See indicator wording for requirement criteria.

PAD indicator 002 (NICE 2011 menu ID: NM34)

The percentage of patients with peripheral arterial disease in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less

PAD 002.1 Rationale

Most cases of PAD are managed in primary care. The focus of treatment is on the cardiovascular complications of atherosclerosis (managing cardiovascular risk factors such as high blood pressure). NICE guidance\textsuperscript{26} highlights that these patients have poor hypertension control, use low levels of statin and anti-platelet therapy and receive low levels of smoking cessation advice. This indicator addresses the issue of blood pressure control.

SIGN clinical guideline 89 recommends that hypertensive patients with PAD receive treatment to reduce their blood pressure. The guideline developers noted that treatment of PAD has often been considered difficult because of concerns that anti-hypertensive drugs, especially beta-blockers, may have adverse effects on PAD (for example, possible drug-induced peripheral vasoconstriction leading to further ischaemia in the leg). The developers did not find any strong evidence to suggest that beta-blockers should not be used in the presence of PAD, although no study was sufficiently large to demonstrate an absence of adverse effects with certainty.

Recommendation 2.6 in the guideline does not specify a target blood pressure in patients with PAD. However, the guideline developers considered that 140/90 mmHg

\textsuperscript{25} SIGN clinical guideline 89. Diagnosis and management of PAD. 2006. http://www.sign.ac.uk/guidelines/fulltext/89/index.html

\textsuperscript{26} NICE CG147. PAD. 2014. https://www.nice.org.uk/guidance/CG147
is a desirable upper limit and that around one third to one half of patients with PAD would be considered hypertensive above this level.

The NICE guideline on hypertension sets blood pressure thresholds for the initiation of drug treatment of hypertension and these are outlined within the rationale for the hypertension indicator set. All patients aged 79 or under with CVD and stage 1 hypertension (clinic blood pressure is 140/90 mmHg or higher and subsequent ABPM daytime average or HBPM average blood pressure is 135/85 mmHg or higher) are recommended drug therapy for hypertension.

The NICE guideline recommends a target clinic blood pressure below 140/90 mmHg in patients aged 79 or under with treated hypertension and a clinic blood pressure below 150/90 mmHg in patients aged 80 or over with treated hypertension.

For the purpose of QOF, a measurement of 150/90 mmHg has been adopted for this indicator.

Health economic modelling of PAD and the costs and consequences of treating high blood pressure over a patient's lifetime suggests that this treatment is a cost-effective use of NHS resources.

**PAD 002.2 Reporting and verification**

See indicator wording for requirement criteria.

**PAD indicator 004 (NICE 2011 menu ID: NM33)**

The percentage of patients with peripheral arterial disease with a record in the preceding 12 months that aspirin or an alternative anti-platelet is being taken

**PAD 004.1 Rationale**

Most cases of PAD are managed in primary care. The focus of management is on the secondary prevention of CVD. It is important to reduce the cardiovascular complications of atherosclerosis through appropriate cardiovascular risk factor management. NICE guidance shows that these patients have poor hypertension control, use low levels of statin and anti-platelet therapy and receive low levels of smoking cessation advice. This indicator addresses the issue of prescribing anti-platelet therapy.

The SIGN clinical guideline on PAD states that anti-platelet therapy is recommended for patients with symptomatic PAD.

NICE guidance highlights studies that show a 23 per cent reduction in serious vascular events with PAD in those who were treated with anti-platelet drugs. When comparing the effects of different anti-platelet drugs, no evidence of statistically significant differences between anti-platelets was found.

Further information

NICE clinical guideline CG147. Lower limb PAD: diagnosis and management. 2012. [www.nice.org.uk/guidance/CG147](http://www.nice.org.uk/guidance/CG147)

---

PAD 004.2 Reporting and verification

See indicator wording for requirement criteria.

Patients already prescribed an anti-coagulant will be excluded from the indicator.
 Stroke and TIA (STIA)

<table>
<thead>
<tr>
<th>Indicator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Records</td>
</tr>
<tr>
<td>STIA001. The contractor establishes and maintains a register of patients with stroke or TIA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Initial diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>STIA008. The percentage of patients with a stroke or TIA (diagnosed on or after 1 April 2014) who have a record of a referral for further investigation between 3 months before or 1 month after the date of the latest recorded stroke or the first TIA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ongoing management</th>
</tr>
</thead>
<tbody>
<tr>
<td>STIA003. The percentage of patients with a history of stroke or TIA in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less</td>
</tr>
<tr>
<td>STIA007. The percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record in the preceding 12 months that an anti-platelet agent, or an anti-coagulant is being taken</td>
</tr>
<tr>
<td>STIA009. The percentage of patients with stroke or TIA who have had influenza immunisation in the preceding 1 August to 31 March</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>45–80%</td>
</tr>
<tr>
<td>5</td>
<td>40–75%</td>
</tr>
<tr>
<td>4</td>
<td>57–97%</td>
</tr>
<tr>
<td>2</td>
<td>55–95%</td>
</tr>
</tbody>
</table>

STIA – rationale for inclusion of indicator set

Stroke is the third most common cause of death in the developed world. One quarter of stroke deaths occur under the age of 65. There is evidence that appropriate diagnosis and management can improve outcomes.

STIA indicator 001

The contractor establishes and maintains a register of patients with stroke or TIA

STIA 001.1 Rationale

For patients diagnosed prior to 1 April 2003 it is accepted that various diagnostic criteria may have been used. For this reason the presence of the diagnosis of stroke or TIA in the records will be acceptable. Generally patients with a diagnosis of transient global amnesia or vertebra-basilar insufficiency are not included in the retrospective register. However, contractors may wish to review patients previously diagnosed and if appropriate attempt to confirm the diagnosis.
It is up to the contractor to decide, on clinical grounds, when to include a patient on the register eg when a ‘dizzy spell’ becomes a TIA. Patient records coded with ‘Amaurosis fugax’, but without a code for TIA are excluded from the register.

**STIA 001.2 Reporting and verification**

See indicator wording for requirement criteria.

**STIA indicator 008 (NICE 2015 menu ID: NM92)**

The percentage of patients with a stroke or TIA (diagnosed on or after 1 April 2014) who have a record of a referral for further investigation between 3 months before or 1 month after the date of the latest recorded stroke or the first TIA

**STIA 008.1 Rationale**

Specialist investigations are often only accessible by a referral to secondary care services, therefore this indicator reflects referral activity rather than confirmation by specific scanning investigations.

Previously this indicator required that practices recorded a referral for further investigation after the last recorded stroke or TIA. From April 2014 this indicator was amended so that practices are only required to record a referral for further investigations following the first TIA or latest stroke for achievement. This is to allow for clinical discretion for referral of subsequent TIAs. However, practices are reminded that current NICE and RCP guidelines for stroke recommend that patients with suspected TIA should receive specialist assessment and investigation within a timeframe based on stroke risk. A TIA is an opportunity to prevent a stroke and therefore good practice is to refer people in line with current national clinical guidelines.

The National Audit Office (NAO) report\(^\text{28}\) notes that only a third of patients with TIA are seen in a TIA clinic. The NAO concern reflects evidence that there is a high early risk of stroke following TIA and that there is insufficient recognition of the serious nature of this diagnosis. A follow-up report by the NAO\(^\text{29}\) highlighted that there is now greater access to TIA clinics in England.

Contractors are advised that a referral should be considered for each new stroke or TIA unless specific agreement has been reached with a local specialist not to refer the patients.

**STIA 008.2 Reporting and verification**

See indicator wording for requirement criteria.

For the purpose of this indicator, the Business Rules will be looking for the latest recording of stroke or the first recorded TIA and then whether or not the referral occurred between three months before or one month after either of these dates.

---


STIA indicator 003 (NICE 2015 menu ID: NM93)

The percentage of patients with a history of stroke or TIA in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less

STIA 003.1 Rationale

This indicator measures the intermediate health outcome of a blood pressure of 150/90 mmHg or less in patients with hypertension and CHD. Its intent is to promote the secondary prevention of CVD through satisfactory blood pressure control. This intermediate outcome can be achieved through lifestyle advice and the use of drug therapy.

NICE guidance on hypertension\(^{30}\) shows a long-term difference of 5-6 mmHg in usual diastolic blood pressure (DBP) is associated with approximately 30–40 per cent less stroke over five years\(^{31}\).

The NICE clinical guideline on hypertension sets blood pressure thresholds for the initiation of drug treatment of hypertension and these are outlined in the rationale for the hypertension indicator set. To summarise, all patients aged 79 or under with CVD and stage one hypertension (clinic blood pressure is 140/90 mmHg or higher and subsequent ABPM daytime average of HBPM average blood pressure is 135/85 mmHg or higher) are recommended drug therapy for hypertension.

The NICE clinical guideline on hypertension recommends a target clinic blood pressure below 140/90 mmHg in patients aged 79 or under with treated hypertension and a clinic blood pressure below 150/90 mmHg in patients aged 80 or over, with treated hypertension.

For the purpose of QOF, an audit standard of 150/90 mmHg has been adopted.

Further information

RCP stroke guideline. 2012.
http://www.basp.ac.uk/Portals/2/Clinical%20Guidelines%20for%20Stroke%202012%20BASP%20Clinical%20Standards%20Committee%202013.pdf

STIA 003.2 Reporting and verification

See indicator wording for requirement criteria.

STIA indicator 007 (NICE 2015 menu ID: NM94)

The percentage of patients with a stroke shown to be non-haemorrhagic, or a history of TIA, who have a record in the preceding 12 months that an anti-platelet agent, or an anti-coagulant is being taken

STIA 007.1 Rationale

Long-term anti-platelet therapy reduces the risk of serious vascular events following a stroke by about a quarter. It is advised that anti-platelet therapy is prescribed for

---


\(^{31}\) Collins et al. Lancet. 1990; 335:827-38
the secondary prevention of recurrent stroke and other vascular events in patients who have sustained an ischaemic cerebrovascular event.

The BNF\textsuperscript{32} makes the following recommendations:

"Following a TIA, long-term treatment with modified-release dipyridamole 200 mg twice daily in combination with aspirin 75 mg once daily is recommended. If patients are intolerant of aspirin, or it is contra-indicated, then modified-release dipyridamole alone is recommended. If patients are intolerant of dipyridamole, or it is contra-indicated, then aspirin alone is recommended. Patients who are intolerant of both aspirin and dipyridamole should receive clopidogrel alone [unlicensed use].

Following an ischaemic stroke (not associated with AF – see below), long-term treatment with clopidogrel 75 mg once daily is recommended. If clopidogrel is contra-indicated or not tolerated, patients should receive modified-release dipyridamole 200 mg twice daily in combination with aspirin 75 mg once daily. If both aspirin and clopidogrel are contra-indicated or not tolerated, then modified-release dipyridamole alone is recommended. If both dipyridamole and clopidogrel are contra-indicated or not tolerated, than aspirin alone is recommended."

It is advised that patients with stroke associated with AF are reviewed for long-term treatment with warfarin or an alternative anti-coagulant (see the AF indicator set).

Further information

http://www.nice.org.uk/guidance/TA210

STIA 007.2 Reporting and verification

See indicator wording for requirement criteria.

STIA indicator 009 (NICE 2015 menu ID: NM140)

The percentage of patients with stroke or TIA who have had influenza immunisation in the preceding 1 August to 31 March

STIA 009.1 Rationale

There is evidence to suggest that flu vaccination reduces risk of stroke by more than 25 per cent\textsuperscript{33}.

This is a current recommendation from the CMO and the JCVI.

Further information


STIA 009.2 Reporting and verification

See indicator wording for requirement criteria.

\textsuperscript{32} BNF. http://bnf.org/bnf/index.htm

\textsuperscript{33} Lavallee et al. Stroke. 2002; 33: 513-518; Nichol et al. NEJM. 2003; 1322-32
# Diabetes mellitus (DM)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DM017. The contractor establishes and maintains a register of all patients aged 17 or over with diabetes mellitus, which specifies the type of diabetes where a diagnosis has been confirmed</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>NICE 2011 menu ID: NM41</td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DM002. The percentage of patients with diabetes, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less</td>
<td>8</td>
<td>53–93%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NICE 2010 menu ID: NM01</td>
</tr>
<tr>
<td>DM003. The percentage of patients with diabetes, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 140/80 mmHg or less</td>
<td>10</td>
<td>38–78%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NICE 2010 menu ID: NM02</td>
</tr>
<tr>
<td>DM004. The percentage of patients with diabetes, on the register, whose last measured total cholesterol (measured within the preceding 12 months) is 5 mmol/l or less</td>
<td>6</td>
<td>40–75%</td>
</tr>
<tr>
<td>DM006. The percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs)</td>
<td>3</td>
<td>57–97%</td>
</tr>
<tr>
<td>DM007. The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 59 mmol/mol or less in the preceding 12 months</td>
<td>17</td>
<td>35–75%</td>
</tr>
<tr>
<td>DM008. The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 64 mmol/mol or less in the preceding 12 months</td>
<td>8</td>
<td>43–83%</td>
</tr>
<tr>
<td>DM009. The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months</td>
<td>10</td>
<td>52–92%</td>
</tr>
<tr>
<td>DM012. The percentage of patients with diabetes, on the register, with a record of a foot examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes in previous ulcer) or 4) ulcerated foot within the preceding 12 months</td>
<td>4</td>
<td>50–90%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NICE 2010 menu ID: NM13</td>
</tr>
</tbody>
</table>
DM014. The percentage of patients newly diagnosed with diabetes, on the register, in the preceding 1 April to 31 March who have a record of being referred to a structured education programme within 9 months after entry on to the diabetes register

NICE 2011 menu ID: NM27

DM018. The percentage of patients with diabetes, on the register, who have had influenza immunisation in the preceding 1 August to 31 March

NICE 2015 menu ID: NM139

**DM – rationale for inclusion of indicator set**

Diabetes mellitus (DM) is one of the common endocrine diseases affecting all age groups with over one million people in the UK having the condition. Effective control and monitoring can reduce mortality and morbidity. Much of the management and monitoring of diabetic patients, particularly patients with type 2 diabetes, is undertaken by the GP and members of the primary care team.

The indicators for diabetes are based on widely recognised approaches to the care of diabetes. Detailed guidelines for health professionals are published by NICE and SIGN.

The SIGN website contains detailed evidence tables, and links to published articles. The English National Service Framework (NSF) for Diabetes website also includes details of the evidence behind a range of recommendations.

NICE has also published guidance on a number of aspects of diabetic control.

Further information


NICE guideline NG17. Type 1 diabetes in adults: diagnosis and management. 2015. [http://www.nice.org.uk/guidance/NG17](http://www.nice.org.uk/guidance/NG17)


The indicators for diabetes are generally those which would be expected to be done, or checked, in an annual review. There is no requirement for the contractor to carry out all of these items (eg retinal screening) but it is the contractor’s responsibility to ensure that they have been done.

---

DM indicator 017 (NICE 2011 menu ID: NM41)

The contractor establishes and maintains a register of all patients aged 17 or over with diabetes mellitus which specifies the type of diabetes where a diagnosis has been confirmed

DM 017.1 Rationale

A greater understanding and knowledge of the complexities of diabetes has led to increasing difficulty in accurately diagnosing or classifying the type of diabetes. In March 2011, a report by the Royal College of General Practitioners (RCGP) and NHS Diabetes was published which examined the issue of coding, classification and diagnosis of diabetes in primary care in England\(^{35}\). The summary findings of the report included an algorithm to provide guidance to healthcare professionals on making a new diagnosis of diabetes. In line with this report, the diabetes register indicator includes all types of diabetes within the proposed algorithm. Gestational diabetes will continue to be excluded from this indicator set.

If it is too early in the clinical course to diagnose the specific type of diabetes, or if the specific diagnosis is uncertain, contractors are asked to use the parent term ‘diabetes mellitus’. Contractors are expected to update these patients’ records when their specific type of diabetes is confirmed. This is advised to be within six to 12 months of the initial diagnosis of diabetes mellitus.

This indicator does not specify how the diagnosis is made and a record of the diagnosis will, for the purposes of the QOF, be regarded as sufficient evidence of diabetes. However, there are a substantial number of patients with diabetes who remain undiagnosed and also a number of patients receiving treatment with an incorrect diagnosis of diabetes. Contractors are therefore encouraged to adopt a systematic approach to the diagnosis of diabetes.

The World Health Organisation (WHO) 2006\(^{36}\) states that fasting plasma glucose ≥7.0 mmol/l (126 mg/dl) or 2-h plasma glucose ≥11.1 mmol/l (200 mg/dl) is used as criteria for diagnosing diabetes.

In 2011 an addendum to the 2006 WHO diagnostic criteria was published to allow the use of glycated haemoglobin (HbA1c) in diagnosing DM\(^{37}\). The addendum does not invalidate the 2006 recommendations on the use of plasma glucose measurements to diagnose diabetes. The WHO recommend that HbA1c can be used as a diagnostic test for diabetes, provided that stringent quality assurance tests are in place and assays are standardised to criteria aligned to the international reference values and there are no conditions present that preclude its accurate measurement. An HbA1c of 48 mmol/mol (6.5 per cent)\(^{38}\) is recommended as the cut-off point for diagnosing diabetes. A value less than 48 mmol/mol (6.5 per cent)


\(^{38}\) HbA1c should now be reported to the International Federation of Clinical Chemistry (IFCC) units of mmol/mol rather than the Diabetes Control and Complications Trial (DCCT) percentage.
does not exclude diabetes diagnosed using glucose tests. The WHO expert group concluded that there is currently insufficient evidence to make any formal recommendation on the interpretation of HbA1c levels below 48 mmol/mol (6.5 per cent).

The use of HbA1c for diagnosing diabetes can avoid the problem of day-to-day variability of glucose values and importantly it avoids the need for the patient to make preceding dietary preparations (such as fasting or consuming a glucose drink).

The WHO also recommends that the diagnosis of diabetes in an asymptomatic patient is not made on the basis of a single abnormal plasma glucose or HbA1c value. At least one additional HbA1c or plasma glucose test result with a value in the diabetic range is required, either fasting, from a random (casual) sample, or from an oral glucose tolerance test (OGTT).

From April 2014 the Business Rules included a READ code for “diabetes in remission”. Successful management of diabetes with lifestyle, medication, pancreatic or islet cell transplant and/or bariatric surgery may result in glucose levels falling below those diagnostic of diabetes. However these people may still experience the macrovascular and microvascular complications of diabetes and therefore need continued monitoring. Experts from the diabetes classification working group have endorsed the use of this code for people where treatment has normalised hyperglycaemia but still require continued monitoring.

Practices may wish to review their patient records and re-code patients previously coded as “diabetes resolved” as “diabetes in remission” if they still require monitoring for the reasons outlined above. The use of “diabetes resolved” continues to be appropriate for example in cases of misdiagnosis.

**DM 017.2 Reporting and verification**

See indicator wording for requirement criteria.

Verification – Commissioners may require randomly selecting a number of patient records of patients coded with the parent term ‘diabetes mellitus’ and requesting information about how long the specific diagnosis has been unknown.

Commissioners may require contractors to demonstrate that they have processes in place to ensure that patient records are updated once a specific diagnosis has been made. Good practice is that this occurs within six to 12 months of the initial diagnosis.

**DM indicator 002 (NICE 2010 menu ID: NM01)**

The percentage of patients with diabetes, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less

**DM 002.1 Rationale**

Blood pressure lowering in patients with diabetes reduces the risk of macrovascular and microvascular disease.
DM003 sets a target of 140/80 mmHg as per the target recommended by NICE while the target of 150/90 mmHg has been set for those patients who cannot manage this, such as those with retinopathy, micro-albuminuria or cerebrovascular disease.

Setting a blood pressure target at a higher level, but expecting most patients to have blood pressure below this, is intended to encourage practitioners to address the needs of the minority of patients whose blood pressure is hard to control and will avoid the possibility of perverse incentives to focus efforts away from those at highest absolute risk.

**DM 002.2 Reporting and verification**

See indicator wording for requirement criteria.

**DM indicator 003 (NICE 2010 menu ID: NM02)**

The percentage of patients with diabetes, on the register, in whom the last blood pressure reading (measured in the preceding 12 months) is 140/80 mmHg or less

**DM 003.1 Rationale**

Blood pressure lowering in patients with diabetes reduces the risk of macrovascular and microvascular disease.

The target of 140/80 mmHg has been set as per the target recommended by NICE.

**DM 003.2 Reporting and verification**

See indicator wording for requirement criteria.

**DM indicator 004**

The percentage of patients with diabetes, on the register, whose last measured total cholesterol (measured within the preceding 12 months) is 5 mmol/l or less

**DM 004.1 Rationale**

It is advised that statin therapy to reduce cholesterol is initiated and titrated as necessary to reduce total cholesterol to less than 5 mmol/l. There is ongoing debate concerning the intervention levels of serum cholesterol in diabetic patients who do not apparently have CVD.

The NICE NG28 recommends initiating lipid lowering therapy in all patients with type 2 diabetes aged over 40 and for patients aged 39 or under recommends initiating drug therapy in patients with type 2 diabetes who have a poor cardiovascular risk factor profile.

The SIGN clinical guideline on the management of diabetes recommends lipid lowering drug therapy for primary prevention in patients with type 2 diabetes aged 40 or over irrespective of baseline cholesterol. For patients with type 1 diabetes SIGN recommends lipid lowering drug therapy for patients aged 40 or over and for patients

---


aged 39 or under with both type 1 and type 2 diabetes, recommends considering lipid lowering drug therapy.

Further information

Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5,963 people with diabetes: a randomised placebo-controlled trial

Mortality from CHD in subjects with type 2 Diabetes and in non-diabetic subjects with and without Prior MI. Haffner et al


**DM 004.2 Reporting and verification**

See indicator wording for requirement criteria.

The contractor would be expected to explore fully with their CCG whether or not a suitable investigative or secondary service could be commissioned for the patient prior to deciding to except them on the basis that the services was unavailable.

**DM indicator 006 (NICE 2015 menu ID: NM95)**

The percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs)

**DM 006.1 Rationale**

The progression of renal disease in patients with diabetes is slowed by treatment with ACE-I and trial evidence suggests that these are most effective when given in the maximum dose quoted in the BNF. Although trial evidence is based largely on ACE-I, it is believed that similar benefits occur from treatment with ARBs in patients who are intolerant of ACE-I.

It is recommended that patients with a diagnosis of micro-albuminuria or proteinuria are commenced on an ACE-I or considered for treatment with ARBs.

Further information


**DM 006.2 Reporting and verification**

See indicator wording for requirement criteria.

**DM indicator 007 (NICE 2010 menu ID: NM14)**

The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 59 mmol/mol or less in the preceding 12 months

---

42 NEJM 1998; 339: 229-234
DM 007.1 Rationale

The three target levels for HbA1c (59, 64 and 75 mmol/mol) in QOF are designed to provide an incentive to improve glycaemic control across the distribution of HbA1c values. The lower level may not be achievable or appropriate for all patients. The 2009 NICE clinical guideline on the management of type 2 diabetes advises against pursuing highly intensive management to levels below 48 mmol/mol in certain patient sub-groups.

There is a near linear relationship between glycaemic control and death rate in patients with type 2 diabetes. In the EPIC Norfolk population cohort, a one per cent higher HbA1c was independently associated with 28 per cent higher risk of death, an association that extended below the diagnostic cut off for diabetes. These results suggest that, as with blood pressure and cholesterol, over the longer term at least, the lower the HbA1c the better.

NICE guidance on type 2 diabetes identifies the following key priorities for implementation to help people with type 2 diabetes achieve better glycaemic control:

- Involve adults with type 2 diabetes in decisions about their individual HbA1c target. Encourage them to achieve the target and maintain it unless any resulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life.
- In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol/mol (7.5 per cent) or higher:
  - reinforce advice about diet, lifestyle and adherence to drug treatment and support the person to aim for an HbA1c level of 53 mmol/mol (7.0 per cent) and
  - intensify drug treatment.
- Do not routinely offer self-monitoring of blood glucose levels for adults with type 2 diabetes unless:
  - the person is on insulin or
  - there is evidence of hypoglycaemic episodes or
  - the person is on oral medication that may increase their risk of hypoglycaemia while driving or operating machinery or the person is pregnant, or is planning to become pregnant - for more information, see NG3.

The NICE and SIGN clinical guidelines are consistent.

Given that there is strong evidence to support tight glycaemic control in type 1 diabetes, which is reflected in current NICE and SIGN guidelines, this indicator aims to balance risks and benefits for patients with type 2 diabetes. Younger patients with little co-morbidity are more likely to reap the benefits of tighter control, whereas less stringent goals may be more appropriate for patients with established CVD, those with a history of hypoglycaemia, or those requiring multiple medications or insulin to achieve a NICE suggested target HbA1c of 48 mmol/mol.

From 1 June 2011, HbA1c results were reported as IFCC-HbA1c mmol/mol (see table one).

Table 1. IFCC values expressed as mmol/mol

<table>
<thead>
<tr>
<th>DCCT values for HbA1c (%)</th>
<th>IFCC values for HbA1c (mmol/mol)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.0</td>
<td>20</td>
</tr>
<tr>
<td>5.0</td>
<td>31</td>
</tr>
<tr>
<td>6.0</td>
<td>42</td>
</tr>
<tr>
<td>6.5</td>
<td>48</td>
</tr>
<tr>
<td>7.0</td>
<td>53</td>
</tr>
<tr>
<td>7.5</td>
<td>59</td>
</tr>
<tr>
<td>8.0</td>
<td>64</td>
</tr>
<tr>
<td>9.0</td>
<td>75</td>
</tr>
<tr>
<td>10.0</td>
<td>86</td>
</tr>
<tr>
<td>11.0</td>
<td>97</td>
</tr>
<tr>
<td>12.0</td>
<td>108</td>
</tr>
</tbody>
</table>

DM 007.2 Reporting and verification

See indicator wording for requirement criteria.

DM indicator 008 (NICE 2015 menu ID: NM96)

The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 64 mmol/mol or less in the preceding 12 months

DM 008.1 Rationale

See DM 007.1

Auditing the proportion of patients with an HbA1c below 64 mmol/mol is designed to provide an incentive to improve glycaemic control across the range of HbA1c values.

DM 008.2 Reporting and verification

See indicator wording for requirement criteria.

DM indicator 009 (NICE 2015 menu ID: NM97)

The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is 75 mmol/mol or less in the preceding 12 months

DM 009.1 Rationale

See DM 007.1.

Auditing the proportion of patients with an HbA1c below 75 mmol/mol is designed to provide an incentive to improve glycaemic control amongst those with high levels of HbA1c who are at particular risk.

DM 009.2 Reporting and verification

See indicator wording for requirement criteria.

DM indicator 012 (NICE 2010 menu ID: NM13)

The percentage of patients with diabetes, on the register, with a record of foot
examination and risk classification: 1) low risk (normal sensation, palpable pulses), 2) increased risk (neuropathy or absent pulses), 3) high risk (neuropathy or absent pulses plus deformity or skin changes in previous ulcer) or 4) ulcerated foot within the preceding 12 months

DM 012.1 Rationale

Patients with diabetes are at high risk of foot complications. Evaluation of skin, soft tissue, musculoskeletal, vascular and neurological condition on an annual basis is important for the detection of feet at raised risk of ulceration.

The foot inspection and assessment includes:

- identifying the presence of sensory neuropathy (loss of ability to feel a monofilament, vibration or sharp touch) and/or the abnormal build-up of callus
- identifying when the arterial supply to the foot is reduced (absent foot pulses, signs of tissue ischemia or symptoms of intermittent claudication)
- identifying deformities or problems of the foot (including bony deformities, dry skin or fungal infection), which may put it at risk
- identifying other factors that may put the foot at risk (which may include reduced capacity for self-care, impaired renal function, poor glycaemic control, cardiovascular and cerebrovascular disease, or previous amputation).

The NICE guideline on diabetic foot problems advises that foot risk is classified as:

- at low current risk: normal sensation, palpable pulses
- at increased risk: neuropathy or absent pulses or other risk factor
- at high risk: neuropathy or absent pulses plus deformity or skin changes or previous ulcer
- ulcerated foot.

The practitioner carrying out the inspection and assessment is advised to:

- discuss with the patient their individual level of risk and agree plans for future surveillance
- initiate appropriate referrals for expert review of those with increased risk
- give advice on action to be taken in the event of a new ulcer/lesion arising
- give advice on the use of footwear which will reduce the risk of a new ulcer/lesion
- give advice on other aspects of foot care which will reduce the risk of a new ulcer/lesion.

For the purposes of QOF the Read codes for ‘moderate risk’ are used to record the concept of ‘increased risk’.

DM 012.2 Reporting and verification

See indicator wording for requirement criteria.

---

DM indicator 014 (NICE 2011 menu ID: NM27)

The percentage of patients newly diagnosed with diabetes, on the register, in the preceding 1 April to 31 March who have a record of being referred to a structured education programme within 9 months after entry on to the diabetes register

DM 014.1 Rationale

Diabetes is a progressive long-term medical condition that is predominantly managed by the person with the diabetes and/or their carer as part of their daily life. Accordingly, understanding of diabetes, informed choice of management options and the acquisition of relevant skills for successful self-management play an important role in achieving optimal outcomes. These needs are not always fulfilled by conventional clinical consultations. Structured educational (SE) programmes have been designed not only to improve people’s knowledge and skills, but also to help motivate and sustain people with both type 1 and type 2 diabetes in taking control of their condition and in delivering effective self-management. The indicator requires that SE is offered (preferably through a group education programme) to every person with diabetes and/or their carer from the time of diagnosis, with annual reinforcement and review. An alternative education programme of equal standard may be offered to people unable or unwilling to participate in group education sessions.

The NICE clinical guideline on type 2 diabetes\(^\text{45}\) considered SE models for diabetes to be both clinically and cost-effective. There are a number of SE programmes available for diabetes. Some programmes will be more suitable for type 1 diabetes and others for type 2 diabetes.

The NICE quality standard for diabetes in adults\(^\text{46}\) is based on NICE clinical guidelines for diabetes\(^\text{47}\). The NICE quality statement on SE states that ‘People with diabetes and/or their carers receive a structured educational programme that fulfils the nationally agreed criteria from the time of diagnosis, with annual review and access to ongoing education’.

NICE QS10 states that a patient educational programme meets five key criteria laid down by the DH and the Diabetes UK Patient Education Working Group:

1. Any programme should be evidence-based and suit the needs of the individual. The programme should have specific aims and learning objectives. It should support the learner plus his or her family and carers in developing attitudes, beliefs, knowledge and skills to self-manage diabetes.
2. The programme should have a structured curriculum that is theory-driven, evidence-based and resource-effective, has supporting materials and is written down.
3. The programme should be delivered by trained educators who have an understanding of educational theory appropriate to the age and needs of the learners and who are trained and competent to deliver the principles and content of the programme.

\(^{45}\)NICE NG28. Type 2 diabetes in adults: management. 2015 www.nice.org.uk/guidance/CG87NG28


\(^{47}\)NICE NG17. Type 1 diabetes in adults: diagnosis and management. 2015. http://www.nice.org.uk/guidance/NG17
4. The programme should be quality assured and be reviewed by trained, competent, independent assessors who measure it against criteria that ensure consistency.

5. The outcomes from the programme should be regularly audited.

Some practices may be able to deliver SE programmes in-house. These programmes would need to meet the requirements outlined above.

This indicator suggests referral to a programme within nine months of entry onto the diabetes register to be appropriate for people with type 1 or type 2 diabetes. A timeframe of nine months for this indicator has been set to take into account the differing expectations for referral into SE programmes from diagnosis for people with type 1 and type 2 diabetes.

**DM 014.2 Reporting and verification**

See indicator wording for requirement criteria.

Where services are not available locally, practices would be expected to discuss this with the CCG and encourage the commissioning of the relevant services. This may take some time so practices may wish to consider whether it would be appropriate to offer the service in-house, or to services available in different CCGs or neighbouring practices etc.

**DM indicator 018 (NICE 2015 menu ID: NM139)**

The percentage of patients with diabetes, on the register, who have had influenza immunisation in the preceding 1 August to 31 March

**DM 018.1 Rationale**

This is a current recommendation from the CMO and the JCVI.

Further information


**DM 018.2 Reporting and verification**

See indicator wording for requirement criteria.
# Asthma (AST)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST001. The contractor establishes and maintains a register of patients with asthma, excluding patients with asthma who have been prescribed no asthma-related drugs in the preceding 12 months</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td><strong>Initial diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST002. The percentage of patients aged 8 or over with asthma (diagnosed on or after 1 April 2006), on the register, with measures of variability or reversibility recorded between 3 months before or any time after diagnosis <em>NICE 2015 menu ID: NM101</em></td>
<td>15</td>
<td>45–80%</td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AST003. The percentage of patients with asthma, on the register, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control using the 3 RCP questions <em>NICE 2011 menu ID: NM23</em></td>
<td>20</td>
<td>45–70%</td>
</tr>
<tr>
<td>AST004. The percentage of patients with asthma aged 14 or over and who have not attained the age of 20, on the register, in whom there is a record of smoking status in the preceding 12 months <em>NICE 2015 menu ID: NM102</em></td>
<td>6</td>
<td>45–80%</td>
</tr>
</tbody>
</table>

**AST – rationale for inclusion of indicator set**

Asthma is a common condition which responds well to appropriate management and which is principally managed in primary care.

**AST indicator 001**

The contractor establishes and maintains a register of patients with asthma, excluding patients with asthma who have been prescribed no asthma-related drugs in the preceding 12 months

**AST 001.1 Rationale**

Proactive structured review as opposed to opportunistic or unscheduled review is associated with reduced exacerbation rates and days lost from normal activity.

The diagnosis of asthma is a clinical one; there is no confirmatory diagnostic blood test, radiological investigation or histopathological investigation. In most patients, the diagnosis can be corroborated by suggestive changes in lung function tests.

One of the main difficulties in asthma is the variable and intermittent nature of asthma. Some of the symptoms of asthma are shared with diseases of other
systems. Features of an airway disorder in adults such as cough, wheeze and breathlessness should be corroborated where possible by measurement of airflow limitation and reversibility. Obstructive airways disease produces a decrease in peak expiratory flow (PEF) and forced expiratory volume in one second (FEV₁) but which persist after bronchodilators have been administered. One or both of these should be measured, but may be normal if the measurement is made between episodes of bronchospasm. If repeatedly normal in the presence of symptoms, then a diagnosis of asthma is in doubt.

A proportion of patients with COPD will also have asthma eg they have large reversibility – 400 mls or more on FEV₁ – but do not return to over 80 per cent predicted and have a significant smoking history. These patients will be recorded on both the asthma and COPD registers.

**Children**

A definitive diagnosis of asthma can be difficult to obtain in young children. Asthma is to be suspected in any child with wheezing, ideally heard by a health professional on auscultation and distinguished from upper airway noises.

In school children, bronchodilator responsiveness, PEF variability or tests of bronchial hyperactivity may be used to confirm the diagnosis, with the same reservations as above.

Focus the initial assessment in children suspected of having asthma on the:

- presence of key features in the history and examination
- careful consideration of alternative diagnoses.

**Further information**

SIGN clinical guideline 141. SIGN and BTS. British guideline on the management of asthma. 2014. [http://www.sign.ac.uk/guidelines/fulltext/141/index.html](http://www.sign.ac.uk/guidelines/fulltext/141/index.html)

It is well recognised that asthma is a variable condition and many patients will have periods when they have minimal symptoms. It is inappropriate to attempt to monitor symptom-free patients on no therapy or very occasional therapy.

This produces a significant challenge for the QOF. It is important that resources in primary care are targeted to patients with the greatest need – in this instance, patients who will benefit from asthma review rather than insistence that all patients with a diagnostic label of asthma are reviewed on a regular basis.

It is for this reason that the asthma register is constructed annually by searching for patients with a history of asthma, excluding those who have had no prescription for asthma-related drugs in the preceding 12 months. This indicator has been constructed in this way as most clinical computer systems will be able to identify the defined patient list.

**AST 001.2 Reporting and verification**

See indicator wording for requirement criteria.
Part of the register criteria for asthma is based on appropriate prescribing of therapies. From October 2014, the Business Rules were updated to exclude drug therapies which are licensed only for use in patients with a diagnosis of COPD as they are not licensed as a treatment for asthma.

Patients with asthma whose sole asthma medication is one of the inhalers listed above then they will no longer appear on your QOF asthma register. Patients receiving additional, appropriate asthma treatment such as short-acting bronchodilators or steroid inhalers will remain on the register. Practices may wish to review the records of any patients affected by this change to review their asthma treatment however, a change in prescribing should only be done where clinically appropriate.

**AST indicator 002**

The percentage of patients aged 8 or over with asthma (diagnosed on or after 1 April 2006), on the register, with measures of variability or reversibility recorded between 3 months before or any time after diagnosis

**AST 002.1 Rationale**

There is no single infallible test to confirm a diagnosis of asthma. On the basis of the clinical history and examination it will be possible to decide if the probability of asthma is high, intermediate or low and the aim of investigations is to demonstrate objectively the presence of variability in order to support or reject the diagnosis. There are Read codes for ‘suspected asthma’ and ‘suspected respiratory condition’ which may be used whilst investigations are undertaken and the diagnosis confirmed.

Further information about the diagnosis of asthma is provided in the BTS-SIGN asthma guideline. It is crucial that diagnostic spirometry is performed to published quality standards.

**Asthma history**

The diagnosis of asthma is suspected when a patient presents a history of variable wheeze, chest tightness, shortness of breath or cough, commonly triggered by viral infections and/or allergy and/or exercise. A personal or family history of atopy (including positive skin prick testing) increases the probability of asthma.

Practices may wish to confirm a diagnosis of asthma for those patients who were diagnosed with asthma in previous QOF years before they were eight years of age. Once the patient turns eight it is acceptable to re-examine the diagnosis using tests of variability or reversibility. In those patients who are not receiving long-term anti-

---

http://www.brit-thoracic.org.uk and http://www.sign.ac.uk

http://dx.doi.org/10.4104/pcrj.2009.00054
inflammatory therapy they should be treated as a new presenting case and the diagnosis re-evaluated.

If asthma is probable

In symptomatic patients airway obstruction may be demonstrated by spirometry (FEV₁/FVC ratio <0.7) and (if available) nitric oxide can be used to measure airway inflammation.

Variability of symptoms and/or lung function may be demonstrated in a reversibility test or may occur spontaneously over time in response to triggers or to treatment; demonstration of variability supports the diagnosis of asthma and may be conveniently achieved in primary care in a number of ways:

- Spirometry may be used to demonstrate reversibility in symptomatic patients with demonstrated airflow obstruction. A bronchodilator reversibility test can be performed with inhaled or nebulised short acting beta agonist and if the obstruction reverses then asthma is confirmed. Significant reversibility is a change in FEV₁ >12 per cent and 200 ml (the absolute change is scaled down according to predicted FEV₁ in children). Increases of >400 mls are strongly suggestive of asthma. Lower levels of bronchodilator reversibility may be demonstrated in some patients with COPD⁵⁰. Normal spirometry, however, does not exclude asthma; indeed the variable nature of asthma means that many of the milder patients seen in primary care will be asymptomatic at the time of the lung function test and will have completely normal lung function with no reversibility at the time of testing.

- Variability of PEF. This may be demonstrated by monitoring diurnal, or day to day variation (recorded twice a day for two weeks using the same peak flow meter) and/or demonstrating an increase after therapy (15 minutes after short-acting bronchodilator, after six weeks of inhaled steroids, or up to two weeks after oral steroid treatment) and/or after exposure to triggers (such as exercise, laughter, or allergens). Significant variability is a change of 20 per cent and >60 l/min (the absolute change is scaled down in children to 20 per cent of predicted PEF). PEF are effort dependent and patients need to be taught the correct technique.

- Variability in objective measures of asthma symptom scores (eg RCP questions⁵¹, ACQ⁵², ACT questionnaire⁵³, or GINA Control Tool⁵⁴). Symptom scores may be particularly useful in patients unable to undertake accurate serial measures of lung function and to aid clinical interpretation of lung function (eg normal lung function in a symptomatic patient might suggest an alternative

⁵² Juniper EF, O’Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Euro Respiratory Journal. 1999;14:902-7
cause for the symptoms).

A trial of treatment, with repeated lung function measurements and/or symptoms scores over time will demonstrate objective improvement of symptoms and lung function in people with asthma, thereby confirming the diagnosis. In children it is particularly important to reduce and stop treatment to exclude spontaneous improvement\(^{55}\).

**If the probability of asthma is intermediate**

Spirometry is the key investigation for distinguishing obstructive and restrictive respiratory conditions and will determine subsequent investigations\(^{56}\). More specialist assessment may be required in those in whom the diagnosis is still unclear, which may include assessment of airway inflammation (eg nitric oxide measurement), bronchial hyper-responsiveness testing and consideration of alternative diagnoses. It is recommended that children with combined food allergy and asthma and any patient with late onset asthma where there is a suspicion of an occupational cause are referred for specialist assessment.

**If another diagnosis is more likely**

If an alternative diagnosis is suspected, investigation and management are to follow guidelines for that condition.

**Co-morbidity: asthma and COPD**

A proportion of patients with asthma will have both asthma and COPD eg they have airway obstruction that does not reverse to normal but also have substantial reversibility\(^{57}\).

**AST 002.2 reporting and verification**

See indicator wording for requirement criteria.

**AST indicator 003 (NICE 2011 menu ID: NM23)**

The percentage of patients with asthma, on the register, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control using the 3 RCP questions

**AST 003.1 Rationale**

Structured care has been shown to produce benefits for patients with asthma. The reckoning of morbidity, PEF levels, inhaler technique and current treatment and the promotion of self-management skills are common themes of good structured care.

---

\(^{55}\) Brand P. New guidelines on recurrent wheeze in preschool children: implications for primary care. PCRJ 2008; 17:243-245


The BTS/SIGN clinical guideline\textsuperscript{58} proposes a structured system for recording inhaler technique, morbidity, PEF levels, current treatment and asthma action plans.

The clinical guideline recommends the use of standard questions for the monitoring of asthma. Proactive structured review, rather than opportunistic or unscheduled review, is associated with reduced exacerbation rate and fewer days lost from normal activity.

The QOF now explicitly requires that the following RCP questions\textsuperscript{59} are used as an effective way of assessing symptoms:

In the last month:

- have you had difficulty sleeping because of your asthma symptoms (including cough)?
- have you had your usual asthma symptoms during the day (cough, wheeze, chest tightness or breathlessness)?
- has your asthma interfered with your usual activities (for example, housework, work/school, etc.)?

The questions are to be asked at the same time and as part of the review. A response of ‘no’ to all questions is consistent with well-controlled asthma\textsuperscript{60}.

If the asthma appears to be uncontrolled, the following are to be managed appropriately before increasing asthma therapy:

- smoking behaviour (because smoking interferes with asthma control)
- poor inhaler technique
- inadequate adherence to regular preventative asthma therapy
- rhinitis.

There is increasing evidence to support personalised asthma action plans in adults with persistent asthma. Contractors may wish to follow the advice of the BTS/SIGN guideline and offer a personalised asthma action plan to patients.

Peak flow is a valuable guide to the status of a patient’s asthma, especially during exacerbations. However, it is much more useful if there is a record of their best peak flow (that is, peak flow when they are well). Many guidelines for exacerbations are based on the ratio of current to best peak flows. For patients aged 19 or over no particular time limit is needed for measuring best peak flow. However in view of the reduction in peak flow with age, it is recommended that the measurement be updated every few years. For patients aged 18 or under the peak flow will be changing; therefore it is recommended that the best peak flow be re-assessed annually. Inhaler technique is to be reviewed regularly. The BTS/SIGN clinical guideline emphasises the importance of assessing ability to use inhalers before prescribing and regularly reviewing technique, especially if control is inadequate.

\textsuperscript{58} BTS/SIGN clinical guideline 141. Management of asthma. 2014. \url{http://www.sign.ac.uk/guidelines/fulltext/141/index.html}

\textsuperscript{59} RCP. Pearson MG, Bucknall CE, editors. Measuring clinical outcomes in asthma: patient focused approach.

Inhalers are to be prescribed only after patients have received training in the use of the device and have demonstrated satisfactory technique. Reassess inhaler technique as part of their structured asthma review.

During an asthma review the following takes place:

- assess symptoms (using the three RCP questions)
- measure peak flow
- assess inhaler technique face-to-face
- consider a personalised asthma plan.

If the asthma appears to be uncontrolled, follow the additional steps outlined above.

**AST 003.2 Reporting and verification**

See indicator wording for requirement criteria.

The Business Rules require that contractors code the review and the responses to the three RCP questions separately and on the same day in order to meet the requirements of this indicator.

**AST indicator 004**

The percentage of patients with asthma aged 14 or over and who have not attained the age of 20, on the register, in whom there is a record of smoking status in the preceding 12 months

**AST 004.1 Rationale**

Many young people start to smoke at an early age. It is therefore justifiable to ask about smoking on an annual basis in this age group.

Studies of smoking related to asthma are surprisingly few in number. Starting smoking as a teenager increases the risk of persisting asthma. There are very few studies that have considered the question of whether smoking affects asthma severity. One controlled cohort study suggested that exposure to passive smoke at home delayed the recovery from an acute attack. There is also epidemiological evidence that smoking is associated with poor asthma control\(^{61}\).

It is recommended that smoking cessation be encouraged as it is good for general health and may decrease asthma severity\(^{62}\).

**AST 004.2 Reporting and verification**

See indicator wording for requirement criteria.

A number of 'smoking habit' codes have been removed from the relevant code clusters from April 2014 as they cannot be used to identify if the patient is a current smoker, an ex-smoker or has never smoked. Accepted codes are available in the Business Rules\(^{63}\).

---


\(^{63}\) HSCIC. Business Rules. [http://www.hscic.gov.uk/gofesextractspecs](http://www.hscic.gov.uk/gofesextractspecs)
## Chronic obstructive pulmonary disease (COPD)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD001. The contractor establishes and maintains a register of patients with COPD</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>Initial diagnosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD002. The percentage of patients with COPD (diagnosed on or after 1 April 2011) in whom the diagnosis has been confirmed by post bronchodilator spirometry between 3 months before and 12 months after entering on to the register</td>
<td>5</td>
<td>45–80%</td>
</tr>
<tr>
<td><em>NICE 2015 menu ID: NM103</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD003. The percentage of patients with COPD who have had a review, undertaken by a healthcare professional, including an assessment of breathlessness using the Medical Research Council dyspnoea scale in the preceding 12 months</td>
<td>9</td>
<td>50–90%</td>
</tr>
<tr>
<td><em>NICE 2015 menu ID: NM104</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD004. The percentage of patients with COPD with a record of FEV\textsubscript{1} in the preceding 12 months</td>
<td>7</td>
<td>40–75%</td>
</tr>
<tr>
<td><em>NICE 2015 menu ID: NM105</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD005. The percentage of patients with COPD and Medical Research Council dyspnoea grade ≥3 at any time in the preceding 12 months, with a record of oxygen saturation value within the preceding 12 months</td>
<td>5</td>
<td>40–90%</td>
</tr>
<tr>
<td><em>NICE 2012 menu ID: NM63</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COPD007. The percentage of patients with COPD who have had influenza immunisation in the preceding 1 August to 31 March</td>
<td>6</td>
<td>57–97%</td>
</tr>
<tr>
<td><em>NICE 2015 menu ID: NM106</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### COPD – rationale for inclusion of indicator set

COPD is a common disabling condition with a high mortality. The most effective treatment is smoking cessation. Oxygen therapy has been shown to prolong life in the later stages of the disease and has also been shown to have a beneficial impact on exercise capacity and mental state. Some patients respond to inhaled steroids. Many patients respond symptomatically to inhaled beta-agonists and anti-cholinergics. Pulmonary rehabilitation has been shown to produce an improvement in quality of life.

The majority of patients with COPD are managed by GPs and members of the primary care team with onward referral to secondary care when required. This
indicator set focuses on the diagnosis and management of patients with symptomatic COPD.

**COPD indicator 001**

The contractor establishes and maintains a register of patients with COPD

**COPD 001.1 Rationale**

A diagnosis of COPD is considered in any patient who has symptoms of a persistent cough, sputum production, or dyspnoea and/or a history of exposure to risk factors for the disease. The diagnosis is confirmed by post bronchodilator spirometry.

See COPD002.1

Where patients have a long-standing diagnosis of COPD and the clinical picture is clear, it would not be essential to confirm the diagnosis by spirometry in order to enter the patient onto the register. However, where there is doubt about the diagnosis contractors may wish to carry out post bronchodilator spirometry for confirmation.

NICE clinical guideline CG101 recommended a change to the diagnostic threshold for COPD in 2010.

**Table 2. Gradation of severity of airflow obstruction**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV₁, % predicted</td>
<td>Severity of airflow obstruction</td>
<td>Post bronchodilator</td>
<td>Post bronchodilator</td>
<td>Post bronchodilator</td>
</tr>
<tr>
<td>&lt; 0.7</td>
<td>≥ 80%</td>
<td>Mild</td>
<td>Stage 1 – Mild</td>
<td>Stage 1 – Mild*</td>
</tr>
<tr>
<td>&lt; 0.7</td>
<td>50-79%</td>
<td>Mild</td>
<td>Moderate</td>
<td>Stage 2 – Moderate</td>
</tr>
<tr>
<td>&lt; 0.7</td>
<td>30-49%</td>
<td>Moderate</td>
<td>Severe</td>
<td>Stage 3 – Severe</td>
</tr>
<tr>
<td>&lt; 0.7</td>
<td>&lt; 30%</td>
<td>Severe</td>
<td>Very severe</td>
<td>Stage 4 – Very severe**</td>
</tr>
</tbody>
</table>

* Symptoms present to diagnose COPD in patients with mild airflow obstruction (see recommendation 1.1.1.1).

** Or FEV₁ (forced expiratory volume in one second) < 50 per cent with respiratory failure.

**COPD 001.2 Reporting and verification**

See indicator wording for requirement criteria.

Where patients have co-existing COPD and asthma they will be included on both disease registers. Approximately 15 per cent of patients with COPD will also have asthma.

---


COPD indicator 002 (NICE 2015 menu ID: NM103)

The percentage of patients with COPD (diagnosed on or after 1 April 2011) in whom the diagnosis has been confirmed by post bronchodilator spirometry between 3 months before and 12 months after entering on to the register.

COPD 002.1 Rationale

A diagnosis of COPD relies on clinical judgement based on a combination of history, physical examination and confirmation of the presence of airflow obstruction using spirometry.

The NICE clinical guideline on COPD provides the following definition of COPD:

- Airflow obstruction is defined as a reduced FEV₁/FVC ratio (where FEV₁ is forced expired volume in one second and FVC is forced vital capacity), such that FEV₁/FVC is < 0.7.
- If FEV₁ is greater than or equal to 80 per cent predicted normal a diagnosis of COPD would only be made in the presence of respiratory symptoms, for example breathlessness or cough.

The NICE clinical guideline requires post bronchodilator spirometry for diagnosis and gradation of severity of airways obstruction. Failure to use post bronchodilator readings has been shown to overestimate the prevalence of COPD by 25 per cent. Spirometry is to be performed after the administration of an adequate dose of an inhaled bronchodilator (eg 400 mcg salbutamol).

Prior to performing post bronchodilator spirometry, patients do not need to stop any therapy, such as long-acting bronchodilators or inhaled steroids.

Routine reversibility testing is not recommended. However, where doubt exists as to whether the diagnosis is asthma or COPD, reversibility testing may add additional information to post bronchodilator readings alone and peak flow charts are useful. It is acknowledged that COPD and asthma can co-exist and that many patients with asthma who smoke will eventually develop irreversible airways obstruction. Where asthma is present, these patients would be managed as asthma patients as well as COPD patients. This will be evidenced by a greater than 400mls response to a reversibility test and a post bronchodilator FEV₁ of less than 80 per cent of predicted normal as well as an appropriate medical history.

Patients with reversible airways obstruction will be included on the asthma register. Patients with coexisting asthma and COPD will be included on the register for both conditions.

The guideline on COPD recommends that all health professionals involved in the care of patients with COPD have access to spirometry and be competent in the interpretation of the results. Quality statement 1 (diagnosis) in the NICE quality standard for COPD in adults, states that patients with COPD have the diagnosis.

---


confirmed by post bronchodilator spirometry carried out on calibrated equipment by healthcare professionals competent in its performance and interpretation.

COPD 002.2 Reporting and verification
See indicator wording for requirement criteria.

COPD indicator 003 (NICE 2015 menu ID: NM104)
The percentage of patients with COPD who have had a review, undertaken by a healthcare professional, including an assessment of breathlessness using the Medical Research Council dyspnoea scale in the preceding 12 months

COPD 003.1 Rationale
COPD is increasingly recognised as a treatable disease with large improvements in symptoms, health status, exacerbation rates and even mortality if managed appropriately. Appropriate management is based on NICE clinical guideline CG101 and international GOLD guidelines in terms of both drug and non-drug therapy.

In making assessments of the patient’s condition as part of an annual review and when considering management changes it is essential that health care professionals are aware of:

- current lung function
- exacerbation history
- the degree of breathlessness (Medical Research Council (MRC) dyspnoea scale).

A tool such as the Clinical COPD Questionnaire68 could be used to assess current health status.

Additionally there is evidence that inhaled therapies can improve the quality of life in some patients with COPD. However, there is evidence that patients require training in inhaler technique and that such training requires reinforcement. Where a patient is prescribed an inhaled therapy their technique is to be assessed during any review.

The MRC dyspnoea scale gives a measure of breathlessness and is recommended as part of the regular review. It is available in the NICE clinical guideline on COPD, section 1.1, diagnosing COPD table one.

COPD 003.2 Reporting and verification
See indicator wording for requirement criteria.

COPD indicator 004 (NICE 2015 menu ID: NM105)
The percentage of patients with COPD with a recorded FEV₁ in the preceding 12 months

COPD 004.1 Rationale
There is a gradual deterioration in lung function in patients with COPD. This deterioration accelerates with the passage of time. There are important interventions

---

68 Clinical COPD Questionnaire. [http://www.ccq.nl/](http://www.ccq.nl/)
which can improve quality of life in patients with severe COPD. It is therefore important to monitor respiratory function in order to identify patients who might benefit from pulmonary rehabilitation or continuous oxygen therapy.

The NICE clinical guideline on COPD recommends that FEV₁ and inhaler technique are assessed at least annually for patients with mild/moderate/severe COPD (and at least twice a year for patients with very severe COPD). The purpose of regular monitoring is to identify patients with increasing severity of disease who may benefit from referral for more intensive treatments/diagnostic review.

Further information

NICE clinical guideline CG101 (table six).

Contractors should identify those patients who could benefit from long-term oxygen therapy and pulmonary rehabilitation.

These measures require specialist referral because of the need to measure arterial oxygen saturation to assess suitability for oxygen therapy and the advisability of specialist review of patients prior to starting pulmonary rehabilitation.

The long-term administration of oxygen (more than 15 hours per day) to patients with chronic respiratory failure has been shown to increase survival and improve exercise capacity. Referral for consideration for long-term oxygen therapy and/or pulmonary rehabilitation is to be made to those with appropriate training and expertise. This may include a respiratory physician, a general physician or a GP with a special interest (GPwSI) in respiratory disease. The specific clinical criteria for referral for long-term oxygen therapy and pulmonary rehabilitation are set out in NICE clinical guideline CG101.

**COPD 004.2 Reporting and verification**

See indicator wording for requirement criteria.

**COPD indicator 005 (NICE 2012 menu ID: NM63)**

The percentage of patients with COPD and Medical Research Council dyspnoea grade ≥3 at any time in the preceding 12 months, with a record of oxygen saturation value within the preceding 12 months

**COPD 005.1 Rationale**

As COPD progresses, patients often become hypoxaemic. Many patients tolerate mild hypoxaemia well, but once the resting partial pressure of oxygen in arterial blood (PaO₂) falls below 8 KPa patients begin to develop signs of right-sided HF (corpulmonale), principally peripheral oedema. The prognosis is poor and if untreated the five year survival is less than 50 per cent.

In stable COPD, patients use oxygen therapy for long periods during the day and night. Long-term oxygen therapy can improve survival in patients with COPD who have severe hypoxaemia, where PaO₂ is less than 8 KPa. It can also reduce the incidence of polycythaemia (that is, raised red cell count), reducing the progression of pulmonary hypertension and improving psychological wellbeing.
NICE clinical guideline CG101 recommends that patients with oxygen saturations of 92 per cent or lower when breathing air, be considered for oxygen therapy. Pulse oximetry (SpO2) provides an estimate of arterial oxygen saturation (SaO2) and is non-invasive.

Pulse oximetry allows practitioners to assess patients’ level of oxygen saturation to determine whether referral for clinical assessment and long-term oxygen therapy is appropriate. Pulse oximetry is a valuable screening tool for identifying patients who are appropriate for referral for long-term oxygen therapy. A normal pulse oximetry reading (SpO2 greater than 92 per cent) can reliably identify patients who do not need referral. However, pulse oximetry cannot predict which patients with an abnormal reading (SpO2 of 92 per cent or lower) have sufficiently severe hypoxaemia to require long-term oxygen therapy, therefore these patients require further assessment.

**COPD 005.2 Reporting and verification**

See indicator wording for requirement criteria.

The Business Rules require that a record that pulse oximetry has been performed AND the resulting oxygen saturation value are recorded to meet the requirements for this indicator.

**COPD indicator 007 (NICE 2015 menu ID: NM106)**

The percentage of patients with COPD who have had influenza immunisation in the preceding 1 August to 31 March

**COPD 007.1 Rationale**

This is a current recommendation from the CMO and the JCVI.

Further information


**COPD 007.2 Reporting and verification**

See indicator wording for requirement criteria.
Dementia (DEM)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Records</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEM001. The contractor establishes and maintains a register of patients diagnosed with dementia</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Ongoing management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEM004. The percentage of patients diagnosed with dementia whose care plan has been reviewed in a face-to-face review in the preceding 12 months</td>
<td>39</td>
<td>35–70%</td>
</tr>
<tr>
<td>DEM005. The percentage of patients with a new diagnosis of dementia recorded in the preceding 1 April to 31 March with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded between 12 months before or 6 months after entering on to the register</td>
<td>6</td>
<td>45–80%</td>
</tr>
</tbody>
</table>

DEM – rationale for inclusion of indicator set

Dementia is a syndrome characterised by an insidious but ultimately catastrophic progressive global deterioration in intellectual function and is a main cause of late-life disability. The prevalence of dementia increases with age and is estimated to be approximately seven per cent in those over 65. Alzheimer’s disease accounts for around 62 per cent of cases of dementia with vascular dementia accounting for around 17 per cent.\(^{69}\), \(^{70}\)

The annual incidence of dementia of the Alzheimer's type rises to 34.3/100 person years at risk in the 90 year age group; the prevalence is higher in women than in men due to the longer lifespan of women. Other types of dementia such as Lewy Body dementia and fronto-temporal dementia are relatively rare but can be very distressing. In a third of cases, dementia is associated with other psychiatric symptoms (depressive disorder, adjustment disorder, generalised anxiety disorder, alcohol related problems). A complaint of subjective memory impairment is an indicator of dementia especially where there is altered functioning in terms of activities of daily living.

---

\(^{69}\) Alzheimer’s Society. Dementia UK: update 2014.  
DEM indicator 001

The contractor establishes and maintains a register of patients diagnosed with dementia

DEM 001.1 Rationale

It is expected that the diagnosis will largely be recorded following patients being referred to secondary care with suspected dementia or as an additional diagnosis when a patient is seen in secondary care. However it is also important to include patients where it is inappropriate or not possible to refer to a secondary care provider for a diagnosis and where the GP has made a diagnosis based on their clinical judgement and knowledge of the patient.

DEM 001.2 Reporting and verification

See indicator wording for requirement criteria.

DEM indicator 004 (NICE 2015 menu ID: NM107)

The percentage of patients diagnosed with dementia whose care plan has been reviewed in a face-to-face review in the preceding 12 months

DEM 004.1 Rationale

Where a patient does not already have a care plan or an advanced care plan in place, it is expected that the practice will develop a care plan.

The face-to-face care plan or advanced care plan review focuses on support needs of the patient and their carer. In particular the review should address the following key issues:

- an appropriate physical, mental health and social review for the patient,
- a record of the patients’ wishes for the future,
- communication and co-ordination arrangements with secondary care (if applicable),
- identification of the patients’ carer(s); and

1. obtain appropriate permissions to authorise the practice to speak directly to the nominated carer(s) and provide details of support services available to the patient and their family, if applicable, the carer’s needs for information commensurate with the stage of the illness and his or her and the patient’s health and social care needs,
2. as appropriate, the carer should be included in the care plan or advanced care plan discussions,
3. if applicable, the impact of caring on the care-giver,
4. offer the carer a health check\(^\text{71}\) to address any physical and mental health impacts, including signposting to any other relevant services to support their health and wellbeing.

Patients diagnosed with dementia are expected to be offered annual face-to-face

\[^{71}\text{Where the carer is registered at a different practice, the patients practice should inform the patient’s carer that they can seek advice from their own practice.}\]
appointments specifically to review their diagnosis and/or their care plan or advanced care plan. The practice will agree with the patient and their carer, what is to be covered in the review and the duration of the consultation - where appropriate, extended consultations may take up to 30 minutes. Ideally the first such appointment would be within six months of diagnosis.

A series of well-designed cohort and case control studies have demonstrated that patients with Alzheimer-type dementia do not complain of common physical symptoms, but experience them to the same degree as the general population. Patient assessments therefore include the assessment of any behavioural changes caused by:

- concurrent physical conditions (eg joint pain or inter-current infections)
- new appearance of features intrinsic to the disorder (eg wandering) and delusions or hallucinations due to the dementia or as a result of caring behaviour (eg being dressed by a carer).

Depression could also be considered as it is more common in patients with dementia than those without.

Patients and carers are to be given relevant information about the diagnosis and sources of help and support (bearing in mind issues of confidentiality). Evidence suggests that healthcare professionals can improve satisfaction for carers by acknowledging and dealing with their distress and providing more information on dementia. As the illness progresses, needs may change and the review may focus more on issues such as respite care.

There is good evidence from well-designed cohort studies and case control studies of the benefit of healthcare professionals asking about the impact of caring for a person with dementia and the effect this has on the caregiver. It is important to remember that male carers are less likely to complain spontaneously and that the impact of caring is dependent not on the severity of the cognitive impairment but on the presentation of the dementia, for example, on factors such as behaviour and affect. If the carer is not registered at the practice, but the GP is concerned about issues raised in the consultation, then with appropriate permissions they can contact the carer’s own GP for further support and treatment.

As the illness progresses and more agencies are involved, the review could additionally focus on assessing the communication between health and social care and non-statutory sectors as appropriate, to ensure that potentially complex needs are addressed. Communication and referral issues highlighted in the review need to be followed up as part of the review process.

---

72 The practice should agree with the patient the most suitable length of this for this appointment, this could be provided as two 15 minute appointments if this is more appropriate for the patient.


74 Eccles et al. BMJ 1998; 317: 802-808
Further information


NICE QS1: Dementia. https://www.nice.org.uk/guidance/qs1

NICE QS30: supporting people to live well with dementia. https://www.nice.org.uk/guidance/QS30

Forget me not dementia training. http://www.forgetmenotdementia.co.uk/


**DEM 004.2 Reporting and verification**

See indicator wording for requirement criteria.

Verification – Commissioners may require randomly selecting a number of patient records of patients in which the review has been recorded as taking place to confirm that the four key issues are recorded as having been addressed, if applicable.

**DEM indicator 005 (based on NICE 2010 menu ID: NM09)**

The percentage of patients with a new diagnosis of dementia recorded in the preceding 1 April to 31 March with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded between 12 months before or 6 months after entering on to the register

**DEM 005.1 Rationale**

There is no universal consensus on the appropriate diagnostic tests to be undertaken in those with suspected dementia. However, a review of 14 guidelines and consensus statements found considerable similarity in recommendations. The main reason for undertaking investigations in a patient with suspected dementia is to exclude a potentially reversible or modifying cause for the dementia and to help exclude other diagnoses (eg delirium). Reversible or modifying causes include metabolic and endocrine abnormalities (eg vitamin B12 and folate deficiency, hypothyroidism, diabetes and disorders of calcium metabolism).

---

The NICE clinical guideline on dementia\textsuperscript{76} states that a basic dementia screen is performed at the time of presentation, usually within primary care. It includes:

- routine haematology
- biochemistry tests (including electrolytes, calcium, glucose, and renal and liver function)
- thyroid function tests
- serum vitamin B12 and folate levels.

**DEM 005.2 Reporting and verification**

See indicator wording for requirement criteria.

For the purpose of this indicator, if a test for HbA1c has been carried out within the timeframe permitted by this indicator, then a test for glucose would not be required. All tests are required to be carried out (with the exception of glucose in the above scenario) to meet the requirements of this indicator. Where the test is declined by the patient, then the patient may be exception reported.

This indicator only applies to patients with a new diagnosis of dementia in the QOF year. However, the workload has the potential to span more than one QOF year. Therefore the Business Rules cover 30 months to capture patients whose care could span more than one QOF year eg 12 months before or six months after a new diagnosis is recorded.

This indicator only applies to patients with a new diagnosis of dementia in the QOF year. However, the workload has the potential to span more than one year. The Business Rules will look at a 30 month period of which 18 months is for the diagnosis of dementia (this includes six months for those patients diagnosed in the last six months of the previous year) and the additional 12 months accounts for the 12 months preceding diagnosis for the tests.

\textsuperscript{76} NICE CG42. Dementia: supporting people with dementia and their carers in health and social care. 2006. www.nice.org.uk/guidance/CG42
Depression (DEP)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEP003. The percentage of patients aged 18 or over with a new diagnosis of depression in the preceding 1 April to 31 March, who have been reviewed not earlier than 10 days after and not later than 56 days after the date of diagnosis</td>
<td>10</td>
<td>45–80%</td>
</tr>
</tbody>
</table>

DEP – rationale for inclusion of the indicator set

Depression is common and disabling.

In 2000, the estimated point prevalence for a depressive episode among people aged 16 or over and under the age of 74 in the UK was 2.6 per cent (males 2.3 per cent, females 2.8 per cent). If the broader and less specific category of 'mixed depression and anxiety' is included, these figures increase dramatically to 11.4 per cent (males 9.1 per cent, females 13.6 per cent). It contributes 12 per cent of the total burden of non-fatal global disease and by 2020, looks set to be second after CVD in terms of the world's disabling diseases. Major depressive disorder is increasingly seen as chronic and relapsing, resulting in high levels of personal disability, lost quality of life for patients, their family and carers, multiple morbidity, suicide, higher levels of service use and many associated economic costs. In 2007, the total cost of depression in England was reported to be £7.5 billion of which health service costs comprised £1.7 billion and lost earnings £5.8 billion. When the cost of informal care, lower productivity and other public sector costs are included this figures is estimated at between £20.2-23.8 billion a year.

DEP indicator 003 (based on NICE 2012 menu ID: NM50)

The percentage of patients aged 18 or over with a new diagnosis of depression in the preceding 1 April to 31 March, who have been reviewed not earlier than 10 days after and not later than 56 days after the date of diagnosis

DEP 003.1 Rationale

The NICE clinical guideline on depression in adults states that patients with mild depression or sub-threshold symptoms be reviewed and re-assessed after initial presentation, normally within two weeks.

CG90 recommends that patients with mild or moderate depression who start antidepressants are reviewed after one week if they are considered to present an increased risk of suicide or after two weeks if they are not considered at increased risk of suicide. Patients are then re-assessed at regular intervals determined by their

---


response to treatment and whether or not they are considered to be at an increased risk of suicide.

This indicator promotes a single depression review between 10 and 56 days inclusive after the date of diagnosis. For some patients this may not be their first review as they will have been reviewed initially within a week of the diagnosis. Unless a patient’s symptoms have resolved, further reviews may be required.

Practitioners are reminded of the importance of regular follow-up in this group of patients to monitor response to treatment, identify any adherence issues and provide on-going support. This review could address the following:

- a review of depressive symptoms
- a review of social support
- a review of alternative treatment options where indicated
- follow-up on progress of external referrals
- an enquiry about suicidal ideation
- highlighting the importance of continuing with medication to reduce the risk of relapse
- the side-effects and efficacy of medication. In the USA, 40 per cent of patients prescribed an antidepressant will discontinue its use within one month. Analysis of the GPRD\textsuperscript{80} from 1993 to 2005 found that more than half of patients treated with antidepressants had only received prescriptions for one or two months of treatment and that this pattern had not changed over the 13-year period.

Additionally, clinicians may wish to use formal assessment questionnaires such as PHQ9, HADS and BDI-II to monitor response to treatment.

In most clinical circumstances, the review would be performed during a face-to-face consultation so that body language and non-verbal cues may be observed. However, there is some evidence that telephone review may be appropriate for patients starting anti-depressants\textsuperscript{81,82} or for patients with mild depression who are not considered at increased risk of suicide and:

- the patient is well known to the GP who is conducting the telephone consultation
- the GP feels confident in their ability to perform a telephone consultation in this context
- the patient has failed to attend a face-to-face review and is proactively contacted on the telephone by a GP
- the patient has expressed a preference for telephone follow-up.

Only face-to-face or telephone contact with a GP or nurse practitioner is acceptable to meet the requirements for this indicator.

**DEP 003.2 Reporting and verification**

See indicator wording for requirement criteria.

Those patients whose on-going care is being provided by specialist mental health services should be exception reported.

It is recommended that where the diagnosis is made by specialist mental health services and the patient has been discharged for follow-up by the primary care team, the contractor should find out the diagnosis date in order to record this and invite the patient for a review within the timeframe specified.

Suspected depression seen in secondary care may not always be referred to specialist mental health services for further assessment and management. It may be in the form of a discharge letter from an acute medical or surgical ward, A&E or from an outpatient appointment. It may be reasonable in these circumstances for a contractor to contact the patient to ask them to attend for an assessment to assess if they have a clinical diagnosis of depression. In such cases, the biopsychosocial assessment (BPA) can be carried out at that time.

The disease register for the depression indicator for the purpose of calculating the APDF is defined as all patients aged 18 or over, diagnosed on or after 1 April 2006, who have an unresolved record of depression in their patient record.

Verification – Commissioners may ask contractors about the percentage of telephone reviews conducted and who they were delivered by.
### Mental health (MH)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MH001. The contractor establishes and maintains a register of patients with schizophrenia, bipolar affective disorder and other psychoses and other patients on lithium therapy</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MH002. The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a comprehensive care plan documented in the record, in the preceding 12 months, agreed between individuals, their family and/or carers as appropriate</td>
<td>6</td>
<td>40–90%</td>
</tr>
<tr>
<td>MH003. The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood pressure in the preceding 12 months</td>
<td>4</td>
<td>50–90%</td>
</tr>
<tr>
<td>MH007. The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of alcohol consumption in the preceding 12 months</td>
<td>4</td>
<td>50–90%</td>
</tr>
<tr>
<td>MH008. The percentage of women aged 25 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years</td>
<td>5</td>
<td>45–80%</td>
</tr>
<tr>
<td>MH009. The percentage of patients on lithium therapy with a record of serum creatinine and TSH in the preceding 9 months</td>
<td>1</td>
<td>50–90%</td>
</tr>
<tr>
<td>MH010. The percentage of patients on lithium therapy with a record of lithium levels in the therapeutic range in the preceding 4 months</td>
<td>2</td>
<td>50–90%</td>
</tr>
</tbody>
</table>

**MH – rationale for inclusion of indicator set**

This indicator set reflects the complexity of mental health problems, and the complex mix of physical, psychological and social issues that present to GPs.

Indicators MH002, MH003, MH007 and MH008 relate to the care of patients with a diagnosis of schizophrenia, bipolar or other affective disorders. Indicators MH009 and MH010 relate to the care of patients who are currently prescribed lithium.
Indicator MH001 requires contractors to establish and maintain a register of individuals with a diagnosis of serious mental illness eg schizophrenia, bipolar or other affective disorders and other patients on lithium therapy.

For many patients with mental health problems, the most important indicators relate to the interpersonal skills of the doctor, the time given in consultations and the opportunity to discuss a range of management options.

This indicator set focuses on patients with serious mental illness. There are separate indicator sets that focus on patients with depression and dementia.

**Mental health indicators MH003, MH007 and MH008**

It is recommended that patients receive health promotion and prevention advice appropriate to their age, gender and health status.

The NICE clinical guideline on psychosis and schizophrenia in adults\(^{83}\) recommends primary care utilise registers to monitor the physical health of patients with psychosis or schizophrenia.

The NICE clinical guideline on bipolar disorder\(^{84}\) recommends that patients with bipolar affective disorder have a physical health review, normally in primary care, performed at least annually, including the following health checks:

- weight or BMI, diet, nutritional status and level of physical activity
- cardiovascular status, including pulse and blood pressure
- metabolic status, including glycosylated haemoglobin (HbA1c) and blood lipid profile
- liver function
- renal and thyroid function, and calcium levels, for people taking long-term lithium.

QOF continues to incentivise annual monitoring of blood pressure, alcohol and smoking status for patients with schizophrenia, bipolar affective disorder and other psychoses. Clinicians should use their professional judgement to decide when and how frequently checks of lipid levels, glucose levels and weight should be carried out, in accordance with the needs of each patient.

In addition to lifestyle factors, such as smoking, poor diet and lack of exercise, antipsychotic drugs vary in their liability for metabolic side effects such as weight gain, lipid abnormalities and disturbance of glucose regulation. Specifically, they increase the risk of the metabolic syndrome, a recognised cluster of features (hypertension, central obesity, glucose intolerance or insulin resistance or dyslipidaemia) which is a predictor of type 2 diabetes and CHD\(^{85}\).


**MH indicator 001**

The contractor establishes and maintains a register of patients with schizophrenia, bipolar affective disorder and other psychoses and other patients on lithium therapy.

**MH 001.1 Rationale**

The register includes all patients with a diagnosis of schizophrenia, bipolar affective disorder and other psychoses and other patients on lithium therapy.

**Remission from serious mental illness**

Historically, patients have been added to the mental health disease register for schizophrenia, bipolar affective disorder and other psychoses, but over time it has become apparent that it would be appropriate to exclude some of them from the associated indicators because their illness is in remission.

Making an accurate diagnosis of remission for a patient with a diagnosis of serious mental illness can be challenging and the evidence base to support when to use the ‘remission code’ is largely based on clinical judgement. A longitudinal international study of recovery from psychotic illnesses found that as many as 56 per cent of patients recovered from psychotic illnesses to some extent, although only 16 per cent recover if a more stringent concept of recovery is used.

In the absence of strong evidence of what constitutes ‘remission’ from serious mental illness, it is advised that clinicians should only consider using the remission codes if the patient has been in remission for at least five years, that is where there is:

- no record of antipsychotic medication,
- no mental health in-patient episodes; and
- no secondary or community care mental health follow-up for at least five years.

Where a patient is recorded as being ‘in remission’ they remain on the register (in case their condition relapses at a later date) but they are excluded from the denominator for mental health indicators MH002, MH003, MH007 and MH008.

The accuracy of this diagnosis and the coding should be reviewed on an annual basis by a GP. If a patient who has been coded as ‘in remission’ experience a relapse then this should be recorded as such in their patient record.

In the event that a patient experiences a relapse and is coded as such, they will once again be included in all the associated indicators for schizophrenia, bipolar affective disorder and other psychoses.

**MH 001.2 Reporting and verification**

See indicator wording for requirement criteria.

The register includes patients with a current condition and also those recorded as being in remission, however patients recorded as ‘in remission’ will be excluded from

---

mental health indicators MH002, MH003, MH007 and MH008.

Verification – Commissioners may require randomly selecting a number of patient records of patients in which a ‘remission code’ has been recorded and request evidence as to why it was appropriate for that patient to be considered ‘in remission’.

Contractors may be expected to demonstrate they have a protocol to guide their clinicians as to how this would work and who would be suitable to make the decision. It would not be appropriate for non-clinical members of the practice to make the decision as to when to enter this code.

Commissioners may require contractors to demonstrate that patients coded as being in remission have received no anti-psychotic medications, mental health in-patient admissions, or mental health secondary or community care for at least five years prior to the entry of the remission code in their record.

**MH indicator 002 (NICE 2015 menu ID: NM108)**

The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a comprehensive care plan documented in the records, in the preceding 12 months, agreed between individuals, their family and/or carers as appropriate

**MH 002.1 Rationale**

This indicator reflects good professional practice and is supported by NICE clinical guidelines. Patients on the mental health disease register should have a documented primary care consultation that acknowledges, especially in the event of a relapse, a plan for care. This consultation may include the views of their relatives or carers where appropriate.

Up to half of patients who have a serious mental illness are seen only in a primary care setting. For these patients, it is important that the primary care team takes responsibility for discussing and documenting a care plan in their primary care record.

When constructing the primary care record, research supports the inclusion of the following information:

- patient’s current health status and social care needs including how needs are to be met, by whom, and the patient’s expectations
- how socially supported the individual is: eg friendships/family contacts/voluntary sector organisation involvement. People with mental health problems have fewer social networks than average, with many of their contacts related to health services rather than sports, family, faith, employment, education or arts and culture. One survey found that 40 per cent of people with ongoing mental health problems had no social contacts outside mental health services.

---


• co-ordination arrangements with secondary care and/or mental health services and a summary of what services are actually being received
• occupational status. In England, just over 30 per cent of people with mental health problems are currently in work, the lowest employment rate of any group of working aged people\(^{89}\). People with mental health problems also earn only two thirds of the national average hourly rate (ONS, 2002). Studies show a clear interest in work and employment activities among users of mental health services with up to 90 per cent wishing to go into or back to work\(^{90}\)
• ‘Early warning signs’ from the patient's perspective that may indicate a possible relapse\(^{91}\). Many patients may already be aware of their early warning signs (or relapse signature) but it is important for the primary care team to also be aware of noticeable changes in thoughts, perceptions, feelings and behaviours leading up to their most recent episode of illness as well as any events the patient thinks may have acted as triggers
• the patient's preferred course of action (discussed when well) in the event of a clinical relapse, including who to contact and wishes around medication.

It is recommended that a care plan is accurate, easily understood, reviewed annually and discussed with the patient, their family and/or carers. If a patient is treated under the care programme approach (CPA), then they have a documented care plan discussed with their community key worker available. This is acceptable for the purposes of QOF provided the practice has evidence of a review having taken place with the community key worker and the patient treated under the CPA.

Where a patient has relapsed after being recorded as being in remission their care plan should be updated subsequent to the relapse. Care plans dated prior to the date of the relapse will not be acceptable for QOF purposes.

**MH 002.2 Reporting and verification**

See indicator wording for requirement criteria.

Verification – Commissioners may require contractors to randomly select a number of care plans to ensure that they are being maintained annually.

**MH indicator 003 (NICE 2010 menu ID: NM17)**

The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood pressure in the preceding 12 months

**MH 003.1 Rationale**

Patients with schizophrenia have mortality between two and three times that of the general population and most of the excess deaths are from diseases that are the major causes of death in the general population. A recent prospective record linkage study of the mortality of a community cohort of 370 patients with schizophrenia found

---


\(^{90}\) See Grove and Drurie. Social firms: an instrument for social and economic inclusion. Redhill, Social Firms UK. 1999.

that the increased mortality risk is probably life-long and it suggested that cardiovascular mortality of schizophrenia has increased over the past 25 years relative to the general population. The NICE clinical guideline on bipolar disorder also states that the standardised mortality ratio for cardiovascular death may be twice that of the general population but appears to be reduced if patients adhere to long-term medication.

Hypertension in people with schizophrenia is estimated at 19 per cent compared with 15 per cent in the general population. A cross-sectional study of 4310 patients diagnosed with bipolar disorder in 2001 receiving care at veterans’ administration facilities found a prevalence of hypertension of 35 per cent.

There is evidence to suggest that physical conditions such as cardiovascular disorders go unrecognised in psychiatric patients. A direct comparison of cardiovascular screening (blood pressure, lipid levels and smoking status) of patients with asthma, patients with schizophrenia and other attendees indicated that general practice were less likely to screen patients with schizophrenia for cardiovascular risk compared with the other two groups.

Recording (and treating) cardiovascular risk factors are therefore very important for patients with a serious mental illness.

MH 003.2 Reporting and verification

See indicator wording for requirement criteria.

MH indicator 007 (NICE 2010 menu ID: NM15)

The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of alcohol consumption in the preceding 12 months.

---

MH 007.1 Rationale

Substance misuse by people with schizophrenia is increasingly recognised as a major problem, both in terms of its prevalence and its clinical and social effects. The National Psychiatric Morbidity Survey in England found that 16 per cent of people with schizophrenia were drinking over the recommended limits of 21 units of alcohol for men and 14 units of alcohol for women a week. Bipolar affective disorder is also highly co-morbid with alcohol and other substance abuse.

MH 007.2 Reporting and verification

See indicator wording for requirement criteria.

MH indicator 008 (NICE 2010 menu ID: NM20)

The percentage of women aged 25 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years

MH 008.1 Rationale

A report by the Disability Rights Commission based on the primary care records of 1.7 million primary care patients found that women with schizophrenia were less likely to have had a cervical sample taken in the preceding five years (63 per cent) compared with the general population (73 per cent). This did not apply to patients with bipolar affective disorder. This finding may reflect an underlying attitude that such screening is less appropriate for women with schizophrenia. This indicator therefore encourages contractors to ensure that women with schizophrenia, bipolar affective disorder or other psychoses are given cervical screening according to national guidelines.

MH 008.2 Reporting and verification

See indicator wording for requirement criteria.

MH indicator 009 (NICE 2010 menu ID: NM21)

The percentage of patients on lithium therapy with a record of serum creatinine and TSH in the preceding 9 months

MH 009.1 Rationale

It is important to check thyroid and renal function regularly in patients taking lithium, as there is a much higher than normal incidence of hypothyroidism and

---

hypercalcaemia and of abnormal renal function tests. Overt hypothyroidism has been found in between eight per cent and 15 per cent of patients on lithium.

NICE guideline CG185 recommends practitioners check thyroid function every six months together with levels of thyroid antibodies if clinically indicated (for example, by the thyroid function tests). It also recommends that renal function tests are carried out every six months and more often if there is evidence of impaired renal function.

**MH 009.2 Reporting and verification**

See indicator wording for requirement criteria.

Due to the way repeat prescribing works in general practice, patients on lithium therapy are defined as patients with a prescription of lithium within the preceding six months.

**MH indicator 010 (NICE 2010 menu ID: NM22)**

The percentage of patients on lithium therapy with a record of lithium levels in the therapeutic range in the preceding 4 months

**MH 010.1 Rationale**

Lithium monitoring is essential due to the narrow therapeutic range of serum lithium and the potential toxicity from inter-current illness, declining renal function or co-prescription of drugs, for example thiazide diuretics or non-steroidal anti-inflammatory drugs (NSAIDs) which may reduce lithium excretion.

The National Patient Safety Agency (NPSA) recently conducted a review of the use of oral lithium for bipolar disorder, which demonstrated that wrong or unclear dose or strength and monitoring were key issues for lithium therapy\(^\text{101}\). A search of all medication incidents related to the use of lithium reported to the National Reporting and Learning System between November 2003 and December 2008 identified a total of 567 incidents. Two of these resulted in ‘severe’ harm to the patient, although the majority were reported as ‘no harm’ events\(^\text{102}\).

NICE clinical guideline CG185 recommends the following for patients being prescribed lithium, for their bipolar:

- measure the person’s plasma lithium level every three months for the first year
- after the first year, measure plasma lithium levels every six months, or every three months for people in any of the following groups:
  1. older people
  2. people taking drugs that interact with lithium
  3. people who are at risk of impaired renal or thyroid function, raised calcium levels or other complications.

\(^{101}\) NPSA alert 0921. Safer lithium therapy. 2009. [http://www.nrls.npsa.nhs.uk/resources/type/alerts/?entryid45=65426](http://www.nrls.npsa.nhs.uk/resources/type/alerts/?entryid45=65426)

\(^{102}\) Prescribing Observatory for Mental Health. Topic 7 baseline report. Monitoring of patients prescribed lithium: baseline. 2009.
4. people who have poor symptom control
5. people with poor adherence
6. people whose last plasma lithium level was 0.8 mmol per litre or higher

MH 010.2 Reporting and verification

See indicator wording for requirement criteria.

Due to the way repeat prescribing works in general practice, patients on lithium therapy are defined as patients with a prescription of lithium within the preceding six months.
Cancer (CAN)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Records</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAN001. The contractor establishes and maintains a register of all cancer patients defined as a ‘register of patients with a diagnosis of cancer excluding non-melanotic skin cancers diagnosed on or after 1 April 2003’</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Ongoing management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CAN003. The percentage of patients with cancer, diagnosed within the preceding 15 months, who have a patient review recorded as occurring within 6 months of the date of diagnosis</td>
<td>6</td>
<td>50–90%</td>
</tr>
<tr>
<td>Based on NICE 2012 menu ID: NM62</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**CAN – rationale for inclusion of indicator set**

It is recognised that the principal active management of cancers occurs in the secondary care setting. However, general practice often has a key role in the referral and subsequent support of these patients and in ensuring that care is appropriately co-ordinated. This indicator set is not evidence-based but does represent good professional practice.

**CAN indicator 001**

The contractor establishes and maintains a register of all cancer patients defined as a ‘register of patients with a diagnosis of cancer excluding non-melanotic skin cancers diagnosed on or after 1 April 2003’

**CAN 001.1 Rationale**

The register can be developed prospectively as the intention is to ensure appropriate care and follow-up for patients with a diagnosis of cancer. For the purposes of the register all cancers are included except non-melanomatous skin lesions.

**CAN 001.2 Reporting and verification**

See indicator wording for requirement criteria.

**CAN indicator 003 (based on NICE 2012 menu ID: NM62)**

The percentage of patients with cancer, diagnosed within the preceding 15 months, who have a patient review recorded as occurring within 6 months of the date of diagnosis

**CAN 003.1 Rationale**

A GP will have an average of eight or nine new cancer diagnoses per year and will be looking after 20 to 30 patients with cancer. The increasing number of cancer survivors has led to an increase in the number of people requiring follow-up care, monitoring and management.
Contractors are required to record that a patient review has occurred within six months of diagnosis to achieve this indicator. However, given the importance of primary care practitioners making early contact with patients who have been diagnosed with cancer, good practice would suggest that a review should occur between three to six months of diagnosis.

Most practices will see patients with a new cancer diagnosis following assessment and management in a secondary or tertiary care setting. These patients quickly resume consultations in general practice at an increased rate to pre-diagnosis and treatment, therefore primary care has an important role in managing survivorship. This review represents an opportunity to address patients’ needs for individual assessment, care planning and on-going support and information requirements.

A cancer review in primary care includes:

- the patient’s individual health and support needs, which will vary with, for example, the diagnosis, staging, age and pre-morbid health of the patient and their social support networks. In collaboration with the National Cancer Survivorship Initiative (NCSI)\(^\text{103}\), Macmillan primary care community has produced a template\(^\text{104}\) which recommends that this could cover a discussion of the diagnosis and recording of cancer therapy, an offer of relevant information, medication review, benefits counselling and recording of a carer’s details
- the co-ordination of care between sectors.

Further information on survivorship and the potential role for primary care can be found on the NCSI website\(^\text{105}\).

It is preferable that a review should be face-to-face in most cases. Making contact with a patient over the telephone will meet the requirements for this indicator. Where contact is made over the phone, an offer of a subsequent face-to-face review is advised.

**CAN 003.2 Reporting and verification**

See indicator wording for requirement criteria.

For the purposes of this indicator, the six month timeframe starts from the date of diagnosis irrespective of whether or not the diagnosis was made in primary care.

Verification – Commissioners may wish to review records where a review is claimed to confirm that the review has been completed within six months of diagnosis.


\(^{105}\) NCSI website. [http://www.ncsi.org.uk/](http://www.ncsi.org.uk/)
Chronic kidney disease (CKD)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Records</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CKD005. The contractor establishes and maintains a register of patients aged 18 or over with CKD with classification of categories G3a to G5 (previously stage 3 to 5) <em>NICE 2015 menu ID: NM83</em></td>
<td>6</td>
<td></td>
</tr>
</tbody>
</table>

CKD – rationale for inclusion of indicator set

The updated NICE guideline for CKD\(^{106}\) was published in July 2014. This update of the 2008 guideline reviewed the classification of CKD.

In 2002 the US National Kidney Foundation Kidney Disease Outcomes Quality Initiative published a classification of CKD split into five stages defined by glomerular filtration rate (GFR). The 2008 guideline (CG73) recommended adjusting this classification to sub-divide stage 3 into 3a (GFR 45-59 ml/min/1.73 m²) and 3b (GFR 30-44 ml/min/1.73 m²) on the basis of a clear difference in adverse outcomes associated with the 2 different GFR categories. CG73 also recognised the importance of associated proteinuria.

Updated CG182 recommends classifying CKD using a combination of GFR and Albumin Creatinine Ratio (ACR) categories as G1 to G5, see description in table 3.

In a cross sectional point prevalence study\(^{107}\) of over 130,000 adults in England the age standardised prevalence of people with an estimated GFR <60 ml/min/1.73 m² (CKD stages 3-5) was 8.5 per cent. Those with CKD were more likely to have hypertension, diabetes and CVD compared to people with GFR>60 ml/min/1.73 m², the prevalence of CKD rose with age and female gender. Limited data are available to provide an estimate of the overall population prevalence of CKD (diagnosed and undiagnosed). The available estimate suggests an overall prevalence of 13 per cent.

Further information


This disease area applies to patients with category G3a, G3b, G4 and G5 CKD (eGFR<60 mL/min/1.73 m² confirmed with at least two separate readings over a three month period).

Late presentation of patients with kidney failure increases morbidity, mortality and healthcare associated with costs. The total cost of CKD in England in 2009/10 has

---


been estimated as being circa £1.4 billion\textsuperscript{108}.

Early identification of CKD is therefore important to not only allow appropriate measures to be taken to slow or prevent the progression to more serious CKD, but also to highlight and manage the key associated risks related to patient safety and avoidable harm.

Table 3. Classification of CKD using GFR and ACR categories

<table>
<thead>
<tr>
<th>GFR and ACR categories (including stages of CKD from previous guideline)</th>
<th>Albuminuria categories (mg/mmol)</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;3 Normal to mildly increased</td>
<td>3-30 Moderately increased</td>
<td>&gt;30 Severely increased</td>
</tr>
<tr>
<td></td>
<td>A1</td>
<td>A2</td>
<td>A3</td>
</tr>
<tr>
<td>290 Normal and high (stage 1)</td>
<td>No CKD*</td>
<td>G1 A2</td>
<td>G1 A3</td>
</tr>
<tr>
<td>60-89 Mild reduction related to normal range for a young adult</td>
<td>G2 (stage 2)</td>
<td>G2 A2</td>
<td>G2 A3</td>
</tr>
<tr>
<td>45-59 Mild-moderate reduction G3a (stage 3a)</td>
<td>G3a A1^</td>
<td>G3a A2</td>
<td>G3a A3</td>
</tr>
<tr>
<td>30-44 Moderate-severe reduction G3b (stage 3b)</td>
<td>G3b A1</td>
<td>G3b A2</td>
<td>G3b A3</td>
</tr>
<tr>
<td>&lt;15 Kidney failure G5 (stage 5)</td>
<td>G5 A1</td>
<td>G5 A2</td>
<td>G5 A3</td>
</tr>
</tbody>
</table>

*By definition, in the absence of evidence of kidney damage, these categories are not CKD
^ Consider using eGFRcystatinC to confirm the diagnosis of CKD in people with eGFRcreatinine of 45-59 ml/min/1.73m\textsuperscript{2}, sustained for at least 90 days and no proteinuria (ACR less than 3 mg/mmol)

CKD indicator 005 (NICE 2015 menu ID: NM83)

The contractor establishes and maintains a register of patients aged 18 or over with CKD with classification of categories G3a to G5 (previously stage 3 to 5)

CKD 005.1 Rationale

The NICE guideline on CKD recommends that CKD should be classified using a combination of GFR and ACR categories as detailed in table 3 in the introduction to this section. The 2014/15 indicator CKD001 recommended classification using the US National Kidney Foundation classification system. The classification system for CKD was included in the scope for the guideline update and as a result of this work, the staging system was replaced with a system that classifies GFR and ACR by categories. This was to systematically take into account proteinuria when considering GFR. So the terminology within the guideline recommendations now refers to categories rather than stages.

CKD is common, frequently unrecognised and often exists with other conditions such as CVD and diabetes. A GFR less than 60 ml/min/1.73m2 is strongly associated with increased risk of adverse outcomes (acute kidney injury, end stage kidney disease, all-cause mortality and cardiovascular mortality). Furthermore, a GFR less than 60 is also associated with increased frailty, impaired cognitive ability, increased risk of infection and an increase in prescribing errors.

This indicator aims to establish a register of people with CKD categories G3a to G5 to enable appropriate advice, treatment and support to be provided for people with moderate to severe CKD and so help preserve kidney function and reduce the risk of developing co-morbidity.

Eating a meal containing protein can elevate creatinine, therefore it is recommended that patients do not eat meat in the 12 hours before their creatinine is measured and eGFR estimated.

CKD 005.2 Reporting and verification

See indicator wording for requirement criteria.

The 2015/16 agreement included a commitment by practices to continue to undertake the work for indicators no longer in QOF as clinically appropriate. For CKD, this includes the facilitation of data collections by practices for processing by the renal registry for audit and publication.
Epilepsy (EP)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>EP001. The contractor establishes and maintains a register of patients aged 18 or over receiving drug treatment for epilepsy.</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

**EP – rationale for inclusion of indicator set**

Epilepsy is the most common serious neurological condition, affecting about five to ten per 1000 of the population at any one time. Few epilepsies are preventable, but appropriate clinical management can enable most patients with epilepsy to lead a full and productive life. For the purposes of the QOF, epilepsy is defined as ‘recurrent unprovoked seizures’.

**EP indicator 001**

The contractor establishes and maintains a register of patients aged 18 or over receiving drug treatment for epilepsy

**EP 001.1 Rationale**

The disease register includes patients aged 18 or over, as care for younger patients is generally undertaken outside of primary care.

The phrase ‘receiving treatment’ has been included in order to exclude the large number of patients who may have had epilepsy in the past, may have not received treatment and been fit-free for many years. Some patients may still be coded as ‘epilepsy’ or ‘history of epilepsy’ and will be picked up on computer searches.

Patients who have a past history of epilepsy who are not on drug therapy are excluded from the register. Drugs on repeat prescription will be picked up on a search.

**EP 001.2 Reporting and verification**

See indicator wording for requirement criteria.

Verification – Commissioners may require a comparison of the expected prevalence with the reported prevalence recognising that reported prevalence will be reduced as the register is limited to those patients receiving drug treatment.
Learning disabilities (LD)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Records</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LD003. The contractor establishes and maintains a register of patients with learning disabilities</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>

LD – rationale for inclusion of indicator set

People with learning disabilities are among the most vulnerable and socially excluded in our society. It is estimated that there are approximately 20/1,000 people with mild learning disabilities and 3-4/1,000 with severe and profound learning disabilities in the UK. Over the past three decades, almost all the long-stay NHS beds for people with learning disabilities have closed and virtually all people with learning disabilities are now living in the community and depend on general practice for their primary care needs.

Further information

RCN learning disabilities guidance.
http://www.rcn.org.uk/search?Scope=Local&Keyword=learning%20disabilities%20guidance%20&Relevance=True


LD indicator 003 (NICE 2015 menu ID: NM73)

The contractor establishes and maintains a register of patients with learning disabilities

LD 003.1 Rationale

This register indicator includes people of any age with a learning disability. This is because without a complete register of people with learning disabilities, practices may not be aware of the reasonable adjustments that may be needed for a child or young person with learning disabilities and their family, and of the help and support that may be useful to them. Evidence suggests there are an increasing number of children with learning disabilities now surviving childhood, some of whom will have
profound and multiple disabilities as they grow up. It also suggests that health services are often unprepared for these children and young people and the complexity of their problems.

A full register of patients with learning disabilities will provide primary care practitioners with the first important building block in providing better quality and more appropriate services for this patient population.

Learning disabilities are heterogeneous conditions, but are defined by three core criteria:

- lower intellectual ability (usually defined as an Intelligence Quotient [IQ] of less than 70)
- significant impairment of social or adaptive functioning; and
- onset in childhood.

An IQ below 70 should not be used on its own to determine whether someone has a learning disability. The definition encompasses people with a broad range of disabilities. It includes adults with autism who also have learning disabilities, but not people with a higher level autistic spectrum disorder who may be of average or above average intelligence. The definition does not include all those people who have a “learning difficulty”, eg specific difficulties with learning, such as dyslexia.

Learning disability is defined in Valuing People as the presence of:

- a significantly reduced ability to understand new or complex information, to learn new skills (impaired intelligence), with
- a reduced ability to cope independently (impaired social functioning)
- which started before adulthood (under the age of 18), with a lasting effect on development.

For many people, there is little difficulty in reaching a decision whether they have a learning disability or not. However, in those individuals where there is some doubt about a diagnosis or the level of learning disability, referral to a multi-disciplinary specialist learning disability team (where available) may be necessary to assess the degree of disability and diagnose any underlying condition. In some areas, locality community learning disability teams, working with CCGs, provide expertise and data about and for people with learning disabilities. Contractors may wish to liaise with Social Services Departments, Community Learning Disability Teams and Primary Healthcare Facilitators where available to assist in the construction of a primary care database.

It is a statutory requirement under the Equality Act 2010 and the NHS and Social Care Act 2008 that public sector agencies make ‘reasonable adjustments’ to their practice that will make them as accessible and effective as they would be for people.

---

without disabilities. Reasonable adjustments include removing physical barriers to accessing health services, but importantly also include making whatever alterations are necessary to policies, procedures, staff training and service delivery to ensure that they work equally well for people with learning disabilities\textsuperscript{112}.

Further information


LD 003.2 Reporting and verification

See indicator wording for requirement criteria.

# Osteoporosis: secondary prevention of fragility fractures (OST)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OST004. The contractor establishes and maintains a register of patients: 1. Aged 50 or over and who have not attained the age of 75 with a record of a fragility fracture on or after 1 April 2012 and a diagnosis of osteoporosis confirmed on DXA scan, and 2. Aged 75 or over with a record of a fragility fracture on or after 1 April 2014 and a diagnosis of osteoporosis &lt;br&gt;&lt;br&gt;<em>NICE 2011 menu ID: NM29</em></td>
<td>3</td>
<td></td>
</tr>
<tr>
<td><strong>Ongoing management</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OST002. The percentage of patients aged 50 or over and who have not attained the age of 75, with a record of a fragility fracture on or after 1 April 2012, in whom osteoporosis is confirmed on DXA scan, who are currently treated with an appropriate bone-sparing agent &lt;br&gt;&lt;br&gt;<em>NICE 2011 menu ID: NM30</em></td>
<td>3</td>
<td>30–60%</td>
</tr>
<tr>
<td>OST005. The percentage of patients aged 75 or over with a record of a fragility fracture on or after 1 April 2014 and a diagnosis of osteoporosis, who are currently treated with an appropriate bone-sparing agent &lt;br&gt;&lt;br&gt;<em>NICE 2011 menu ID: NM31</em></td>
<td>3</td>
<td>30–60%</td>
</tr>
</tbody>
</table>

**OST – rationale for inclusion of indicator set**

Osteoporotic fragility fractures can cause substantial pain and severe disability and are associated with decreased life expectancy. Osteoporotic fragility fractures occur most commonly in the spine (vertebrae), hip (proximal femur) and wrist (distal radius). They also occur in the arm (humerus), pelvis, ribs and other bones. Fractures of the hands and feet (for example metacarpal and metatarsal fractures) are not generally regarded as osteoporotic fragility fractures.

Interventions for secondary prevention of fractures in patients who have had an osteoporotic fragility fracture include pharmacological intervention.
OST indicator 004 (NICE 2011 menu ID: NM29)

The contractor establishes and maintains a register of patients:

- Aged 50 or over and who have not attained the age of 75 with a record of a fragility fracture on or after 1 April 2012 and a diagnosis of osteoporosis confirmed on DXA scan; and
- Aged 75 or over with a record of a fragility fracture on or after 1 April 2014 and a diagnosis of osteoporosis

OST 004.1 Rationale

Fragility fractures are fractures that result from low-level trauma, which means mechanical forces that would not ordinarily cause fracture. The WHO has described this as a force equivalent to a fall from a standing height or less. Reduced bone density is a major risk factor for fragility fractures. Osteoporosis is a disease characterised by low bone mass and structural deterioration of bone tissue. The WHO defines osteoporosis as a bone mineral density of 2.5 or more standard deviations below that of a normal young adult (T-score of -2.5 or less) measured by a central dual-energy X-ray absorptiometry (DXA) scan. Bone mineral density is the major criterion used to diagnose and monitor osteoporosis.

The NICE clinical guideline on osteoporosis fragility fractures recommends that a diagnosis of osteoporosis may be assumed in women and men aged 75 or over with a fragility fracture if the responsible clinician considers a DXA scan to be clinically inappropriate or unfeasible. The SIGN clinical guideline on the management of osteoporosis recommends that in frail elderly women (aged 80 or over) a DXA scan would be a prerequisite to establish that bone mass density (BMD) is sufficiently low before starting treatment with bone-sparing agents (bisphosphonates), unless the patient has suffered multiple vertebral fractures.

Osteoporotic fragility fractures can cause substantial pain and severe disability, and are associated with decreased life expectancy. Osteoporotic fragility fractures occur most commonly in the spine (vertebrae), hip (proximal femur) and wrist (distal radius). They also occur in the arm (humerus), pelvis, ribs and other bones. Fractures of the hands and feet (for example, metacarpal and metatarsal fractures) are not generally regarded as osteoporotic fragility fractures.

In women, the prevalence of osteoporosis increases markedly with age after menopause, from approximately two per cent at 50 years, rising to more than 25 per cent at 80 years. The NICE cost impact report for technology appraisal TA161 uses a prevalence of 11 per cent of post-menopausal women aged 50 or over with osteoporosis and a clinically apparent osteoporotic fragility fracture, rising to 19 per

cent for ages 65 or over. There are an estimated 180,000 new fragility fractures in postmenopausal women in the UK each year; three quarters in women aged 65 or over.

Postmenopausal women with an initial fracture are at substantially greater risk of subsequent fractures. Half of patients with a hip fracture have previously had a fragility fracture of another bone.

Hip fractures are associated with increased mortality; estimates of the relative mortality risk vary from two to greater than ten in the 12 months following hip fracture. However, it is unclear to what extend this can be attributed to fracture alone, as opposed to pre-existing co-morbidity.

The SIGN clinical guideline recommends that patients who have suffered one or more fragility fractures are priority targets for investigation and treatment of osteoporosis.

This indicator promotes structured case finding for osteoporosis in patients who have had a fragility fracture. Its aim is to promote the secondary prevention of fragility fracture in patients with osteoporosis.

**OST 004.2 Reporting and verification**

The Business Rules for the two part register will look for the following criteria:

In patients aged 50 or over and who have not attained the age of 75:

- the earliest DXA scan with a positive result of osteoporosis
- the earliest diagnosis of osteoporosis
- a fragility fracture at any point on or after the implementation date (1 April 2012).

In patients aged 75 or over:

- the earliest diagnosis of osteoporosis
- a fragility fracture at any point on or after the implementation date (1 April 2014).

Patients aged 50 or over and under the age of 75 in whom a diagnosis of osteoporosis has not been confirmed with DXA scanning will not be included in the register.

For patients aged 75 or over the diagnosis of osteoporosis can be either confirmed with DXA scanning or clinically assumed (if DXA scan is considered to be clinically inappropriate or unfeasible).

Patients with fragility fractures sustained in the last three months of the year will be excepted from this indicator.

Although this indicator defines two separate registers, the disease register for the purpose of calculating the APDF is defined as the sum of the number of patients on both registers.
**OST indicator 002 (NICE 2011 menu ID: NM30)**

The percentage of patients aged 50 or over and who have not attained the age of 75 with a record of a fragility fracture on or after 1 April 2012, in whom osteoporosis is confirmed on DXA scan, who are currently treated with an appropriate bone-sparing agent

**OST 002.1 Rationale**

The management of osteoporosis includes lifestyle advice, such as advice on adequate nutrition, regular weight-bearing exercise, stopping smoking and avoiding alcohol, to reduce the risks of osteoporosis. Interventions for secondary prevention of fractures in patients who have had an osteoporotic fragility fracture include pharmacological intervention.

The SIGN clinical guideline 142 addresses the pharmacological management in three groups of postmenopausal women: postmenopausal women with multiple vertebral fractures (DXA scan not essential but other destructive diseases are excluded); postmenopausal women with osteoporosis determined by DXA scan and a history of at least one vertebral fracture; and postmenopausal women with osteoporosis determined by DXA scan with or without a previous non-vertebral fracture.

For all these groups bone-sparing agents are indicated to reduce subsequent fracture risk. NICE technology appraisal TA161 states that the bone-sparing agent alendronate is recommended as a treatment option for the secondary prevention of osteoporotic fragility fractures in postmenopausal women who are confirmed to have osteoporosis. When the decision has been made to initiate treatment with alendronate, it is recommended that the preparation prescribed is chosen on the basis of the lowest acquisition cost available. The bone-sparing agents risedronate and etidronate are recommended as alternative treatment options for secondary prevention of osteoporotic fragility fractures in postmenopausal women:

- who are unable to comply with the special instructions for the administration of alendronate, or have a contraindication to or are intolerant of alendronate and
- who also have a combination of T-score, age and number of independent clinical risk factors for fracture as indicated in the following table.
Table 4. T-scores (SD) at (or below) which risedronate or etidronate is recommended when alendronate cannot be taken

<table>
<thead>
<tr>
<th>Age (years)</th>
<th>Number of independent clinical risk factors for fracture*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
</tr>
<tr>
<td>50-54</td>
<td>-**</td>
</tr>
<tr>
<td>55-59</td>
<td>-3.0</td>
</tr>
<tr>
<td>60-64</td>
<td>-3.0</td>
</tr>
<tr>
<td>65-69</td>
<td>-3.0</td>
</tr>
<tr>
<td>70 or over</td>
<td>-2.5</td>
</tr>
</tbody>
</table>

*Independent clinical risk factors for fractures are parental history of hip fracture, alcohol intake of four or more units per day, and rheumatoid arthritis.

**Treatment with risedronate or etidronate is not recommended.

In deciding between risedronate and etidronate, clinicians and patients need to balance the overall proven effectiveness profile of the drugs against their tolerability and adverse effects in individual patients.

The SIGN clinical guideline makes recommendations on men with a diagnosis of osteoporosis determined by DXA scan. It states that to reduce fracture risks at all sites, men with low BMD and/or a history of one or more vertebral fractures or one non-vertebral osteoporotic fractures are treated with oral alendronate.

It is recommended that calcium and vitamin D supplementation are used in combination with bone-sparing agents. The guideline also recommends that patients who have had a fragility fracture who require treatment with a bone-sparing agent also receive appropriate calcium and/or vitamin D supplementation.

OST 002.2 Reporting and verification

See indicator wording for requirement criteria.

OST indicator 005 (NICE 2011 menu ID: NM31)

The percentage of patients aged 75 or over with a record of a fragility fracture on or after 1 April 2014 and a diagnosis of osteoporosis, who are currently treated with an appropriate bone-sparing agent

OST 005.1 Rationale

See OST 002.1.

NICE and SIGN recommend bone-sparing agents for the secondary prevention of osteoporotic fragility fractures in people confirmed to have osteoporosis. In April 2014 this indicator was amended so only people with a record of a diagnosis of osteoporosis in addition to a record of a fragility fracture are included in the denominator. This indicator does not require that a diagnosis of osteoporosis is confirmed by DXA scan in patients aged 75 or over with a fragility fracture. However, it is recommended clinical practice that this group are considered for a DXA scan. NICE recommends that a diagnosis of osteoporosis may be assumed in women aged 75 or over with a fragility fracture if the responsible clinician considers a DXA
scan to be clinically inappropriate or unfeasible\textsuperscript{117}. SIGN recommends that in frail elderly women (aged 80 or over) a DXA scan would be a prerequisite to establish BMD is sufficiently low before starting treatment with bone-sparing agents (biophosphonates), unless the patient has suffered multiple vertebral fractures.

\textbf{OST 005.2 Reporting and verification}

See indicator wording for requirement criteria.

\textsuperscript{117} NICE TA161. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. 2011. \url{http://www.nice.org.uk/guidance/TA161}. 
Rheumatoid arthritis (RA)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Records</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| RA001. The contractor establishes and maintains a register of patients aged 16 or over with rheumatoid arthritis  
*NICE 2012 menu ID: NM55* | 1      |                        |
| Ongoing management               |        |                        |
| RA002. The percentage of patients with rheumatoid arthritis, on the register, who have had a face-to-face review in the preceding 12 months  
*NICE 2012 menu ID: NM58* | 5      | 40–90%                 |

**RA – rationale for inclusion of indicator set**

Rheumatoid arthritis (RA) is a chronic, disabling auto-immune disease characterised by inflammation in the peripheral joints, which causes swelling, stiffness, pain and progressive joint destruction. For a small proportion of people with RA, inflammatory disease outside the joints (ie eye and lung disease, vasculitis) can pose a significant problem. RA affects around one per cent of the population; of these people, approximately 15 per cent have severe RA.

Although the confirmation of diagnosis and initiation of treatment may take place in secondary care, primary care has an important role to play in the management of RA. This may include checking cardiovascular risk and blood pressure, checking the person's risk for osteoporosis and assessing for signs of low mood or depression. An annual face-to-face review in primary care is an opportunity to assess the effect of the disease upon the person’s life, for example side effects to medication and whether they would benefit from any referrals to the multi-disciplinary team.

**RA indicator 001 (NICE 2012 menu ID: NM55)**

The contractor establishes and maintains a register of patients aged 16 or over with rheumatoid arthritis

**RA 001.1 Rationale**

The RA register includes patients aged 16 or over with established and recent-onset disease and in whom there is a definite diagnosis of RA, irrespective of evidence of positive serology and current disease activity status.

The register is restricted to patients aged 16 or over, to conform to international standards for differentiating RA from juvenile idiopathic arthritis.

The register also includes patients with inactive RA. There are three potential groups of patients whose disease may be referred to as inactive:

- patients who are being treated and whose disease is in remission
- patients who are not receiving treatment for RA but have evidence of past disease, for example, joint deformities. This type of RA is sometimes known as
‘burnt out’ RA. These patients are on the register as they remain at risk of the systemic effects of RA

- patients who are not receiving treatment for RA who have no evidence of past disease but there is doubt about their diagnosis. The contractor may wish to request erythrocyte sedimentation rate (ESR) or plasma viscosity, C-reactive protein (CRP), rheumatoid factor and hand X-ray to determine the accuracy of the diagnosis. Inaccurate diagnoses can be removed from the patient’s patient record which would also remove them from the register.

Recognition of synovitis in primary care and prompt referral for specialist advice is key to the early identification and treatment of RA. Synovitis is inflammation of the membrane that lines the inside of synovial joints (most of the joints in the body). Symptoms of inflammation include pain, swelling, heat and loss of function of an affected joint.

Identifying recent-onset RA can be challenging in primary care because of the variety of ways in which synovitis can present itself and the small number of patients who have RA compared with the number of patients with musculoskeletal symptoms. The NICE clinical guideline on RA118 recommends that patients with persistent synovitis are referred for specialist opinion. Urgent referral is needed when any of the following are present:

- the small joints of the hands or feet are affected
- more than one joint is affected
- there has been a delay of three months or longer between the onset of symptoms and seeking medical advice.

Early identification of recent-onset RA is important because long-term outcomes are improved if disease modifying anti-rheumatic drugs (DMARDs) treatment is started within three months of the onset of symptoms.

**RA 001.2 Reporting and verification**

See indicator wording for requirement criteria.

Verification – Commissioners may wish to discuss with contractors the process they use to identify patients with RA, and the number of patients with inactive disease whose diagnoses have been reviewed and the outcomes of this review.

**RA indicator 002 (NICE 2012 menu ID: NM58)**

The percentage of patients with rheumatoid arthritis, on the register, who have had a face-to-face review in the preceding 12 months

**RA 002.1 Rationale**

RA is a chronic disease with a variable course over a long period of time. Therefore, there is a need for regular monitoring to determine disease status, assess severity, efficacy and toxicity of drug therapy and identify co-morbidities or complications.

Patients with satisfactorily controlled established disease require review appointments for ongoing drug monitoring, additional visits for disease flares and rapid access to specialist care. RA and its treatment can also have a negative effect upon a patient’s quality of life. It is recommended that contractors review the following aspects of care with a patient:

- disease activity and damage, which may include requesting C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) or plasma viscosity test
- a discussion of DMARDs, if relevant
- the need for referral for surgery
- the effect the disease is having on their life, for example employment or education
- the need to organise appropriate cross-referral within the multi-disciplinary team.

As a minimum, it is advised that this review covers disease activity and damage, the effect of the disease upon the patient's life and whether they would benefit from any referrals to the multi-disciplinary team.

**RA 002.2 Reporting and verification**

See indicator wording for requirement criteria.

Verification – Commissioners may wish to review patient records to ensure that all essential elements of the review have been performed.
Palliative care (PC)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Records</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PC001. The contractor establishes and maintains a register of all patients in need of palliative care/support irrespective of age</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Ongoing management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PC002. The contractor has regular (at least 3 monthly) multi-disciplinary case review meetings where all patients on the palliative care register are discussed</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>NICE 2015 menu ID: NM111</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

PC – rationale for inclusion of indicator set

Palliative care is the active total care of patients with life-limiting disease and their families by a multi-professional team. The first National End of Life Care (EoLC) Strategy\(^ {119} \) was published in July 2008. It builds on work such as the NHS cancer plan 2000, NICE guidance 2004 and NHS EOLC programme 2005.

The way primary care teams provide palliative care in the last months of life has changed and developed extensively in recent years:

- since the introduction of this indicator set over 99 per cent of practices now using a palliative care register.
- with specific emphasis on the inclusion of patients with non-malignant disease and of all ages since April 2008.
- with patients and carers being offered more choice regarding their priorities and preferences for care including their preferred place of care in the last days of life (evidence shows that more patients achieve a home death if they have expressed a wish to do so).
- by increasing use of anticipatory prescribing to enable rapid control of symptoms if needed and a protocol or integrated care pathway for the final days of life.
- through the identification of areas needing improvement by the NAO eg unnecessary hospital admissions during the last months of life.

The National EoLC Strategy suggests that all contractors adopt a systematic approach to EoLC and work to develop measures and markers of good care. They recommend the Gold Standards Framework (GSF) and the associated After Death Analysis (ADA) as examples of good practice. Evidence suggests that over 60 per cent of practices across the UK now use GSF to some degree to improve provision of palliative care by their primary care team.

---

The introduction of the GSF\textsuperscript{120} to primary care and its associated audit tool, the ADA, are associated with a considerable degree of research and evaluation. The GSF provides ideas and tools that help contractors to focus on implementing high quality patient-centred care.

**PC indicator 001**

The contractor establishes and maintains a register of all patients in need of palliative care/support irrespective of age

**PC 001.1 Rationale**

About one per cent of the population in the UK die each year (over half a million), with an average of 20 deaths per GP per year. A quarter of all deaths are due to cancer, a third from organ failure, a third from frailty or dementia and only one twelfth of patients have a sudden death. It may therefore be possible to predict the majority of deaths, however, this is difficult and errors occur 30 per cent of the time. Two thirds of errors are based on over optimism and one third on pessimism. However, the considerable benefits of identifying these patients include providing the best health and social care to both patients and families and avoiding crises, by prioritising them and anticipating need.

Identifying patients in need of palliative care, assessing their needs and preferences and proactively planning their care, are the key steps in the provision of high quality care at the end of life in general practice. This indicator set is focused on the maintenance of a register (identifying the patients) and on regular multidisciplinary meetings where the team can ensure that all aspects of a patient's care have been assessed and future care can be co-ordinated and planned proactively\textsuperscript{121}.

A patient is included on the register if any of the following apply:

- their death in the next 12 months can be reasonably predicted (rather than trying to predict, clinicians often find it easier to ask 'the 'surprise question' – 'Would I be surprised if this patient were still alive in 12 months?')
- they have advanced or irreversible disease and clinical indicators of progressive deterioration and thereby a need for palliative care eg they have one core and one disease specific indicator in accordance with the GSF Prognostic Indicators Guidance
- they are entitled to a DS 1500 form (the DS 1500 form is designed to speed up the payment of financial benefits and can be issued when a patient is considered to be approaching the terminal stage of their illness. For these purposes, a patient is considered as terminally ill if they are suffering from a progressive disease and are not expected to live longer than six months).

The register applies to all patients fulfilling the criteria regardless of age or diagnosis. The creation of a register will not in itself improve care but it enables the wider practice team to provide more appropriate and patient focussed care.

\textsuperscript{120} GSF. \url{http://www.goldstandardsframework.org.uk/}

\textsuperscript{121} NAO EoLC Report. 'In one PCT 40 per cent of patients who died in hospital in October 2007 did not have medical needs which required them to be treated in hospital, and nearly quarter of these had been in hospital for over a month'. November 2008.
PC 001.2 Reporting and verification

See indicator wording for requirement criteria.

In the rare case of a nil register at year end, if a contractor can demonstrate that it established and maintained a register in the financial year then they will be eligible for payment.

PC indicator 002 (NICE 2015 menu ID: NM111)

The contractor has regular (at least 3 monthly) multi-disciplinary case review meetings where all patients on the palliative care register are discussed

PC 002.1 Rationale

The aims of multidisciplinary case review meetings are to:

- ensure all aspects of the patients care have been considered and documented in the patients records
- improve communication within the team and with other organisations (eg care home, hospital, community nurse specialist) and particularly improve handover of information to out-of-hours services
- co-ordinate each patient's management plan ensuring the most appropriate member of the team takes any action, avoiding duplication
- ensure patients are sensitively enabled to express their preferences and priorities for care, including preferred place of care
- ensure that the information and support needs of carers are discussed, anticipated and addressed where ever reasonably possible.

Many staff directly employed by the contractor find the use of a checklist during the meeting helpful, as it helps to ensure all aspects of care are covered eg supportive care register (SCR) templates SCR1 and SCR2 the assessment tools on the GSF website.

PC 002.2 Reporting and verification

See indicator wording for requirement criteria.

Verification – Commissioners may request that the contractor provides evidence that the meetings took place which could be in the form of minutes of the meetings.

Contractors may also be required to provide written evidence describing the system for initiating and recording meetings.
Section 4: Public health domain

The clinical and health improvement indicators within this domain follow the layout of the clinical domain indicators, referring to sections on the indicator rationale and reporting and verification.

The additional services indicators, within this domain either:

- follow the format of the four areas below along with information to support the indicator:
  1. contractor guidance
  2. reporting and verification

- follow the format of the clinical domain indicators.

Further detail on the above two formats is included in the ‘format’ section below.

Format

For each of the indicators (X.X) using the first format above, there are four descriptions unless it is reported electronically.

X.1 Rationale

This section contains a range of information, dependent on the indicator, including:

- justification for the indicator
- a more detailed description of the indicator
- references which contractors may find useful.

X.2 Reporting and verification

This section outlines the evidence which commissioners may require the contractor to produce for verification purposes. The evidence would not need to be submitted unless requested. In some instances no evidence will be required but may be requested by commissioners at any time.

Commissioners and practices should be aware that the reporting and verification sections for indicators should be considered in conjunction with the requirements outlined in the verification section one and Annex D of the SFE also sets out the full requirements in relation to verification.
Cardiovascular disease – primary prevention (CVD-PP)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CVD-PP001. In those patients with a new diagnosis of hypertension aged 30 or over and who have not attained the age of 75, recorded between the preceding 1 April to 31 March (excluding those with pre-existing CHD, diabetes, stroke and/or TIA), who have a recorded CVD risk assessment score (using an assessment tool agreed with NHS CB) of ≥20% in the preceding 12 months: the percentage who are currently treated with statins</td>
<td>10</td>
<td>40–90%</td>
</tr>
</tbody>
</table>

CVD-PP – rationale for inclusion of indicator set

Cardiovascular disease (CVD) is the most common cause of death in the UK and importantly for patients, the major cause of premature death (before the age of 65). Moreover, of greater significance for the NHS, CVD is not the commonest cause of disability (through stroke and HF particularly) and hospital admission. This results in CVD being the major cost driver for health utilisation and remains the end point disease for many other chronic disorders, especially diabetes and renal disease.

CVD-PP indicator 001 (NICE menu 2011: NM26)

In those patients with a new diagnosis of hypertension aged 30 or over and who have not attained the age of 75, recorded between the preceding 1 April to 31 March (excluding those with pre-existing CHD, diabetes, stroke and/or TIA), who have a recorded CVD risk assessment score (using an assessment tool agreed with NHS England) of ≥20% in the preceding 12 months: the percentage who are currently treated with statins

CVD-PP 001.1 Rationale

For primary prevention of CVD, people at risk need to be identified before CVD has become established. To assess risk in those likely to be at high-risk (for example, people with hypertension) a validated assessment tool is needed that evaluates a range of modifiable and non-modifiable risk factors.

NICE CG181 recommends offering atorvastatin 20 mg for the primary prevention of CVD to patients who have a ten per cent or greater 10-year risk of developing CVD.

CG181 recommends the use of the QRISK2 risk assessment tool. Although QRISK2 is the preferred tool for use, a number of other risk assessment tools may also be used to estimate cardiovascular risk for this indicator. These include:

- Framingham
- Joint British Society 2 (JBS2)
- QRISK.
The three assessment tools listed above allow a structured risk assessment to be undertaken. However, each has a different age threshold; so to include the use of all three tools, the age range for this indicator has been set at aged 30 or over and under the age of 75. Contractors will be expected to use one of the three tools to assess their patients. If the tool normally available on the contractor’s clinical system is not age appropriate, one of the other tools may be used.

Framingham and JBS2 are based on the American Framingham equations. These equations are of limited use in the UK because they were developed in a historic US population. The equations overestimate risk by up to 50 per cent in most contemporary northern European populations, particularly for people living in more affluent areas and underestimate risk in higher risk populations, such as people who are the most socially deprived. Framingham makes no allowance for a family history of premature CHD and does not take account of ethnicity, but does have a full data set.

QRISK has the advantage of including other variables, such as measures of social deprivation, ethnicity and family history. QRISK uses data from UK general practice databases.

**Framingham and JBS2**

The variables needed to estimate risk using the Framingham tool are age, sex, systolic blood pressure (mean of two previous systolic readings), total cholesterol, high density lipoprotein cholesterol, smoking status and presence of left ventricular hypertrophy. JBS2 uses the Framingham variables with the exception of the presence of left ventricular hypertrophy.

Framingham is an assessment of actual, not estimated, risk. The values used should have been recorded no longer than six months before the date of the risk assessment and before any treatment for hypertension. Framingham is not suitable for patients with pre-existing CVD (CHD, angina, stroke, TIA or PAD), diabetes, CKD (if the patient has an eGFR below 60) or familial hypercholesterolemia, or in patients already taking lipid-lowering medication before a new diagnosis of hypertension.

The Framingham risk score may be used in patients aged 35 or over and under the age of 75. JBS2 may be used in people aged 40 or over.

**QRISK**

The QRISK CVD risk calculator was developed by doctors and academics working in the NHS and is based on routinely collected data from GPs across the country. The current version of QRISK is QRISK2. QRISK2 uses the following variables to calculate CVD risk: self-assigned ethnicity, age, sex, smoking status, systolic blood pressure, total cholesterol, HDL cholesterol, BMI, family history of CHD in a first degree relative younger than 60, Townsend deprivation score, treated hypertension, type 2 diabetes, renal disease, AF and RA.

---


QRISK2 may be used in patients aged 25 or over and under the age of 85.

**Clinical effectiveness of primary prevention**

For people without clinical evidence of CVD, statin therapy is associated with a reduction of fatal and nonfatal MI and the composite outcome CHD death or nonfatal MI, fatal and nonfatal stroke and revascularisation. In trials predominantly comprising primary prevention but including a minority of people with established CVD, meta-analysis found that statin therapy was associated with a reduction in the risk of all-cause mortality, fatal and nonfatal MI and the composite outcomes of CHD death, nonfatal MI, fatal or nonfatal stroke and coronary revascularisation.

The NICE clinical guideline on lipid modification makes recommendations on communication about risk assessment and treatment. These include the following:

- Setting aside adequate time during the consultation to provide information on risk assessment and to allow any questions to be answered.
- Documenting the discussion relating to the consultation on risk assessment and the patient’s decision.
- Offering information about the person’s absolute risk of CVD and about the absolute benefits and harms of an intervention over a 10-year period. This information:
  1. presents individualised risk and benefit scenarios
  2. presents the absolute risk of events numerically
  3. uses appropriate diagrams and text.

The guideline also recommends that if the patient’s CVD risk is considered to be at a level that merits intervention but they decline the offer of treatment, they are advised that their CVD risk should be considered again in the future. The guideline also notes that CVD risk may be underestimated in people who are already taking anti-hypertensive or lipid modification therapy, or who have recently stopped smoking.

NICE guidance recommends the decision whether to start statin therapy should be made after an informed discussion between the clinician and patient about the risks and benefits of statin treatment, taking into account additional factors such as potential benefits from lifestyle modifications, informed patient preference, comorbidities, polypharmacy, general frailty and life expectancy.

Before offering statin treatment for primary prevention, discuss the benefits of lifestyle modification and optimise the management of all other modifiable CVD risk factors if possible.

Before starting statin treatment perform baseline blood tests and clinical assessment and treat comorbidities and secondary causes of dyslipidaemia. Include all of the following in the assessment:

- smoking status
- alcohol consumption
- blood pressure
• BMI or other measures of obesity (see the NICE clinical guideline on Obesity\textsuperscript{124})
• total cholesterol, non-HDL cholesterol, HDL cholesterol and triglycerides
• HbA1c
• renal function and eGFR
• transaminase level (alanine aminotransferase or aspartate aminotransferase)
• TSH.

The guideline also states that a target for total or LDL cholesterol is not recommended for people who are treated with a statin for primary prevention of CVD and that once a person has been started on a statin for primary prevention, repeat lipid measurement is unnecessary. It is recommended that clinical judgement and patient preference should guide the review of drug therapy and whether to review the lipid profile.

**CVD-PP 001.2 Reporting and verification**

See indicator wording for requirement criteria.

Patients with the following conditions are excluded from this indicator:

• CHD or angina
• stroke or TIA
• peripheral vascular disease
• familial hypercholesterolemia
• diabetes
• CKD with classification of categories G3a to G5.

Verification – Commissioners may request that the contractor randomly selects a number of case records of patients recorded as having had a risk assessment, to confirm that the key risk factors have been addressed and that biochemical and other clinical data used to inform the risk assessment are up-to-date. Commissioners may also require contractors to demonstrate that age-appropriate risk assessment tools have been used.

\textsuperscript{124} NICE CG43. Obesity prevention. 2006. [www.nice.org.uk/guidance/CG43](http://www.nice.org.uk/guidance/CG43)
Blood pressure (BP)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>BP002. The percentage of patients aged 45 or over who have a record of blood pressure in the preceding 5 years. NICE 2012 menu ID: NM61</td>
<td>15</td>
<td>50–90%</td>
</tr>
</tbody>
</table>

BP indicator 002 (NICE 2012 menu ID: NM61)

The percentage of patients aged 45 or over who have a record of blood pressure in the preceding 5 years

BP 002.1 Rationale

Detecting elevated blood pressure and, where indicated, treating it, is known to be an effective health intervention. Raised blood pressure is common if it is measured on a single occasion but with repeated measurement blood pressure tends to drop. Guideline recommendations for the diagnosis and treatment of hypertension\(^{125}\) are to be followed by practitioners when deciding on whether to treat raised blood pressure.

The age limit of aged 45 or over, has been chosen as the vast majority of patients develop hypertension after this age, this is also in line with the NHS Health Checks Scheme. It is also to align the indicator more closely with the vascular checks programme and the cost-effectiveness modelling undertaken to support that programme. The age range 45 or over, coupled with a five year reference period, is designed to ensure that a blood pressure measurement takes place by the time someone reaches the age of 45.

It is anticipated that contractors will opportunistically check blood pressures in all adult patients.

BP 002.2 Reporting and verification

See indicator wording for requirement criteria.

Generally exception codes do not apply to this indicator. However, practices are able to except patients from this indicator using an indicator specific blood pressure refused code. See the Business Rules for details of the available codes.

Obesity (OB)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>OB002. The contractor establishes and maintains a register of patients aged 18 years or over with a BMI ≥30 in the preceding 12 months</td>
<td>8</td>
<td></td>
</tr>
</tbody>
</table>

**OB – rationale for inclusion of indicator set**

The prevalence of obesity is a major PH challenge for the UK. In England, for example, around a quarter of adults are obese (26 per cent of men and 24 per cent of women)\(^{126}\). In Scotland in 2014, 28 per cent\(^{127}\) of the adult population aged 16 or over and under the age of 65 were obese (BMI >30).

There is a substantive evidence base on the epidemiology of obesity and its association with poor clinical outcomes. In addition to the obvious associated disease burden such as inactivity, degenerative joint disease, lower employment and mood disorders, obesity is also a major contributory factor for some of the most common causes of death and disability in developed economies, most notably greater rates of diabetes\(^{128}\) and accelerated onset of CVD\(^{129}\). Obesity has therefore become a major health issue for the UK. The Foresight UK Tackling Obesities report 2007 estimated the cost to the UK of obesity to be £50 billion in 2050 at today's prices.

Tackling obesity is a high priority in England, the Government published "A call to action on obesity in England" in October 2011. This sets out new national ambitions for tackling excess weight in children and adults and calls on a range of partners to play their part.

Further information


NICE public health guidance 41. Walking and cycling: local measures to promote walking and cycling as forms of travel or recreation. 2012. [https://www.nice.org.uk/guidance/ph41](https://www.nice.org.uk/guidance/ph41)

NICE public health guidance 42. Obesity: working with local communities. 2012. [https://www.nice.org.uk/guidance/ph42](https://www.nice.org.uk/guidance/ph42)


---


\(^{129}\) Gregg et al. JAMA. 2005; 293 (15): 1868-74


**OB indicator 002 (NICE 2014 menu ID: NM85)**

The contractor establishes and maintains a register of patients aged 18 years or over with a BMI ≥30 in the preceding 12 months

**OB 002.1 Rationale**

The register includes all patients whose BMI has been recorded in the practice as part of routine care. It is expected that this data will inform PH measures.

The updated NICE guidance CG189 recommends using BMI as a practical estimate of adiposity in adults. Identifying people with a BMI ≥25 includes a preventative aspect of care in managing obesity and supports interventions for people at risk of obesity ie those who are overweight but not yet obese.

Obesity is a factor in many serious illnesses including type 2 diabetes, heart disease and certain cancers. Women who are obese are estimated to be around 13 times more likely to develop type 2 diabetes and four times more likely to develop hypertension than women who are not obese. Men who are obese are estimated to be around five times more likely to develop type 2 diabetes and 2.5 times more likely to develop hypertension than men who are not obese.

However, fixed BMI values are not recommended for the classification of obesity in children. The NICE guideline on obesity recommends that for children and young people under the age of 18 years, BMI measurement should be related to the UK 1990 BMI growth reference charts to give age- and gender-specific information.

The Guideline Development Group considered that there was a lack of evidence to support specific cut-offs in children and stressed that the cut-offs are necessarily arbitrary. However, they concluded that classifying overweight and obesity in children based on the UK 1990 BMI charts using centiles should be recommended as practical and pragmatic for assessing and monitoring individual children.

**OB 002.2 Reporting and verification**

See indicator wording for requirement criteria.
## Smoking (SMOK)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Records</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| SMOK002. The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months  
*NICE 2011 menu ID: NM38* | 25 | 50–90% |
| **Ongoing management** |        |                        |
| SMOK003. The contractor supports patients who smoke in stopping smoking by a strategy which includes providing literature and offering appropriate therapy | 2 |        |
| SMOK004. The percentage of patients aged 15 or over who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 24 months  
*Based on NICE 2011 menu ID: NM40* | 12 | 40–90% |
| SMOK005. The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months  
*NICE 2011 menu ID: NM39* | 25 | 56–96% |

### SMOK indicator 002 (NICE 2011 menu ID: NM38)

The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months

#### SMOK 002.1 Rationale

See SMOK004.1 and SMOK005.

#### SMOK 002.2 Reporting and verification

See indicator wording for requirement criteria. The contractor should report smoking status using the following guidance:

**Smokers**

For patients who smoke, smoking status should be recorded in the preceding 12 months.
Non-smokers

It is recognised that life-long non-smokers are very unlikely to start smoking and repeatedly asking smoking status can be unnecessary. Smoking status for this group of patients should be recorded in the preceding 12 months for until the end of the financial year in which the patient reaches the age of 25.

Once a patient is over the age of 25 years (eg in the financial year in which they reach the age of 26 or in any year following that financial year) to be classified as a non-smoker they should be recorded as:

- never smoked which is both after their 25th birthday and after the earliest diagnosis date for the disease which led to the patients inclusion on the SMOK002 register (eg one of the conditions listed on the SMOK002 register).

Ex-smokers

Ex-smokers can be recorded as such in the preceding 12 months for SMOK002. Practices may choose to record ex-smoking status on an annual basis for three consecutive financial years and after that smoking status need only be recorded if there is a change. This is to recognise that once a patient has been an ex-smoker for more than three years they are unlikely to restart.

For the purposes of QOF users of electronic cigarettes who have never smoked or given up smoking should be classified as non-smokers or ex-smokers respectively.

The disease register for the purpose of calculating APDF for SMOK002 and SMOK005 is defined as the sum of the number of patients on the disease registers for each of the conditions listed in the indicator wording. Patients with one or more co-morbidities eg diabetes and CHD are only counted once.

SMOK indicator 003 (NICE 2015 menu ID: NM113)

The contractor supports patients who smoke in stopping smoking by a strategy which includes providing literature and offering appropriate therapy

**SMOK 003.1 Rationale**

There is good evidence about the effectiveness of healthcare professionals in assisting patients to stop smoking.

A number of studies have recently shown benefits from the prescription of nicotine replacement therapy to buproprion in patients who have indicated a wish to quit smoking.

The strategy does not need to be written by the practice team. A local or national protocol could be adapted for use specifically by the contractor and implemented.

The provision of dedicated smoking cessation services remains the responsibility of NHS England.

**SMOK 003.2 Reporting and verification**

See indicator wording for requirement criteria.
Verification – Commissioners may choose to review prescribing data and may also examine the literature available for patients who wish to quit smoking. Signs of implementation may be evident in the contractor’s prescribing data or in the patient leaflets that are used by the contractor.

There is no APDF calculation for SMOK003 and SMOK004.

**SMOK indicator 004 (based on NICE 2011 menu ID: NM40)**

The percentage of patients aged 15 or over who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 24 months

**SMOK 004.1 Rationale**

The aim of this domain is to increase the proportion of successful smoking quit attempts by providing the best available support and treatment. A wide range of diseases and conditions are caused by cigarette smoking, including cancers, respiratory diseases, CHD and other circulatory diseases, stomach and duodenal ulcers, ED and infertility, osteoporosis, cataracts, age-related macular degeneration and periodontitis (US DH and Human Services 2004). Smoking during pregnancy can cause serious pregnancy related health problems, these include: complications during labour and an increased risk of miscarriage, premature birth, still birth, low birth-weight and sudden unexpected death in infancy. Smoking during pregnancy also increases the risk of infant mortality by an estimated 40 per cent.

In 2011, 20 per cent of the adult population of Great Britain were cigarette smokers. The overall prevalence of smoking has been at approximately this level since 2007. Around 33 per cent of the population of England tried to stop in 2011, but only two to three per cent of the population succeed in stopping. Many of these attempts fail because they are made without treatment.

There is good evidence to suggest that offering support and treatment is sufficient to motivate some smokers to attempt to stop who would not have done so with brief advice to quit alone. For example, a Cochrane review that included 132 trials of nicotine replacement therapy (NRT), with over 40,000 people in the main analysis, found evidence that all forms of NRT made it more likely that a person’s attempt to quit smoking would succeed. The chances of stopping smoking were increased by 50 to 70 per cent.

NHS Stop Smoking Services, combine psychological support and medication.

---


Results for April 2012 to March 2013 showed that 724,247 people who had contact with the service had set a quit date. Four weeks later, 373,872 people had successfully quit (based on self-report) representing half of those who set a quit date\textsuperscript{135}.

‘An offer of support and treatment’ means offering a referral or self-referral to a local NHS Stop Smoking Service adviser (who might be a member of the practice team) plus pharmacotherapy. Where such support is not acceptable to the patient, an alternative form of brief support, such as follow-up appointments with a GP or practice nurse trained in smoking cessation, may be offered.

The NICE public health guidance on smoking cessation\textsuperscript{136} states that healthcare professionals who advise on, or prescribe, NRT, varenicline or bupropion:

- offer NRT, varenicline or bupropion, as appropriate, to patients who are planning to stop smoking
- offer advice, encouragement and support, including referral to the NHS Stop Smoking Service, to help patients in their attempt to quit
- when deciding which therapies to use and in which order, discuss the options with the client and take into account:
  1. whether a first offer of referral to the NHS Stop Smoking Service has been made
  2. contra-indications and the potential for adverse effects
  3. the client's personal preferences
  4. the availability of appropriate counselling or support
  5. the likelihood that the client will follow the course of treatment
  6. their previous experience of smoking cessation aids.

The guidance also states that managers and providers of NHS Stop Smoking Services:

- offer behavioural counselling, group therapy, pharmacotherapy, or a combination of treatments that have been proven to be effective
- ensure clients receive behavioural support from a person who has had training and supervision that complies with the 'Standard for training in smoking cessation treatments'\textsuperscript{137} or its updates
- provide tailored advice, counselling and support, particularly to clients from minority ethnic and disadvantaged groups
- provides services in the language chosen by clients, wherever possible.

NICE public health guidance also states that stop smoking advisers and other healthcare practitioners who advise on, supply, or prescribe, pharmacotherapies should encourage people who are already using an unlicensed nicotine-containing

\textsuperscript{135} HSCIC. Statistics on NHS Stop Smoking Services 2012/13 published 2013. \url{http://www.hscic.gov.uk/catalogue/PUB12228}
\textsuperscript{136} NICE public health guidance 10. Stop smoking services. 2008. \url{http://www.nice.org.uk/guidance/PH10}
\textsuperscript{137} HDA. Standard for training in smoking cessation treatments. 2003.
product (such as unlicensed electronic cigarettes) to switch to a licensed product\textsuperscript{138}.

Due to the potential for ex-smokers to resume smoking within three years of cessation, it is good clinical practice to ask patients with a history of smoking their current smoking status and offer treatment and advice where necessary. It is also good practice to ask and record the smoking status of newly registered patients and to offer support and treatment where necessary.

For further information see NICE public health guidance 1, 10, 45 and 48.

**SMOK 004.2 Reporting and verification**

See indicator wording for requirement criteria.

There is no APDF calculation for SMOK003 and SMOK004.

**SMOK indicator 005 (NICE 2011 menu ID: NM39)**

The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 12 months

**SMOK 005.1 Rationale**

See SMOK 004.1 for guidance on 'support and treatment' and smoking cessation.

This indicator relates to patients who are on the disease registers for CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma and mental health who are recorded as current smokers.

**CHD**

Smoking is known to be associated with an increased risk of CHD.


**PAD**

PAD is associated with older age and with smoking. Cigarette smoking is a very important contributor to PAD and as such the management of PAD includes smoking cessation.

**Stroke or TIA**

There are few RCTs of the effects of risk factor modification in the secondary prevention of ischaemic or haemorrhagic stroke. However, inferences can be drawn

from the finds of primary prevention trials that cessation of cigarette smoking be advocated.


Hypertension

There is no strong direct link between smoking and blood pressure. However, there is overwhelming evidence of the relationship between smoking and cardiovascular and pulmonary diseases. The NICE clinical guideline on hypertension recommends that patients who smoke are offered advice and help to stop smoking.

Diabetes

The risk of vascular complications in patients with diabetes is substantially increased. Smoking is an established risk factor for cardiovascular and other diseases.

COPD

Smoking cessation is the single most effective and cost-effective intervention to reduce the risk of developing COPD and stop its progression.


Asthma

There are a surprisingly small number of studies on smoking related asthma. Starting smoking as a teenager increases the risk of persisting asthma. One controlled cohort study suggested that exposure to passive smoke at home delayed recovery from an acute attack. Smoking reduces the benefits of inhaled steroids and this adds further justification for recording this outcome. There is also epidemiological evidence that smoking is associated with poor asthma control.

CKD

There is good evidence from observational studies that patients with CKD are at increased cardiovascular risk and hence the rationale for including CKD.

Schizophrenia, bipolar affective disorder or other psychoses

Patients with a serious mental illness are far more likely to smoke than the general, a


UK community cohort study of people with schizophrenia found that 73 per cent smoked, this compares with only around 22 per cent of the general population who currently smoke. Premature death and smoking related diseases, such as respiratory disorders and heart disease, are however, more common among patients with serious mental illness who smoke than in the general population of smokers.

See requirements for recording smoking status for further information.

**SMOK 005.2 Reporting and verification**

See indicator wording for requirement criteria.

The disease register for the purpose of calculating APDF for SMOK002 and SMOK005 is defined as the sum of the number of patients on the disease registers for each of the conditions listed in the indicator wording. Patients with one or more co-morbidities e.g. diabetes and CHD are only counted once.

---


143 McDonald C. Cigarette smoking in patients with schizophrenia. BJP. 2000; 176: 596-7
Public health domain – additional services

For contractors providing additional services the following indicators apply.

Please note exception reporting does not apply to those additional services indicators that do not have achievement thresholds.

Cervical screening (CS)

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>CS001. The contractor has a protocol that is in line with national guidance agreed with NHS CB for the management of cervical screening, which includes staff training, management of patient call/recall, exception reporting and the regular monitoring of inadequate sample rates</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>CS002. The percentage of women aged 25 or over and who have not attained the age of 65 whose notes record that a cervical screening test has been performed in the preceding 5 years</td>
<td>11</td>
<td>45–80%</td>
</tr>
<tr>
<td>CS004. The contractor has a policy for auditing its cervical screening service and performs an audit of inadequate cervical screening tests in relation to individual sample-takers at least every 2 years</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>

CS indicator 001

The contractor has a protocol that is in line with national guidance agreed with NHS England for the management of cervical screening, which includes staff training, management of patient call/recall, exception reporting and the regular monitoring of inadequate sample rates

CS 001.1 Rationale

If a robust system for the management of cervical screening is not in place then this is an area of great risk for general practice. The policy may have been drawn up outside the practice and is recommended to be in line with national guidance.

See guidance on exception reporting in section CS 002.1 contractor guidance.

The contractor’s protocol could be in the form of a written policy covering the issues outlined in the indicator wording.

CS 001.2 Reporting and verification

See indicator wording for requirement criteria.

The relevant practice staff are to be aware of the policy and commissioners may require that the contractor can demonstrate how the systems operate.
CS indicator 002

The percentage of women aged 25 or over and who have not attained the age of 65 whose notes record that a cervical screening test has been performed in the preceding 5 years

CS 002.1 Rationale

This indicator is designed to encourage and incentivise contractors to continue to achieve high levels of uptake in cervical screening.

The contractor may be required to provide evidence of the number of eligible women, aged 25 or over and under the age of 65, who have had a cervical screening test performed in the last five years/60 months.

This indicator differs from all the other additional service indicators in that a sliding scale will apply between 45 and 80 per cent, in a similar way to the clinical indicators.

Exception reporting (as detailed in the clinical domain) will apply and specifically includes women who have had a hysterectomy involving the complete removal of the cervix.

The exception reporting rules regarding criteria A require that three separate invitations are offered to the patient before that patient can be recorded as ‘did not attend’. Therefore:

- in those areas where the first two invitations are sent via the central screening service, then contractors are responsible for offering the third invitation before exception reporting patients as DNA; or
- where the central screening service sends out only one letter, then contractors are responsible for offering the second and third invitations before exception reporting patients as DNA.

The exception reporting criteria is not applicable to contractors that have opted to run their own call/recall system. These contractors will still be required to offer all three invitations directly in order to meet the DNA criteria. Copies of the letters sent by the contractor may be required for assessment purposes.

Women can choose to withdraw from the national screening programme. As the indicator requires that screening is delivered every five years, in order for a woman to be exception reported for this period, criteria G which requires that a discussion has taken place between the patient and the practitioner before ‘informed dissent’ can be recorded.

Women who withdraw from cervical screening call/recall will receive no further offers of screening from the central screening service.

**CS 002.2 Reporting and verification**

See indicator wording for requirement criteria.

Commissioners may require that the contractor can provide a computer print-out showing the number of eligible women on the contractor list, the number exception reported and the number who have had a cervical screening test performed in the preceding five years. Contractors can exception report patients in the same way as the clinical indicators and commissioners may enquire how patients who are exception reported are identified and recorded.

**CS indicator 004**

The contractor has a policy for auditing its cervical screening service and performs an audit of inadequate cervical screening tests in relation to individual sample-takers at least every 2 years.

**CS 004.1 Contractor guidance**

In this audit the criteria, the results, corrective action, the results of the re-audit and a discussion of them needs to be presented. The standard or level of performance against which the criterion is judged would usually involve looking for sample-takers who are obvious outliers in relation to the reading laboratory's average for inadequate samples.

**CS 004.2 Written evidence**

See indicator wording for requirement criteria.

Commissioners may require that an audit of inadequate samples is recorded.

Commissioners may also request a discussion takes place with sample-takers covering the audit and any educational needs which arose and how these were met.
**Contraception (CON)**

<table>
<thead>
<tr>
<th>Indicator</th>
<th>Points</th>
<th>Achievement thresholds</th>
</tr>
</thead>
<tbody>
<tr>
<td>CON001. The contractor establishes and maintains a register of women aged 54 or under who have been prescribed any method of contraception at least once in the last year, or other clinically appropriate interval eg last 5 years for an IUS</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>CON003. The percentage of women, on the register, prescribed emergency hormonal contraception one or more times in the preceding 12 months by the contractor who have received information from the contractor about long acting reversible methods of contraception at the time of or within 1 month of the prescription NICE 2015 menu ID: NM115</td>
<td>3</td>
<td>50–90%</td>
</tr>
</tbody>
</table>

**CON – rationale for inclusion of indicator set**

The vast majority of contractors are providing the additional service for contraception and many are also providing enhanced services including long acting reversible contraception (LARC) methods. All contractors providing any level of contraception need to be able to advise women about all methods to ensure they can make an informed choice. It is advised that clinical staff in practices are aware of local services and local referral pathways.

This indicator set seeks to increase the awareness of women seeking contraceptive advice in general practices of LARC methods and thus to increase the percentage of women using these methods.

**CON indicator 001**

The contractor establishes and maintains a register of women aged 54 or under who have been prescribed any method of contraception at least once in the last year, or other clinically appropriate interval eg last 5 years for an IUS

**CON 001.1 Rationale**

Any woman who has been prescribed any method at least once in the last year (or the appropriate prescribing interval for method of choice) is included on the register.

**CON 001.2 Reporting and verification**

See indicator wording for requirement criteria.

This register is applicable to all methods of contraception that have been prescribed by the contractor:

- emergency hormonal contraception (EHC)
- combined oral contraception
- progestogen only oral contraception
- contraceptive patch
- contraceptive diaphragm
intrauterine device (IUD)
- intrauterine system (IUS)
- contraceptive injectable.

The indicator is prospective from 1 April 2009.

**CON indicator 003 (NICE 2015 menu ID: NM115)**

The percentage of women, on the register, prescribed emergency hormonal contraception one or more times in the preceding 12 months by the contractor, who have received information from the contractor about long acting reversible methods of contraception at the time of or within 1 month of the prescription

**CON 003.1 Rationale**

Women requiring EHC are given detailed information about and offered a choice of all methods, including LARC. It is often possible (and in many cases ideal practice) to commence an ongoing method of contraception at the same time as EHC is given.

Some women seeking EHC may be best served by being offered an emergency IUD. Emergency IUDs offer a slightly longer window period for action after unprotected intercourse than hormonal EC; they have a higher efficacy in prevention of pregnancy – and they provide excellent ongoing contraception if required.

Information from the contractor in written and verbal form. Leaflets can be obtained from a number of sources however the FPA, a UK-wide sexual health charity, has an excellent range of contraception leaflets including 'Your guide to Contraception', which, amongst other things, indicated LARC and non-LARC methods clearly through the use of shading.

**CON 003.2 Reporting and verification**

See indicator wording for requirement criteria.
Section 5: Exception reporting

Exception reporting is intended to allow contractors to pursue the quality improvement agenda without being penalised for patient specific clinical circumstances or other circumstances beyond the contractor’s control which lead to failure to achieve the indicator. For example, where a medication cannot be prescribed due to a contra-indication or side-effect, where patients do not attend for review or where secondary care services are not available.

A variety of interpretations and applications of the nationally defined exception reporting criteria are possible. This exception reporting guidance is valid from April 2013 and supersedes any previous guidance issued. It is supplementary to the paragraphs included in section one of this document. This guidance is intended to help commissioners and practices understand what constitutes good practice in exception reporting and to provide additional clarity in order to help maintain a consistent approach to exception reporting.

Principles

The overriding principles to follow in deciding to except a patient are that:

- the duty of care remains for all patients, irrespective of exception reporting arrangements
- it is good practice for clinicians to review from time to time those patients who are excepted from treatment eg to have continuing knowledge of health status and personal health goals
- the decision to exception report should be based on clinical judgement, relevant to the patient, with clear and auditable reasons coded or entered in free text on the patient record
- there should be no blanket exceptions: the relevant issues with each patient should be considered by the clinician at each level of the clinical indicator set.

In each case where a patient is exception reported, in addition to recording what should be reported for payment purposes (in accordance with the Business Rules), the contractor should also ensure that the clinical reason for the exception is fully recorded in a way that can facilitate an audit in the patient record. This is both in order to manage the care of that particular patient and for the purpose of verification.

Definitions

There is an important distinction to be made between ‘exclusions’ and ‘exceptions’.

Exclusions are patients on a particular clinical register, but who for definitional reasons are not included in a particular indicator denominator. For example, an indicator (and therefore the denominator) may refer only to patients of a specific age group, patients with a specific status (eg those who smoke), or patients with a specific length of diagnosis, within the register for that clinical area.
Exceptions are patients who are on the disease register and who would ordinarily be included in the indicator denominator. However they are excepted from the indicator denominator because they meet at least one of the exception criteria set out in the SFE. Although patients may be excepted from the denominator, they should still be the recipients of best clinical care and practice.

Although Annex D of the SFE sets out nine reasons why a patient may be exception reported, the national QOF achievement system (CQRS) identifies exception reporting against a limited number of codes. For example, criteria A and G are both coded as 'informed dissent' or 'patient refused'. Any patient is only excepted once by the system for a given indicator, but any patient’s clinical record could contain more than one type of exception reporting Read code entered by the contractor. It is therefore not possible to collect completely accurate or meaningful data on exceptions broken down by each of the criteria defined in the SFE from the national systems. Therefore the HSCIC only reports the total numbers of patients excepted for each indicator.

For the purposes of managing the care of the patient and for subsequent audit and verification, it is important that the reason the patient meets one or more of the exception reporting criteria and any underlying clinical reason for this is recorded in the patient’s clinical record. For example, where a patient has not tolerated medication, the nature of the contraindication should be recorded in the patient’s notes as well as the exception reporting code applied.

Exception reporting criteria

Patients may be excepted if they fall within the strict criteria detailed below:

- patients who have been recorded as refusing to attend review who have been invited on at least three occasions during the financial year to which the achievement payments relate (except in the case of indicator CS002, where the patient should have been invited on at least three occasions during the period of time specified in the indicator during which achievement is to be measured (eg the preceding five years ending on 31 March in the financial year to which achievement payments relate)
- patients for whom it is not appropriate to review the chronic disease parameters due to particular circumstances, for example, a patient who has a terminal illness or is extremely frail
- patients newly diagnosed or who have recently registered with the contractor who should have measurements made within three months and delivery of clinical standards within nine months eg blood pressure or cholesterol measurements within target levels
- patients who are on maximum tolerated doses of medication whose levels remain sub-optimal
- patients for whom prescribing a medication is not clinically appropriate eg those who have an allergy, contra-indication or have experienced an adverse reaction
- where a patient has not tolerated medication
- where a patient does not agree to investigation or treatment (informed dissent) and this has been recorded in their patient record following a discussion with the patient
- where the patient has a supervening condition which makes treatment of their condition inappropriate eg cholesterol reduction where the patient has liver disease
- where an investigative service or secondary care service is unavailable.

When exception reporting on criteria A and B, these patients are removed from the denominator for all indicators in that disease area where the care had not been delivered. For example, a contractor with 100 patients on the coronary heart disease (CHD) disease register, of which four patients have been recalled for follow-up on three occasions but have not attended and one patient has become terminally ill with metastatic breast carcinoma during the year, the denominator for reporting would be 95. However, all 100 patients with CHD would be included in the calculation of APDF (practice prevalence). This would apply to all relevant indicators in the CHD set.

Contractors may exception report patients from single indicators if they meet criteria in C to I, for example a patient who has HF due to LVSD but who is intolerant of ACE-inhibitors (ACE-I) and ARB could be exception reported from HF003. This would result in the patient being removed from the denominator for that indicator only.

Contractors should report the number of exceptions for each indicator set and individual indicator. Contractors will not be expected to report why individual patients were exception reported. However, contractors may be called on to explain why they have 'excepted' patients from an indicator and this can be identifiable in the patient record.

When an appropriate exception code has been added to the patient record, it applies only to the QOF year in which it was added. If the timeframe defined to deliver the care described in the indicator wording spans more than one QOF year, the exception would need to be added for each relevant QOF year.

**Examples of exception reporting**

Examples of each of the nine criteria for exception reporting are detailed below:

**Patients who have been recorded as refusing to attend review who have been invited on at least three occasions during the preceding 12 months**

Invitations to attend a review should be made to the individual patient and can be in writing or by telephone. This can include a note at the foot of the patient's prescription requesting that they attend for review.

The three invitations need to have taken place within the financial year in question (eg 1 April 2016 to 31 March 2017 if applying to the year 2016/17). There should be three separate invitations at three unique periods of time. The only exception to this rule is indicator CS002, where the period in which the three invitations are sent reflects the timeframe of the indicator eg five years.
Practices may make use of methods other than written letters to offer patient appointments. However, this must be with the explicit consent of the patient concerned and their acceptance to be contacted via another media. The invitation must also be specific to individual patient. For example:

'appointment for patient x, at 00.00, on DD/MM/YYYY, at practice Y'

A telephone call invitation may lead to the application of exception criteria G, 'informed dissent', if the patient refuses to take up the invitation to attend.

The following are examples that are not acceptable as an invitation:

- a generic invitation on the right hand side of the script to attend a clinic or an appointment eg influenza immunisation
- a notice in the waiting room inviting particular groups of patient to attend clinics or make appointments (eg influenza immunisation).

**Influenza immunisation indicators**

Exception reporting for influenza immunisation has caused some confusion because it is also remunerated through an ES. For the ES, payment is based on the number of at-risk patients immunised. The enhanced service nevertheless requires the contractor to develop a proactive approach and a robust call and reminder system for the at-risk groups.

For QOF, the payment is based on the percentage of patients immunised in each relevant disease area. Exception reporting rules apply to the QOF indicators and patients need to have been personally invited on at least three occasions that year to be excluded from the denominator for achievement under criteria A.

**Cervical screening indicators**

Exception reporting (as detailed in the clinical domain) will apply and specifically includes women who have had a hysterectomy involving the complete removal of the cervix.

The exception reporting rules regarding criteria A require that three separate invitations are offered to the patient before that patient can be recorded as 'did not attend'. Therefore:

- in those areas where the first two invitations are sent via the central screening service, then contractors are responsible for offering the third invitation before exception reporting patients as DNA, or
- where the central screening service sends out only one letter, then contractors are responsible for offering the second and third invitations before exception reporting patients as DNA.

The exception reporting criteria is not applicable to contractors that have opted to run their own call/recall system. These contractors will still be required to offer all three invitations directly in order to meet the DNA criteria. Copies of the letters sent by the contractor may be required for assessment purposes.

Women can choose to withdraw from the national screening programme. As the
indicator requires that screening is delivered every five years, in order for a woman to be exception reported for this period, criteria G which requires that a discussion has taken place between the patient and the practitioner before 'informed dissent' can be recorded.

Women who withdraw from cervical screening call/recall will receive no further offers of screening from the central screening service.

**Patients for whom it is not appropriate to review the chronic disease parameters due to particular circumstances eg terminal illness, extreme frailty**

The overriding principle is that blanket exception reporting is not acceptable and individual decisions based on clinical judgment should be made.

It is not acceptable to exclude all patients above a certain age or all those with a particular diagnosis eg dementia or cancer. However, age, diagnosis, co-morbidity, health and functional status should be taken into account when deciding whether to exception report individual patients under this criteria.

In each individual case there is a question of degree which requires clinical judgement to be exercised.

**Patients newly diagnosed or who have recently registered with the contractor, who should have measurements made within three months and delivery of clinical standards within nine months eg blood pressure or cholesterol measurements within target levels**

Exception reporting is done automatically through the national achievement analysis system. Where the contractor has delivered the appropriate clinical standard within the timeframe for the indicator, the achievement would automatically override the exception.

**Patients who are on maximum tolerated doses of medication whose levels remain sub-optimal**

The over-riding principle is that blanket exception reporting is not acceptable and each case is to be considered on its own merits, making a clinical judgment (see criteria B).

It is not acceptable to exclude all patients who are under the care of a consultant. Each case needs to be carefully considered and all reasonable efforts made to provide optimal care.

Even when a patient is under the care of a consultant only, the contractor should ensure it has evidence that all the requirements of the contract have been carried out. If this evidence is not available, the contractor should assume that the action has not been carried out. The patient should not be exception reported on the basis that they are under the care of a consultant. The contractor should either fulfil the requirements of the relevant indicator(s) or obtain evidence from secondary care that the particular test/check has been carried out. Where the secondary care clinician, in agreement with the primary care clinician, has exercised clinical judgement and decided further action or testing is inappropriate, exception reporting will be allowed. This should be noted in the patient record.
Patients for whom prescribing a medication is not clinically appropriate eg those who have an allergy, another contra-indication or have experienced an adverse reaction

The nature of the contra-indication, allergy or adverse drug reaction should be recorded in the patient record as well as the exception reporting code applied.

Where a patient has not tolerated medication

The nature of the intolerance should be recorded in the patient record as well as the exception reporting code applied.

Where a patient does not agree to investigation or treatment (informed dissent) and this has been recorded in their patient record following a discussion with the patient

A personal contact or discussion should be documented in the patient's record for this criteria to apply. This can include face-to-face, video conferencing or telephone contact between a health professional and the patient. These methods of communication relate to the informed dissent discussion only, they do not apply to consultations.

Patients not responding to invitations to attend or failing to arrive at appointments cannot be exception reported under criteria G, eg DNA alone does not fulfil the criteria for informed dissent. Patients failing to respond after three invitations can be exception reported under criteria A.

The informed dissent should have been given in the period 1 April 2016 to 31 March 2017 if applying to the year 2016/17) (except cervical screening where a patient has withdrawn from the call and recall system).

Where the patient has a supervening condition which makes treatment of their condition inappropriate eg cholesterol reduction where the patient has liver disease

The nature of the supervening condition should be recorded in the patient’s notes as well as the exception reporting code applied.

Where an investigative or secondary care service is unavailable

The contractor would be expected to explore fully with their CCG, whether or not a suitable investigative or secondary service could be commissioned for the patient prior to deciding to except them on the basis that the service was unavailable.
Exception reporting FAQs

Do exception codes apply to registers?

Patients can only be 'excepted' from indicators and not registers within QOF.

Is exception reporting done on an indicator by indicator basis?

The codes for criteria A (patient refused to attend), B (patient unsuitable), G (informed dissent) except the patient from all the indicators in the indicator set. Other exception criteria must be applied on an indicator by indicator basis such as those indicators which have disease specific codes to record contraindications and intolerances (D, E and F) or where a patient has a supervening condition (H) or where a secondary care service is unavailable (I).

Achievement overrules an exception, therefore even if a patient has been exception reported from an indicator and the practice then delivers the activity described (ie not with the particular indicator in mind but by default) then this would count towards achievement.

For example, if a patient is exception reported from the diabetes indicator set in July, but the practice checks the patient’s blood pressure in December for an unrelated reason and it is 140/80 or less, then that patient would count towards the achievement for DM003.

Can patients newly registered with a practice who have not had assessments undertaken within the required time from initial diagnosis be exception reported?

Patients who are not seen within the allotted time cannot be exception reported. The reason is practices could simply exception report any patient who had not met the target, thereby meeting the requirement whether reviews were taking place or not.

If a patient newly registers or is newly diagnosed in the last three months of the year (1 January – 31 March) they are automatically excepted from measurement indicators. Similarly, for target indicators they are automatically excepted for the last nine months of the year (1 July – 31 March). These patients will however, go in to the denominator for relevant indicators in subsequent years therefore practices should make every effort to deliver the care required in line with good clinical practice.

If an indicator requires that a patient is invited for a review but is exception reported ie patient unsuitable or patient did not attend, should they be invited to attend for a review the following QOF year?

Exceptions in QOF are valid only for the QOF year that the code was entered with the exception of CS002. Therefore, the three invites would need to be sent out each year and only when the patients has refused to attend all three appointments can the practice exception report that patient.

How long is an exception code valid?

When an appropriate exception code has been added to the patient record, it applies only to the QOF year in which it was added. If the timeframe defined to deliver the
care described in the indicator wording spans two QOF years, the exception would need to be added for each of the QOF years.

For example DM014 requires that a patient has been referred to a structured education programme within nine months of them being added to the diabetes register. If a patient is diagnosed within the last nine months of the 2015/16 year (from 1 July 2015) and a valid exception code is recorded by 31 March 2016, then that patient is excepted for the 2015/17 QOF year. If the nine months from diagnosis window extends in to the 2016/17 QOF year, then the practice would need to re-enter that exception code for 2016/17.

Will practice exception reporting data be published?

Exception reporting data for all practices in England is published by the HSCIC each year.

If a practice exception reports all eligible patients within a disease area ie where a secondary care service is not available, can the practice still claim the points?

If all patients are exception reported then this will result in non-achievement of the indicator(s) and no payment will be due.
## Section 6: Glossary of acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>A&amp;E</td>
<td>Accident and Emergency</td>
</tr>
<tr>
<td>ABPI</td>
<td>Ankle Brachial Pressure Index</td>
</tr>
<tr>
<td>ABPM</td>
<td>Ambulatory Blood Pressure Monitoring</td>
</tr>
<tr>
<td>ACCORD</td>
<td>Action to Control Cardiovascular Risk in Diabetes</td>
</tr>
<tr>
<td>ACE-Inhibitor or ACE-I</td>
<td>Angiotensin Converting Enzyme Inhibitor</td>
</tr>
<tr>
<td>ACR</td>
<td>Albumin Creatinine Ratio</td>
</tr>
<tr>
<td>ADA</td>
<td>After Death Analysis</td>
</tr>
<tr>
<td>AF</td>
<td>Atrial Fibrillation</td>
</tr>
<tr>
<td>AFI1</td>
<td>AF Investigators I Study</td>
</tr>
<tr>
<td>AMA</td>
<td>American Medical Association</td>
</tr>
<tr>
<td>APDF</td>
<td>Adjusted Practice Disease Factor</td>
</tr>
<tr>
<td>ARB</td>
<td>Angiotensin Receptor Blocker</td>
</tr>
<tr>
<td>AST</td>
<td>Asthma</td>
</tr>
<tr>
<td>ATC</td>
<td>Antithrombotic Trialists Collaboration</td>
</tr>
<tr>
<td>ATS/ERS</td>
<td>American Thoracic Society/European Respiratory Society</td>
</tr>
<tr>
<td>BDI-II</td>
<td>Beck Depression Inventory, second edition</td>
</tr>
<tr>
<td>BMD</td>
<td>Bone Mass Density</td>
</tr>
<tr>
<td>BMI</td>
<td>Body Mass Index</td>
</tr>
<tr>
<td>BMA</td>
<td>British Medical Association</td>
</tr>
<tr>
<td>BMJ</td>
<td>British Medical Journal</td>
</tr>
<tr>
<td>BNF</td>
<td>British National Formulary</td>
</tr>
<tr>
<td>BP</td>
<td>Blood Pressure</td>
</tr>
<tr>
<td>BPA</td>
<td>Bio-psychosocial Assessment</td>
</tr>
<tr>
<td>BTS</td>
<td>British Thoracic Society</td>
</tr>
<tr>
<td>CABG</td>
<td>Coronary Artery Bypass Grafting</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>CAN</td>
<td>Cancer</td>
</tr>
<tr>
<td>CCG</td>
<td>Clinical Commissioning Group</td>
</tr>
<tr>
<td>CG</td>
<td>Clinical guideline (NICE)</td>
</tr>
<tr>
<td>CHD</td>
<td>Coronary Heart Disease</td>
</tr>
<tr>
<td>CHADS2</td>
<td>Congestive (HF) Hypertension Age (75 or over) Diabetes Stroke</td>
</tr>
<tr>
<td>CHA₂DS₂-VASc</td>
<td>Congestive (HF) Hypertension Age (75 or over) Diabetes Stroke (prior stroke) Vascular Disease (peripheral artery disease) Age (65–74 years) Sex Category (ie female)</td>
</tr>
<tr>
<td>CKD</td>
<td>Chronic Kidney Disease</td>
</tr>
<tr>
<td>CMO</td>
<td>Chief Medical Officer</td>
</tr>
<tr>
<td>CON</td>
<td>Contraception</td>
</tr>
<tr>
<td>COPD</td>
<td>Chronic Obstructive Pulmonary Disease</td>
</tr>
<tr>
<td>CPA</td>
<td>Care Programme Approach</td>
</tr>
<tr>
<td>CPI</td>
<td>Contractor Population Index</td>
</tr>
<tr>
<td>CQRS</td>
<td>Calculating Quality Reporting Service</td>
</tr>
<tr>
<td>CRP</td>
<td>C-Reactive Protein</td>
</tr>
<tr>
<td>CS</td>
<td>Cervical Screening</td>
</tr>
<tr>
<td>CTV3</td>
<td>Clinical Terms Version 3</td>
</tr>
<tr>
<td>CVD</td>
<td>Cardiovascular Disease</td>
</tr>
<tr>
<td>CVD-PP</td>
<td>CVD Primary Prevention</td>
</tr>
<tr>
<td>DBP</td>
<td>Diastolic Blood Pressure</td>
</tr>
<tr>
<td>DCCT</td>
<td>Diabetes Control and Complications Trial</td>
</tr>
<tr>
<td>DH</td>
<td>Department of Health</td>
</tr>
<tr>
<td>DEM</td>
<td>Dementia</td>
</tr>
<tr>
<td>DEP</td>
<td>Depression</td>
</tr>
<tr>
<td>DM</td>
<td>Diabetes Mellitus</td>
</tr>
<tr>
<td>DMARD</td>
<td>Disease Modifying Anti-Rheumatic Drugs</td>
</tr>
<tr>
<td>DNA</td>
<td>Did Not Attend</td>
</tr>
<tr>
<td>DXA</td>
<td>Dual-Energy X-ray Absorptiometry</td>
</tr>
<tr>
<td>ED</td>
<td>Erectile Dysfunction</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>EHC</td>
<td>Emergency Hormone Contraception</td>
</tr>
<tr>
<td>eGFR</td>
<td>Estimated Glomerular Filtration Rate</td>
</tr>
<tr>
<td>EOLC</td>
<td>End of Life Care</td>
</tr>
<tr>
<td>EP</td>
<td>Epilepsy</td>
</tr>
<tr>
<td>ES</td>
<td>Enhanced Service</td>
</tr>
<tr>
<td>ESR</td>
<td>Erythrocyte Sedimentation Rate</td>
</tr>
<tr>
<td>FBC</td>
<td>Full Blood Count</td>
</tr>
<tr>
<td>FEV₁</td>
<td>Forced Expiratory Volume in One Second</td>
</tr>
<tr>
<td>FVC</td>
<td>Forced Vital Capacity</td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular Filtration Rate</td>
</tr>
<tr>
<td>GMS</td>
<td>General Medical Services</td>
</tr>
<tr>
<td>GOLD</td>
<td>The Global Initiative for Chronic Obstructive Lung Disease</td>
</tr>
<tr>
<td>GP</td>
<td>General Practitioner</td>
</tr>
<tr>
<td>GPC</td>
<td>General Practitioners Committee</td>
</tr>
<tr>
<td>GPES</td>
<td>General Practice Extraction Service</td>
</tr>
<tr>
<td>GPRD</td>
<td>General Practice Research Database</td>
</tr>
<tr>
<td>GPwSI</td>
<td>GP with a Special Interest</td>
</tr>
<tr>
<td>GSF</td>
<td>Gold Standards Framework</td>
</tr>
<tr>
<td>HADS</td>
<td>Hospital Anxiety and Depression Scale</td>
</tr>
<tr>
<td>HbA1c</td>
<td>Glycated Haemoglobin</td>
</tr>
<tr>
<td>HBPM</td>
<td>Home Blood Pressure Monitoring</td>
</tr>
<tr>
<td>HDA</td>
<td>Health Development Agency</td>
</tr>
<tr>
<td>HF</td>
<td>Heart Failure</td>
</tr>
<tr>
<td>HSCIC</td>
<td>Health and Social Care Information Centre</td>
</tr>
<tr>
<td>HYP</td>
<td>Hypertension</td>
</tr>
<tr>
<td>IFCC</td>
<td>International Federation of Clinical Chemistry and Laboratory Medicine</td>
</tr>
<tr>
<td>IUD</td>
<td>Intrauterine Device</td>
</tr>
<tr>
<td>IUS</td>
<td>Intrauterine System</td>
</tr>
<tr>
<td>IQ</td>
<td>Intelligence Quotient</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>JBS</td>
<td>Joint British Societies</td>
</tr>
<tr>
<td>JBS2</td>
<td>Joint British Society 2</td>
</tr>
<tr>
<td>JCVI</td>
<td>Joint Committee on Vaccination and Immunisation</td>
</tr>
<tr>
<td>KPa</td>
<td>KiloPascal</td>
</tr>
<tr>
<td>LARC</td>
<td>Long Acting Reversible Contraception</td>
</tr>
<tr>
<td>LD</td>
<td>Learning Disabilities</td>
</tr>
<tr>
<td>LDL</td>
<td>Low Density Lipoprotein</td>
</tr>
<tr>
<td>LVSD</td>
<td>Left Ventricular Systolic Dysfunction</td>
</tr>
<tr>
<td>MAT</td>
<td>Maternity</td>
</tr>
<tr>
<td>MH</td>
<td>Mental Health</td>
</tr>
<tr>
<td>MI</td>
<td>Myocardial Infarction</td>
</tr>
<tr>
<td>mmHg</td>
<td>Millimetres of Mercury</td>
</tr>
<tr>
<td>mmol/l</td>
<td>Millimoles per Litre</td>
</tr>
<tr>
<td>MRC</td>
<td>Medical Research Council</td>
</tr>
<tr>
<td>NAO</td>
<td>National Audit Office</td>
</tr>
<tr>
<td>NEJM</td>
<td>New England Journal of Medicine</td>
</tr>
<tr>
<td>NG</td>
<td>NICE guideline (clinical guidelines update reference from 2015)</td>
</tr>
<tr>
<td>NHS</td>
<td>National Health Service</td>
</tr>
<tr>
<td>NHS CB</td>
<td>NHS Commissioning Board (NHS England)</td>
</tr>
<tr>
<td>NICE</td>
<td>National Institute for Health and Care Excellence</td>
</tr>
<tr>
<td>NPSA</td>
<td>National Patient Safety Agency</td>
</tr>
<tr>
<td>NRT</td>
<td>Nicotine Replacement Therapy</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>Non-Steroidal Anti-Inflammatory Drugs</td>
</tr>
<tr>
<td>NSF</td>
<td>National Service Framework</td>
</tr>
<tr>
<td>OB</td>
<td>Obesity</td>
</tr>
<tr>
<td>OGTT</td>
<td>Oral Glucose Tolerance Test</td>
</tr>
<tr>
<td>ONS</td>
<td>Office for National Statistics</td>
</tr>
<tr>
<td>OST</td>
<td>Osteoporosis</td>
</tr>
<tr>
<td>PaO2</td>
<td>Partial Pressure of Oxygen in Arterial Blood</td>
</tr>
<tr>
<td>PAD</td>
<td>Peripheral Arterial Disease</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>PC</td>
<td>Palliative Care</td>
</tr>
<tr>
<td>PCRJ</td>
<td>Primary Care Respiratory Journal</td>
</tr>
<tr>
<td>PEF</td>
<td>Peak Expiratory Flow</td>
</tr>
<tr>
<td>PH</td>
<td>Public health</td>
</tr>
<tr>
<td>PHQ9</td>
<td>Nine item Patient Health Questionnaire</td>
</tr>
<tr>
<td>PVD</td>
<td>Peripheral Vascular Disease</td>
</tr>
<tr>
<td>QOF</td>
<td>Quality and Outcomes Framework</td>
</tr>
<tr>
<td>QS</td>
<td>Quality standard (NICE)</td>
</tr>
<tr>
<td>RA</td>
<td>Rheumatoid Arthritis</td>
</tr>
<tr>
<td>RCGP</td>
<td>Royal College of General Practitioners</td>
</tr>
<tr>
<td>RCP</td>
<td>Royal College of Physicians</td>
</tr>
<tr>
<td>RCN</td>
<td>Royal College of Nurses</td>
</tr>
<tr>
<td>RCTs</td>
<td>Randomised Controlled Trials</td>
</tr>
<tr>
<td>SCR</td>
<td>Supportive Care Register</td>
</tr>
<tr>
<td>SFE</td>
<td>Statement of Financial Entitlements</td>
</tr>
<tr>
<td>SIGN</td>
<td>Scottish Intercollegiate Guidelines Network</td>
</tr>
<tr>
<td>SMOK</td>
<td>Smoking</td>
</tr>
<tr>
<td>SaO2</td>
<td>Arterial Oxygen Saturation</td>
</tr>
<tr>
<td>SpO2</td>
<td>Pulse Oximetry</td>
</tr>
<tr>
<td>SPAF1</td>
<td>Stroke Prevention in AF I Study</td>
</tr>
<tr>
<td>STIA</td>
<td>Stroke or Transient Ischemic Attack</td>
</tr>
<tr>
<td>TA</td>
<td>Technology appraisal (NICE)</td>
</tr>
<tr>
<td>TIA</td>
<td>Transient Ischemic Attack</td>
</tr>
<tr>
<td>TSH</td>
<td>Thyroid Stimulating Hormone</td>
</tr>
<tr>
<td>UK</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>US</td>
<td>United States</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organisation</td>
</tr>
</tbody>
</table>
Section 7: Queries

Queries fall into three main categories:

1. those which can be resolved by referring to guidance and/or FAQs
2. those requiring interpretation of the guidance or Business Rules
3. those not anticipated in guidance.

Queries may incorporate one or more of the following areas: Business Rules, coding, payment, CQRS, GPES, and clinical or policy issues. The recipient of the query will liaise with other relevant parties in order to respond and where necessary the query will be redirected.

---

146 HSCIC. http://www.hscic.gov.uk/qofextractspecs
147 Where an issue relating to clinical indicators cannot be resolved with simple clarification of the guidance, this will fall in to the NICE process of reviewing QOF indicators.
## Section 8: QOF quick guide

### CLINICAL DOMAIN

<table>
<thead>
<tr>
<th>Atrial Fibrillation (AF)</th>
<th>Changes</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Indicator wording timeframe (months)</th>
<th>Business Rules timeframe (months)</th>
<th>Exception code timeframe (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AF001 AF001</td>
<td>NO CHANGE</td>
<td>5</td>
<td>-</td>
<td>5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>AF004 AF004 NM46</td>
<td>NO CHANGE</td>
<td>6</td>
<td>40-70</td>
<td>6</td>
<td>40-70</td>
<td>6 (currently treated)</td>
<td>6 (drugs)</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
<tr>
<td>AF006 AF006 NM81</td>
<td>NO CHANGE</td>
<td>12</td>
<td>40-90</td>
<td>12</td>
<td>40-90</td>
<td>12</td>
<td>12</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
<tr>
<td>AF007 AF007 NM82</td>
<td>NO CHANGE</td>
<td>12</td>
<td>40-70</td>
<td>12</td>
<td>40-70</td>
<td>6 (currently treated)</td>
<td>6 (drugs)</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
</tbody>
</table>
### Secondary prevention of coronary heart disease (CHD)

<table>
<thead>
<tr>
<th>Code</th>
<th>Code</th>
<th>Notes</th>
<th>Changes</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'rame</th>
<th>BR t'rame</th>
<th>Exception t'rame</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHD001</td>
<td>CHD001</td>
<td>- The contractor establishes and maintains a register of patients with coronary heart disease</td>
<td>NO CHANGE</td>
<td>4</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CHD002</td>
<td>CHD002</td>
<td>NM86 The percentage of patients with coronary heart disease in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less</td>
<td>NO CHANGE</td>
<td>17</td>
<td>53-93</td>
<td>17</td>
<td>53-93</td>
<td>12</td>
<td>12</td>
<td>12 (EXC) 9 (REG/DIAG)</td>
</tr>
<tr>
<td>CHD005</td>
<td>CHD005</td>
<td>NM88 The percentage of patients with coronary heart disease with a record in the preceding 12 months that aspirin, an alternative anti-platelet therapy, or an anti-coagulant is being taken</td>
<td>NO CHANGE</td>
<td>7</td>
<td>56-96</td>
<td>7</td>
<td>56-96</td>
<td>12</td>
<td>12</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
<tr>
<td>CHD007</td>
<td>CHD007</td>
<td>NM87 The percentage of patients with coronary heart disease who have had influenza immunisation in the preceding 1 August to 31 March</td>
<td>NO CHANGE</td>
<td>7</td>
<td>56-96</td>
<td>7</td>
<td>56-96</td>
<td>1 Aug to 31 Mar</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
<td></td>
</tr>
</tbody>
</table>

### Heart failure (HF)

<table>
<thead>
<tr>
<th>Code</th>
<th>Code</th>
<th>Notes</th>
<th>Changes</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'rame</th>
<th>BR t'rame</th>
<th>Exception t'rame</th>
</tr>
</thead>
<tbody>
<tr>
<td>HF001</td>
<td>HF001</td>
<td>- The contractor establishes and maintains a register of patients with heart failure</td>
<td>NO CHANGE</td>
<td>4</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HF002</td>
<td>HF002</td>
<td>NM116 The percentage of patients with a diagnosis of heart failure (diagnosed on or after 1 April 2006) which has been confirmed by an echocardiogram or by specialist assessment 3 months before or 12 months after entering on to the register</td>
<td>NO CHANGE</td>
<td>6</td>
<td>50-90</td>
<td>6</td>
<td>50-90</td>
<td>From 1 April 2006</td>
<td>From 1 April 2006</td>
<td>12 (EXC) 3 (REG/DIAG) +12 (ECEXC)</td>
</tr>
<tr>
<td>HF003</td>
<td>HF003</td>
<td>NM89 In those patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction, the percentage of patients who are currently treated with an ACE-I or ARB</td>
<td>NO CHANGE</td>
<td>10</td>
<td>60-100</td>
<td>10</td>
<td>60-100</td>
<td>6 (currently treated)</td>
<td>6 (drugs)</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
<tr>
<td>HF004</td>
<td>HF004</td>
<td>NM90 In those patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction who are currently treated with an ACE-I or ARB, the percentage of patients who are additionally currently treated with a beta-blocker licensed for heart failure</td>
<td>NO CHANGE</td>
<td>9</td>
<td>40-65</td>
<td>9</td>
<td>40-65</td>
<td>6 (currently treated)</td>
<td>6 (drugs)</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
</tbody>
</table>

### Hypertension (HYP)

<table>
<thead>
<tr>
<th>Code</th>
<th>Code</th>
<th>Notes</th>
<th>Changes</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'rame</th>
<th>BR t'rame</th>
<th>Exception t'rame</th>
</tr>
</thead>
<tbody>
<tr>
<td>HYP001</td>
<td>HYP001</td>
<td>- The contractor establishes and maintains a register of patients with established hypertension</td>
<td>NO CHANGE</td>
<td>6</td>
<td>-</td>
<td>6</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HYP006</td>
<td>HYP006</td>
<td>NM91 The percentage of patients with hypertension in whom the last blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less</td>
<td>NO CHANGE</td>
<td>20</td>
<td>45-80</td>
<td>20</td>
<td>45-80</td>
<td>12</td>
<td>12</td>
<td>12 (EXC) 9 (REG/DIAG)</td>
</tr>
</tbody>
</table>
### Peripheral arterial disease (PAD)

<table>
<thead>
<tr>
<th>Changes</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'rame</th>
<th>BR t'rame</th>
<th>Exception t'rame</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAD001</td>
<td>NO CHANGE</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PAD002</td>
<td>NO CHANGE</td>
<td>2</td>
<td>40-90</td>
<td>2</td>
<td>40-90</td>
<td>12</td>
<td>12 (REG/DIAG)</td>
</tr>
<tr>
<td>PAD004</td>
<td>NO CHANGE</td>
<td>2</td>
<td>40-90</td>
<td>2</td>
<td>40-90</td>
<td>12 (being taken)</td>
<td>12 (drugs)</td>
</tr>
</tbody>
</table>

### Stroke and transient ischaemic attack (STIA)

<table>
<thead>
<tr>
<th>Changes</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'rame</th>
<th>BR t'rame</th>
<th>Exception t'rame</th>
</tr>
</thead>
<tbody>
<tr>
<td>STIA001</td>
<td>NO CHANGE</td>
<td>2</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>STIA008</td>
<td>NO CHANGE</td>
<td>2</td>
<td>45-80</td>
<td>2</td>
<td>45-80</td>
<td>-</td>
<td>From 1 April 2014 +1 (SCAN_DAT)</td>
</tr>
<tr>
<td>STIA003</td>
<td>NO CHANGE</td>
<td>5</td>
<td>40-75</td>
<td>5</td>
<td>40-75</td>
<td>12</td>
<td>12 (REG/DIAG)</td>
</tr>
<tr>
<td>STIA007</td>
<td>NO CHANGE</td>
<td>4</td>
<td>57-97</td>
<td>4</td>
<td>57-97</td>
<td>12 (being taken)</td>
<td>12 (drugs)</td>
</tr>
<tr>
<td>STIA009</td>
<td>NO CHANGE</td>
<td>2</td>
<td>55-95</td>
<td>2</td>
<td>55-95</td>
<td>1 Aug to 31 Mar</td>
<td>1 Aug to 31 Mar</td>
</tr>
</tbody>
</table>

### Diabetes mellitus (DM)

<table>
<thead>
<tr>
<th>Changes</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'rame</th>
<th>BR t'rame</th>
<th>Exception t'rame</th>
</tr>
</thead>
<tbody>
<tr>
<td>DM017</td>
<td>NO CHANGE</td>
<td>6</td>
<td>6</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Diabetes mellitus (DM)</td>
<td>Changes</td>
<td>15/16 Points</td>
<td>15/16 Threshold</td>
<td>16/17 Points</td>
<td>16/17 Threshold</td>
<td>Wording t'frame</td>
<td>BR t'frame</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------</td>
<td>--------------</td>
<td>----------------</td>
<td>--------------</td>
<td>----------------</td>
<td>----------------</td>
<td>------------</td>
</tr>
<tr>
<td>DM002</td>
<td>NO CHANGE</td>
<td>8</td>
<td>53-93</td>
<td>8</td>
<td>53-93</td>
<td>12 (the last)</td>
<td>12</td>
</tr>
<tr>
<td>DM003</td>
<td>NO CHANGE</td>
<td>10</td>
<td>38-78</td>
<td>10</td>
<td>38-78</td>
<td>12 (the last)</td>
<td>12</td>
</tr>
<tr>
<td>DM004</td>
<td>NO CHANGE</td>
<td>6</td>
<td>40-75</td>
<td>6</td>
<td>40-75</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>DM006</td>
<td>NO CHANGE</td>
<td>3</td>
<td>57-97</td>
<td>3</td>
<td>57-97</td>
<td>-</td>
<td>6</td>
</tr>
<tr>
<td>DM007</td>
<td>NO CHANGE</td>
<td>17</td>
<td>35-75</td>
<td>17</td>
<td>35-75</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>DM008</td>
<td>NO CHANGE</td>
<td>8</td>
<td>43-83</td>
<td>8</td>
<td>43-83</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>DM009</td>
<td>NO CHANGE</td>
<td>10</td>
<td>52-92</td>
<td>10</td>
<td>52-92</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>DM012</td>
<td>NO CHANGE</td>
<td>4</td>
<td>50-90</td>
<td>4</td>
<td>50-90</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>DM014</td>
<td>NO CHANGE</td>
<td>11</td>
<td>40-90</td>
<td>11</td>
<td>40-90</td>
<td>1 April to 31 March</td>
<td>21 (12+9)</td>
</tr>
<tr>
<td>DM018</td>
<td>NO CHANGE</td>
<td>3</td>
<td>55-95</td>
<td>3</td>
<td>55-95</td>
<td>1 Aug to 31 Mar</td>
<td>1 Aug to 31 Mar</td>
</tr>
</tbody>
</table>
### Asthma (AST)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Changes</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t’rame</th>
<th>BR t’rame</th>
<th>Exception t’rame</th>
</tr>
</thead>
<tbody>
<tr>
<td>AST001</td>
<td>The contractor establishes and maintains a register of patients with asthma, excluding patients with asthma who have been prescribed no asthma-related drugs in the preceding 12 months</td>
<td>NO CHANGE</td>
<td>4</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>AST002</td>
<td>The percentage of patients aged 8 or over with asthma (diagnosed on or after 1 April 2006), on the register, with measures of variability or reversibility recorded between 3 months before and anytime after diagnosis</td>
<td>NO CHANGE</td>
<td>15</td>
<td>45-80</td>
<td>15</td>
<td>45-80</td>
<td>From 1 April 2006 3 (ASTSPIR/PEFR)</td>
<td>From 1 April 2006 3 (ASTSPIR/PEFR)</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
<tr>
<td>AST003</td>
<td>The percentage of patients with asthma, on the register, who have had an asthma review in the preceding 12 months that includes an assessment of asthma control using the 3 RCP questions</td>
<td>NO CHANGE</td>
<td>20</td>
<td>45-70</td>
<td>20</td>
<td>45-70</td>
<td>12</td>
<td>12</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
<tr>
<td>AST004</td>
<td>The percentage of patients with asthma aged 14 or over and who have not attained the age of 20, on the register, in whom there is a record of smoking status in the preceding 12 months</td>
<td>NO CHANGE</td>
<td>6</td>
<td>45-80</td>
<td>6</td>
<td>45-80</td>
<td>12</td>
<td>12</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
</tbody>
</table>

### Chronic obstructive pulmonary disease (COPD)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Changes</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t’rame</th>
<th>BR t’rame</th>
<th>Exception t’rame</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD001</td>
<td>The contractor establishes and maintains a register of patients with COPD</td>
<td>NO CHANGE</td>
<td>3</td>
<td>-</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>COPD002</td>
<td>The percentage of patients with COPD (diagnosed on or after 1 April 2011), in whom the diagnosis has been confirmed by post bronchodilator spirometry between 3 months before and 12 months after entering on to the register</td>
<td>NO CHANGE</td>
<td>5</td>
<td>45-80</td>
<td>5</td>
<td>45-80</td>
<td>From 1 April 2011 COPDSPI R -3 COPDSPI R +12</td>
<td>From 1 April 2011 COPDSPI R -3 COPDSPI R +12</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
<tr>
<td>COPD003</td>
<td>The percentage of patients with COPD who have had a review, undertaken by a healthcare professional, including an assessment of breathlessness using the Medical Research Council dyspnoea scale in the preceding 12 months</td>
<td>NO CHANGE</td>
<td>9</td>
<td>50-90</td>
<td>9</td>
<td>50-90</td>
<td>12</td>
<td>12</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
<tr>
<td>COPD004</td>
<td>The percentage of patients with COPD with a record of FEV1 in the preceding 12 months</td>
<td>NO CHANGE</td>
<td>7</td>
<td>40-75</td>
<td>7</td>
<td>40-75</td>
<td>12</td>
<td>12</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
<tr>
<td>COPD005</td>
<td>The percentage of patients with COPD and Medical Research Council dyspnoea grade ≥3 at any time in the preceding 12 months, with a record of oxygen saturation value within the preceding 12 months</td>
<td>NO CHANGE</td>
<td>5</td>
<td>40-90</td>
<td>5</td>
<td>40-90</td>
<td>12</td>
<td>12</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
</tbody>
</table>
### Chronic obstructive pulmonary disease (COPD)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Changes</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'frame</th>
<th>BR t'frame</th>
<th>Exception t'frame</th>
</tr>
</thead>
<tbody>
<tr>
<td>COPD007</td>
<td>The percentage of patients with COPD who have had influenza immunisation in the preceding 1 August to 31 March</td>
<td>NO CHANGE</td>
<td>6</td>
<td>57-97</td>
<td>6</td>
<td>57-97</td>
<td>1 Aug to 31 Mar</td>
<td>1 Aug to 31 Mar</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
</tbody>
</table>

### Dementia (DEM)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Changes</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'frame</th>
<th>BR t'frame</th>
<th>Exception t'frame</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEM001</td>
<td>The contractor establishes and maintains a register of patients diagnosed with dementia</td>
<td>NO CHANGE</td>
<td>5</td>
<td>-</td>
<td>5</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>DEM002</td>
<td>The percentage of patients diagnosed with dementia whose care plan has been reviewed in a face-to-face review in the preceding 12 months</td>
<td>NO CHANGE</td>
<td>15</td>
<td>35-70</td>
<td>39</td>
<td>35-70</td>
<td>12</td>
<td>12</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
<tr>
<td>DEM003</td>
<td>The percentage of patients with a new diagnosis of dementia recorded in the preceding 1 April to 31 March, who have been reviewed not earlier than 10 days after and not later than 56 days after the date of diagnosis</td>
<td>NO CHANGE</td>
<td>6</td>
<td>45-80</td>
<td>6</td>
<td>45-80</td>
<td>1 Apr to 31 March 12 months before/6 months after</td>
<td>18</td>
<td>12 and 6 (tests) (EXC) 3 (REG/DIAG)</td>
</tr>
</tbody>
</table>

### Depression (DEP)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Changes</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'frame</th>
<th>BR t'frame</th>
<th>Exception t'frame</th>
</tr>
</thead>
<tbody>
<tr>
<td>DEP003</td>
<td>The percentage of patients aged 18 or over with a new diagnosis of depression in the preceding 1 April to 31 March, who have been reviewed not earlier than 10 days after and not later than 56 days after the date of diagnosis</td>
<td>NO CHANGE</td>
<td>10</td>
<td>45-80</td>
<td>10</td>
<td>45-80</td>
<td>1 Apr to 31 March 10-56 days (from DEPR)</td>
<td>15</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
</tbody>
</table>

### Mental Health (MH)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Changes</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'frame</th>
<th>BR t'frame</th>
<th>Exception t'frame</th>
</tr>
</thead>
<tbody>
<tr>
<td>MH001</td>
<td>The contractor establishes and maintains a register of patients with schizophrenia, bipolar affective disorder and other psychoses and other patients on lithium therapy</td>
<td>NO CHANGE</td>
<td>4</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MH002</td>
<td>The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a comprehensive care plan documented in the record, in the preceding 12 months, agreed between individuals, their family and/or carers as appropriate</td>
<td>NO CHANGE</td>
<td>6</td>
<td>40-90</td>
<td>6</td>
<td>40-90</td>
<td>12</td>
<td>12</td>
<td>12 (EXC) 3 (REG/DIAG)</td>
</tr>
</tbody>
</table>
### Mental Health (MH)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Points</th>
<th>Threshold</th>
<th>Wording</th>
<th>BR</th>
<th>Exception</th>
</tr>
</thead>
<tbody>
<tr>
<td>MH003</td>
<td>The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of blood pressure in the preceding 12 months</td>
<td>15/16</td>
<td>4</td>
<td>50-90</td>
<td>12</td>
<td>12 (EXC)</td>
</tr>
<tr>
<td>MH007</td>
<td>The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who have a record of alcohol consumption in the preceding 12 months</td>
<td>15/16</td>
<td>4</td>
<td>50-90</td>
<td>12</td>
<td>12 (EXC)</td>
</tr>
<tr>
<td>MH008</td>
<td>The percentage of women aged 25 or over and who have not attained the age of 65 with schizophrenia, bipolar affective disorder and other psychoses whose notes record that a cervical screening test has been performed in the preceding 5 years</td>
<td>15/16</td>
<td>5</td>
<td>45-80</td>
<td>5</td>
<td>5 years</td>
</tr>
<tr>
<td>MH009</td>
<td>The percentage of patients on lithium therapy with a record of serum creatinine and TSH in the preceding 9 months</td>
<td>15/16</td>
<td>1</td>
<td>50-90</td>
<td>9</td>
<td>12 (EXC)</td>
</tr>
<tr>
<td>MH010</td>
<td>The percentage of patients on lithium therapy with a record of lithium levels in the therapeutic range in the preceding 4 months</td>
<td>15/16</td>
<td>2</td>
<td>50-90</td>
<td>6</td>
<td>12 (EXC)</td>
</tr>
</tbody>
</table>

### Cancer (CAN)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Points</th>
<th>Threshold</th>
<th>Wording</th>
<th>BR</th>
<th>Exception</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAN001</td>
<td>The contractor establishes and maintains a register of all cancer patients defined as a ‘register of patients with a diagnosis of cancer excluding non-melanotic skin cancers diagnosed on or after 1 April 2003’</td>
<td>15/16</td>
<td>5</td>
<td>5</td>
<td>From 1 April 2003</td>
<td>-</td>
</tr>
<tr>
<td>CAN003</td>
<td>The percentage of patients with cancer, diagnosed within the preceding 15 months, who have a patient review recorded as occurring within 6 months of the date of diagnosis</td>
<td>15/16</td>
<td>6</td>
<td>50-90</td>
<td>15</td>
<td>12 (EXC)</td>
</tr>
</tbody>
</table>

### Chronic kidney disease (CKD)

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
<th>Points</th>
<th>Threshold</th>
<th>Wording</th>
<th>BR</th>
<th>Exception</th>
</tr>
</thead>
<tbody>
<tr>
<td>CKD001</td>
<td>The contractor establishes and maintains a register of patients aged 18 or over with CKD with classification categories G3a to G5 (previously (US National Kidney Foundation) stage 3 to 5)</td>
<td>15/16</td>
<td>6</td>
<td>50-90</td>
<td>6</td>
<td>12 (EXC)</td>
</tr>
<tr>
<td>Epilepsy (EP)</td>
<td>15/16 Points</td>
<td>15/16 Threshold</td>
<td>16/17 Points</td>
<td>16/17 Threshold</td>
<td>Wording t'rame</td>
<td>BR t'rame</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
<td>----------------</td>
<td>-------------</td>
<td>----------------</td>
<td>---------------</td>
<td>-----------</td>
</tr>
<tr>
<td>EP001 EP001</td>
<td>1</td>
<td>-</td>
<td>1</td>
<td></td>
<td>NO CHANGE</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Learning disability (LD)</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'rame</th>
<th>BR t'rame</th>
<th>Exception t'frame</th>
</tr>
</thead>
<tbody>
<tr>
<td>LD001 LD003 NM73</td>
<td>4</td>
<td>-</td>
<td>4</td>
<td></td>
<td>NO CHANGE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Osteoporosis: secondary prevention of fragility fractures (OST)</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'rame</th>
<th>BR t'rame</th>
<th>Exception t'frame</th>
</tr>
</thead>
<tbody>
<tr>
<td>OST004 OST004 NM29</td>
<td>3</td>
<td>-</td>
<td>3</td>
<td></td>
<td>NO CHANGE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OST002 OST002 NM30</td>
<td>3</td>
<td>30-60</td>
<td>3</td>
<td></td>
<td>30-60</td>
<td>6 (drugs)</td>
<td>12 (EXC) (REG/DIAG)</td>
</tr>
<tr>
<td>OST005 OST005 NM31</td>
<td>3</td>
<td>30-60</td>
<td>3</td>
<td></td>
<td>30-60</td>
<td>6 (drugs)</td>
<td>12 (EXC) (REG/DIAG)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Palliative care (PC)</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'rame</th>
<th>BR t'rame</th>
<th>Exception t'frame</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC001 PC001</td>
<td>3</td>
<td>-</td>
<td>3</td>
<td></td>
<td>NO CHANGE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PC002 PC002 NM111</td>
<td>3</td>
<td>-</td>
<td>3</td>
<td></td>
<td>NO CHANGE</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## PUBLIC HEALTH DOMAIN

### Cardiovascular disease - primary prevention (CVD-PP)

<table>
<thead>
<tr>
<th>CVD-PP001</th>
<th>CVD-PP001</th>
<th>NM26</th>
<th>In those patients with a new diagnosis of hypertension aged 30 or over and who have not attained the age of 75, recorded between the preceding 1 April to 31 March (excluding those with pre-existing CHD, diabetes, stroke and/or TIA), who have a recorded CVD risk assessment score (using an assessment tool agreed with the NHS CB) of ≥20% in the preceding 12 months: the percentage who are currently treated with statins</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t’frame</th>
<th>BR t’frame</th>
<th>Exception t’frame</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>NO CHANGE</td>
<td>10</td>
<td>40-90</td>
<td>10</td>
<td>40-90</td>
<td>1 April to 31 March 12 Currently treated (6)</td>
<td>12 (drugs)</td>
<td>12 (EXC) 3 (REG/_DIAG)</td>
</tr>
</tbody>
</table>

### Blood pressure (BP)

<table>
<thead>
<tr>
<th>BP002</th>
<th>BP002</th>
<th>NM61</th>
<th>The percentage of patients aged 45 or over who have a record of blood pressure in the preceding 5 years</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t’frame</th>
<th>BR t’frame</th>
<th>Exception t’frame</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>NO CHANGE</td>
<td>15</td>
<td>50-90</td>
<td>15</td>
<td>50-90</td>
<td>5 years</td>
<td>5 years</td>
<td>3 (REG)</td>
</tr>
</tbody>
</table>

### Obesity (OB)

<table>
<thead>
<tr>
<th>OB001</th>
<th>OB002</th>
<th>NM85</th>
<th>The contractor establishes and maintains a register of patients aged 18+ years or over with a BMI ≥30 in the preceding 12 months</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t’frame</th>
<th>BR t’frame</th>
<th>Exception t’frame</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>NO CHANGE</td>
<td>8</td>
<td>-</td>
<td>8</td>
<td>-</td>
<td>12</td>
<td>12</td>
<td>-</td>
</tr>
</tbody>
</table>

### Smoking (SMOK)

<table>
<thead>
<tr>
<th>SMOK002</th>
<th>SMOK002</th>
<th>NM38</th>
<th>The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t’frame</th>
<th>BR t’frame</th>
<th>Exception t’frame</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>NO CHANGE</td>
<td>25</td>
<td>50-90</td>
<td>25</td>
<td>50-90</td>
<td>12</td>
<td>12 Non-smoker rules/Ex-smoker rules</td>
<td>12 (EXC) 3 (REG/_DIAG)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SMOK003</th>
<th>SMOK003</th>
<th>NM113</th>
<th>The contractor supports patients who smoke in stopping smoking by a strategy which includes providing literature and offering appropriate therapy</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t’frame</th>
<th>BR t’frame</th>
<th>Exception t’frame</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>NO CHANGE</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SMOK004</th>
<th>SMOK004</th>
<th>NM40</th>
<th>The percentage of patients aged 15 or over who are recorded as current smokers who have a record of an offer of support and treatment within the preceding 24 months</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t’frame</th>
<th>BR t’frame</th>
<th>Exception t’frame</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>NO CHANGE</td>
<td>12</td>
<td>40-90</td>
<td>12</td>
<td>40-90</td>
<td>24</td>
<td>24</td>
<td>12 (EXC) 3 (REG)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SMOK005</th>
<th>SMOK005</th>
<th>NM39</th>
<th>The percentage of patients with any or any combination of the following conditions: CHD, PAD, stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar affective disorder or other psychoses who are recorded as current smokers</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t’frame</th>
<th>BR t’frame</th>
<th>Exception t’frame</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>NO CHANGE</td>
<td>25</td>
<td>56-96</td>
<td>25</td>
<td>56-96</td>
<td>12</td>
<td>12</td>
<td>12 (EXC) 3 (REG/_DIAG)</td>
</tr>
</tbody>
</table>
who have a record of an offer of support and treatment within the preceding 12 months

<table>
<thead>
<tr>
<th>Cervical Screening (CS)</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'rame</th>
<th>BR t'rame</th>
<th>Exception t'frame</th>
</tr>
</thead>
<tbody>
<tr>
<td>CS001 CS001</td>
<td>NO CHANGE</td>
<td>7</td>
<td>-</td>
<td>7</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CS002 CS002</td>
<td>NO CHANGE</td>
<td>11</td>
<td>45-80</td>
<td>11</td>
<td>45-80</td>
<td>5 years</td>
<td>5 years (CYTEXC) 3 (REG)</td>
</tr>
<tr>
<td>CS004 CS004</td>
<td>NO CHANGE</td>
<td>2</td>
<td>-</td>
<td>2</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contraception (CON)</th>
<th>15/16 Points</th>
<th>15/16 Threshold</th>
<th>16/17 Points</th>
<th>16/17 Threshold</th>
<th>Wording t'rame</th>
<th>BR t'rame</th>
<th>Exception t'frame</th>
</tr>
</thead>
<tbody>
<tr>
<td>CON001 CON001</td>
<td>NO CHANGE</td>
<td>4</td>
<td>-</td>
<td>4</td>
<td>-</td>
<td>5 years</td>
<td>Appropriate interval</td>
</tr>
<tr>
<td>CON003 CON003 Based on NM115</td>
<td>NO CHANGE</td>
<td>3</td>
<td>50-90</td>
<td>3</td>
<td>50-90</td>
<td>12 months</td>
<td>12 (EXC) 3 (REG)</td>
</tr>
</tbody>
</table>